| Date | Ticker | Company | Drug | Type | Phase | PoA | Mkt Size | Notes |
|---|---|---|---|---|---|---|---|---|
|
2026-04-28 Today |
INSM | PDUFA | Phase 2 | — | $6B | For NTM lung disease. sNDA filing. Extracted from SEC filing: 8-K | ||
|
2026-04-28 Today |
HNSPF | Trial | Phase 2 | — | $8B | Primary completion for HS-10374 trial (NCT06176508) in Psoriatic Arthritis | ||
|
2026-04-29 in 1 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for Cisplatin + Gemcitabine trial (NCT03682068) in Unresectable Locally | ||
|
2026-04-29 in 1 days |
VRNA | Trial | Phase 2 | — | $15B | Primary completion for Glycopyrrolate 21.25 mcg trial (NCT07016412) in Chronic Obstructive | ||
|
2026-04-29 in 1 days |
VRNA | Trial | Phase 2 | — | $15B | Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmon | ||
|
2026-04-29 in 1 days |
AGIO | Earnings | — | — | — | Agios announced it will host a conference call on April 29, 2026 at 8:00 a.m. ET to discus | ||
|
2026-04-30 in 2 days |
AZN | AdCom | — | 92% | $8B | APR 30 2026 2 days 🏛️ AdCom Truqap (capivasertib (Truqap) + abir...) $AZN AstraZeneca PTEN | ||
|
2026-04-30 in 2 days |
AXSM | PDUFA | — | 92% | $4B | APR 30 2026 2 days 💊 PDUFA Auvelity (supplemental) (dextromethorphan HBr / bupro...) $AXSM | ||
|
2026-04-30 in 2 days |
AZN | AdCom | — | 85% | $12B | APR 30 2026 2 days 🏛️ AdCom (camizestrant (NDA 220359)) $AZN AstraZeneca HR+/HER2- advance | ||
|
2026-04-30 in 2 days |
PTCT | Trial | Phase 3 | — | $200M | Primary completion for PTC923 trial (NCT05166161) in Phenylketonuria | ||
|
2026-04-30 in 2 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for Enfortumab Vedotin trial (NCT04960709) in Muscle Invasive Bladder C | ||
|
2026-04-30 in 2 days |
NVS | Trial | Phase 3 | — | $12B | Primary completion for Remibrutinib trial (NCT05156281) in Relapsing Multiple Sclerosis | ||
|
2026-04-30 in 2 days |
VRTX | Trial | Phase 3 | — | $6B | Primary completion for IVA trial (NCT05153317) in Cystic Fibrosis | ||
|
2026-04-30 in 2 days |
RHHBY | Trial | Phase 3 | — | $25B | Primary completion for Rituximab trial (NCT03274492) in Diffuse Large B-Cell Lymphoma | ||
|
2026-04-30 in 2 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Prednisone trial (NCT03274492) in Diffuse Large B-Cell Lymphoma | ||
|
2026-04-30 in 2 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Polatuzumab Vedotin trial (NCT03274492) in Diffuse Large B-Cell Lym | ||
|
2026-04-30 in 2 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Cyclophosphamide trial (NCT03274492) in Diffuse Large B-Cell Lympho | ||
|
2026-04-30 in 2 days |
OTSKF | Trial | Phase 3 | — | $6B | Primary completion for Centanafadine Hydrochloride trial (NCT05279313) in Attention Defici | ||
|
2026-04-30 in 2 days |
DNLI | Trial | Phase 2 | — | $12B | Primary completion for BIIB122 225 mg trial (NCT06602193) in Parkinson Disease | ||
|
2026-04-30 in 2 days |
ANRO | Trial | Phase 2 | — | $15B | Primary completion for DR30206 trial (NCT07056777) in Gastrointestinal Cancer | ||
|
2026-04-30 in 2 days |
AZNCF | Trial | Phase 3 | — | $20B | Primary completion for Tozorakimab trial (NCT06897748) in Chronic Obstructive Pulmonary Di | ||
|
2026-04-30 in 2 days |
CNTA | Trial | Phase 2 | — | $2B | Primary completion for ORX750 trial (NCT07096674) in Narcolepsy Type 1 | ||
|
2026-04-30 in 2 days |
MRK | Trial | Phase 3 | — | $1B | Primary completion for Tulisokibart trial (NCT05270668) in Diffuse Cutaneous Systemic Scle | ||
|
2026-04-30 in 2 days |
VRTX | Trial | Phase 2 | — | $6B | Primary completion for Placebo (matched to pregabalin) trial (NCT06619860) in Diabetic Per | ||
|
2026-04-30 in 2 days |
PFE | Trial | Phase 2 | — | $18B | Primary completion for vepdegestrant trial (NCT06125522) in Breast Cancer | ||
|
2026-04-30 in 2 days |
PFE | Trial | Phase 2 | — | $18B | Primary completion for Samuraciclib trial (NCT06125522) in Breast Cancer | ||
|
2026-04-30 in 2 days |
GSK | Trial | Phase 2 | — | $6B | Primary completion for Zanamivir trial (NCT04494412) in Influenza, Human | ||
|
2026-04-30 in 2 days |
TTIPF | Trial | Phase 2 | — | $300M | Primary completion for TTI-0102 trial (NCT06644534) in MELAS Syndrome | ||
|
2026-04-30 in 2 days |
TLSA | Trial | Phase 2 | — | $2B | Primary completion for Foralumab TZLS-401 100 µg trial (NCT06890923) in Non-Active Seconda | ||
|
2026-04-30 in 2 days |
AZN | AdCom | — | 92% | — | APR 30 2026 2 days 🏛️ AdCom Truqap (capivasertib (Truqap) + abir...) $AZN AstraZeneca PTEN | ||
|
2026-04-30 in 2 days |
AXSM | PDUFA | — | 92% | — | APR 30 2026 2 days 💊 PDUFA Auvelity (supplemental) (dextromethorphan HBr / bupro...) $AXSM | ||
|
2026-05-01 in 73 days |
CELZ | Trial | Phase 2 | — | $6B | Primary completion for CELZ-201-DDT trial (NCT06053242) in Chronic Low-back Pain | ||
|
2026-05-01 in 73 days |
AZNCF | Trial | Phase 2 | — | $8B | Primary completion for AZD7798 trial (NCT06450197) in Moderate to Severe Crohn's Disease | ||
|
2026-05-01 in 73 days |
ARGX | Other | — | — | — | Argenx announced that COO Karen Massey will become CEO in May 2026, succeeding Tim Van Hau | ||
|
2026-05-01 in 73 days |
RHHBY | Other | — | — | — | Roche announces the appointment of Mark Dawson, M.D., Ph.D., as Head of Roche Pharma Resea | ||
|
2026-05-04 in 76 days |
AZN | Trial | Phase 2 | — | $8B | Primary completion for AZD7798 trial (NCT06681324) in Crohn's Disease | ||
|
2026-05-04 in 76 days |
VRTX | Earnings | — | — | — | Vertex Pharmaceuticals announced it will report first quarter 2026 financial results on Ma | ||
|
2026-05-05 in 77 days |
COGT | Earnings | — | — | — | MAY 5 2026 7 days 📊 Earnings Cogent Biosciences Q1 2026 Earnings $COGT Cogent Biosciences | ||
|
2026-05-05 in 77 days |
BNTX | Trial | Phase 3 | — | $15B | Primary completion for BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) trial (NCT070693 | ||
|
2026-05-05 in 77 days |
RCKT | Trial | Phase 2 | — | $200M | Primary completion for RP-L102 trial (NCT04248439) in Fanconi Anemia Complementation Group | ||
|
2026-05-05 in 77 days |
CYTK | Earnings | — | — | — | Cytokinetics announced it will report first quarter 2026 results on May 5, 2026. This is a | ||
|
2026-05-05 in 77 days |
BNTX | Earnings | — | — | — | BioNTech announced it will report fourth quarter and full year 2025 financial results alon | ||
|
2026-05-05 in 77 days |
CRL | Other | — | — | — | Charles River CEO Jim Foster is retiring on May 5, 2026, after over 30 years in the positi | ||
|
2026-05-05 in 77 days |
PFE | Other | — | — | — | Pfizer is inviting the public to view and listen to a webcast of an analyst conference cal | ||
|
2026-05-06 in 78 days |
CYTK | Earnings | — | — | — | MAY 6 2026 8 days 📊 Earnings Cytokinetics Q1 2026 Earnings $CYTK Cytokinetics Q1 2026 earn | ||
|
2026-05-06 in 78 days |
SWTX | Earnings | — | — | — | MAY 6 2026 8 days 📊 Earnings SpringWorks Therapeutics Q1 2026 Earnings $SWTX SpringWorks T | ||
|
2026-05-06 in 78 days |
VRDN | Earnings | 3 | — | — | MAY 6 2026 8 days 📊 Earnings Viridian Therapeutics Q1 2026 Earnings $VRDN Viridian Therape | ||
|
2026-05-07 in 79 days |
ARVN | Earnings | — | — | — | MAY 7 2026 9 days 📊 Earnings Arvinas Q1 2026 Earnings $ARVN Arvinas / Pfizer Q1 2026 earni | ||
|
2026-05-07 in 79 days |
RLAY | Earnings | — | — | — | MAY 7 2026 9 days 📊 Earnings Relay Therapeutics Q1 2026 Earnings $RLAY Relay Therapeutics | ||
|
2026-05-07 in 79 days |
PRAX | Earnings | — | — | — | MAY 7 2026 9 days 📊 Earnings Praxis Precision Medicines Q1 2026 Earnings $PRAX Praxis Prec | ||
|
2026-05-07 in 79 days |
GERN | Earnings | — | — | — | MAY 7 2026 9 days 📊 Earnings Geron Corporation Q1 2026 Earnings $GERN Geron Corporation Q1 | ||
|
2026-05-07 in 79 days |
OTSKF | Trial | Phase 3 | — | $2B | Primary completion for Sibeprenlimab 400 mg trial (NCT05248646) in Immunoglobulin A Nephro | ||
|
2026-05-07 in 79 days |
GILD | Earnings | — | — | — | Gilead Sciences announced it will release first quarter 2026 financial results on May 7, 2 | ||
|
2026-05-08 in 80 days |
RYTM | Earnings | — | — | — | MAY 8 2026 10 days 📊 Earnings Rhythm Pharmaceuticals Q1 2026 Earnings $RYTM Rhythm Pharmac | ||
|
2026-05-08 in 80 days |
VERA | Earnings | — | — | — | MAY 8 2026 10 days 📊 Earnings Vera Therapeutics Q1 2026 Earnings $VERA Vera Therapeutics Q | ||
|
2026-05-08 in 80 days |
PTGX | Earnings | 3 | — | — | MAY 8 2026 10 days 📊 Earnings Protagonist Therapeutics Q1 2026 Earnings $PTGX Protagonist | ||
|
2026-05-08 in 80 days |
INCY | Trial | Phase 2 | — | $3B | Primary completion for INCB177054 trial (NCT06873789) in Solid Tumors | ||
|
2026-05-08 in 80 days |
AZN | Trial | Phase 2 | — | $15B | Primary completion for AZD3470 trial (NCT06137144) in Lymphoma | ||
|
2026-05-09 in 81 days |
LNTH | PDUFA | NDA | — | — | For Prostate cancer. NDA filing. Extracted from SEC filing: 8-K | ||
|
2026-05-09 in 81 days |
OTSKF | Trial | Phase 3 | — | $1B | Primary completion for JNT-517 Tablet trial (NCT06637514) in Phenylketonuria (PKU) | ||
|
2026-05-10 in 82 days |
CLCS | Trial | Phase 2 | — | $800M | Primary completion for mesenchymal stem cells trial (NCT06416709) in Lung Injury | ||
|
2026-05-11 in 83 days |
NVS | Trial | Phase 2 | — | $300M | Primary completion for CPK850 trial (NCT03374657) in Retinitis Pigmentosa | ||
|
2026-05-11 in 83 days |
ALPMY | Trial | Phase 2 | — | $3B | Primary completion for enfortumab vedotin (EV) trial (NCT03288545) in Carcinoma, Transitio | ||
|
2026-05-11 in 83 days |
DSKYF | Earnings | — | — | — | Daiichi Sankyo delayed its full-year earnings report from April 27 to May 11, with the fiv | ||
|
2026-05-12 in 84 days |
SVA | Trial | Phase 3 | — | $8B | Primary completion for Sinovac PCV13 trial (NCT06617715) in Pneumococcal Infectious Diseas | ||
|
2026-05-12 in 84 days |
AGIO | PDUFA | NDA | — | — | For pyruvate kinase deficiency. NDA filing. Extracted from SEC filing: 8-K | ||
|
2026-05-12 in 84 days |
HCM | Trial | Phase 2 | — | $6B | Primary completion for HMPL-760 planned dose 1 trial (NCT06601504) in Relapsed/Refractory | ||
|
2026-05-13 in 85 days |
REGN | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT06161441) in Resectable Non-small Cell Lung Ca | ||
|
2026-05-13 in 85 days |
REGN | Trial | Phase 3 | — | $1B | Primary completion for Cemiplimab trial (NCT06161441) in Resectable Non-small Cell Lung Ca | ||
|
2026-05-13 in 85 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Placebo trial (NCT06161441) in Resectable Non-small Cell Lung Cance | ||
|
2026-05-13 in 85 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Fianlimab trial (NCT06161441) in Resectable Non-small Cell Lung Can | ||
|
2026-05-13 in 85 days |
VRCA | Other | — | — | — | For Basal Cell Carcinoma. Verrica Pharmaceuticals announced acceptance of a late-breaking | ||
|
2026-05-14 in 86 days |
AZNCF | Trial | Phase 3 | — | $3B | Primary completion for AZD0901 trial (NCT06346392) in Gastric Cancer | ||
|
2026-05-14 in 86 days |
AZNCF | Trial | Phase 3 | — | $3B | Primary completion for Ramucirumab+ paclitaxel trial (NCT06346392) in Gastric Cancer | ||
|
2026-05-14 in 86 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for Eplontersen trial (NCT06194825) in Transthyretin Amyloid Cardiomyop | ||
|
2026-05-14 in 86 days |
BIIB | Trial | Phase 2 | — | $15B | Primary completion for BIIB080 trial (NCT05399888) in Mild Cognitive Impairment Due to Alz | ||
|
2026-05-14 in 86 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Entrectinib trial (NCT02568267) in Breast Cancer | ||
|
2026-05-15 in 87 days |
VRDN | Trial Readout | 3 | — | $2B | MAY 15 2026 17 days 🔬 Trial Readout (elegrobart (VRDN-003)) $VRDN Viridian Therapeutics Ac | ||
|
2026-05-15 in 87 days |
RLAY | Trial Readout | 2 | — | $6B | MAY 15 2026 17 days 🔬 Trial Readout (zovegalisib (RLY-2608)) $RLAY Relay Therapeutics PIK3 | ||
|
2026-05-15 in 87 days |
NMRA | Trial | Phase 3 | — | $15B | Primary completion for NMRA-335140 trial (NCT06058013) in Major Depressive Disorder | ||
|
2026-05-15 in 87 days |
JHPCY | Trial | Phase 3 | — | $500M | Primary completion for Remimazolam Tosilate for injection trial (NCT07036419) in Operative | ||
|
2026-05-15 in 87 days |
ARWR | Trial | Phase 3 | — | $3B | Primary completion for Plozasiran Injection trial (NCT06347133) in Hypertriglyceridemia | ||
|
2026-05-15 in 87 days |
ALC | Trial | Phase 2 | — | $4B | Primary completion for Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution trial (NCT0 | ||
|
2026-05-15 in 87 days |
SNY | Trial | Phase 3 | — | $1B | Primary completion for Venglustat (GZ402671) trial (NCT05280548) in Fabry Disease | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 3 | — | $800M | Primary completion for BL-B01D1 trial (NCT06405425) in Urothelial Carcinoma | ||
|
2026-05-15 in 87 days |
CODX | Trial | Phase 3 | — | $6B | Primary completion for ELIXCYTE trial (NCT05526001) in Knee Osteoarthritis | ||
|
2026-05-15 in 87 days |
EXEL | Trial | Phase 3 | — | $1B | Primary completion for XL092 trial (NCT05425940) in Colorectal Cancer | ||
|
2026-05-15 in 87 days |
ALC | Trial | Phase 3 | — | $2B | Primary completion for Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution trial (NCT0 | ||
|
2026-05-15 in 87 days |
MNMD | Trial | Phase 3 | — | $8B | Primary completion for MM120 (LSD D-Tartrate) trial (NCT06741228) in Generalized Anxiety D | ||
|
2026-05-15 in 87 days |
ITCI | Trial | Phase 3 | — | $15B | Primary completion for Lumateperone trial (NCT06462612) in Bipolar Disorder, Manic | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 3 | — | $18B | Primary completion for Eribulin trial (NCT06343948) in HR+HER2- Breast Cancer | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 3 | — | $2B | Primary completion for BL-M07D1 trial (NCT06316531) in HER2-positive Breast Cancer | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 3 | — | $2B | Primary completion for Irinotecan trial (NCT06304974) in Esophageal Squamous Cell Carcinom | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed+Cisplatin or Carboplatin trial (NCT06382116) in Non-smal | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for T-DM1 trial (NCT06316531) in HER2-positive Breast Cancer | ||
|
2026-05-15 in 87 days |
BHVN | Trial | Phase 3 | — | $5B | Primary completion for BHV-7000 trial (NCT06309966) in Focal Epilepsy | ||
|
2026-05-15 in 87 days |
EXEL | Trial | Phase 3 | — | $8B | Primary completion for Regorafenib trial (NCT05425940) in Colorectal Cancer | ||
|
2026-05-15 in 87 days |
JNGHF | Trial | Phase 3 | — | $800M | Primary completion for SHR2554; Chidamide analog tablets trial (NCT06122389) in Relapsed/R | ||
|
2026-05-15 in 87 days |
GRFS | Trial | Phase 3 | — | $2B | Primary completion for Xembify trial (NCT05645107) in Hypogammaglobulinemia | ||
|
2026-05-15 in 87 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Ubrogepant trial (NCT05125302) in Migraine | ||
|
2026-05-15 in 87 days |
TNGX | Trial | Phase 2 | — | $4B | Primary completion for TNG462 trial (NCT05732831) in Locally Advanced Solid Tumor | ||
|
2026-05-15 in 87 days |
SKBBY | Trial | Phase 2 | — | $5B | Primary completion for PD-1 trial (NCT06405425) in Urothelial Carcinoma | ||
|
2026-05-15 in 87 days |
GILD | Trial | Phase 3 | — | $2B | Primary completion for Lenacapavir Injection trial (NCT06513312) in Pre-Exposure Prophylax | ||
|
2026-05-15 in 87 days |
ALT | Trial | Phase 2 | — | $8B | Primary completion for Pemvidutide trial (NCT06987513) in Alcohol Use Disorder (AUD) | ||
|
2026-05-15 in 87 days |
EVMN | Trial | Phase 2 | — | $3B | Primary completion for EVO756 trial (NCT06873516) in Chronic Spontaneous Urticaria | ||
|
2026-05-15 in 87 days |
ARWR | Trial | Phase 2 | — | $25B | Primary completion for ARO-INHBE trial (NCT06700538) in Obesity | ||
|
2026-05-15 in 87 days |
GILD | Trial | Phase 3 | — | $5B | Primary completion for Sacituzumab Govitecan-hziy trial (NCT05101096) in Advanced Solid Tu | ||
|
2026-05-15 in 87 days |
SBFM | Trial | Phase 2 | — | $8B | Primary completion for Clifutinib Besylate trial (NCT05133882) in Acute Myeloid Leukemia, | ||
|
2026-05-15 in 87 days |
LLY | Trial | Phase 2 | — | $15B | Primary completion for Mevidalen trial (NCT06538116) in Alzheimer Disease | ||
|
2026-05-15 in 87 days |
CODX | Trial | Phase 2 | — | $100M | Primary completion for Test Product HY07121 trial (NCT06639256) in Safety | ||
|
2026-05-15 in 87 days |
BLCO | Trial | Phase 2 | — | $6B | Primary completion for BL1107 Low dose trial (NCT07168902) in Glaucoma | ||
|
2026-05-15 in 87 days |
AGIO | Trial | Phase 2 | — | $4B | Primary completion for Tebapivat trial (NCT06924970) in Sickle Cell Disease | ||
|
2026-05-15 in 87 days |
ENTX | Trial | Phase 2 | — | $900M | Primary completion for EBP05 trial (NCT05965167) in Hypoparathyroidism | ||
|
2026-05-15 in 87 days |
WST | Trial | Phase 2 | — | $1B | Primary completion for RVU120 (SEL120) trial (NCT06243458) in Low Risk Myelodysplastic Syn | ||
|
2026-05-15 in 87 days |
GILD | Trial | Phase 2 | — | $2B | Primary completion for Emtricitabine/tenofovir disoproxil fumarate (F/TDF) trial (NCT06513 | ||
|
2026-05-15 in 87 days |
GLUE | Trial | Phase 2 | — | $18B | Primary completion for Oral MRT-2359 trial (NCT05546268) in NSCLC | ||
|
2026-05-18 in 90 days |
REGN | Trial | Phase 2 | — | $25B | Primary completion for Trevogrumab-Part A trial (NCT06299098) in Obesity | ||
|
2026-05-18 in 90 days |
REGN | Trial | Phase 3 | — | $400M | Primary completion for Garetosmab trial (NCT06299098) in Obesity | ||
|
2026-05-20 in 92 days |
MRK | Trial | Phase 2 | — | $4B | Primary completion for coformulation pembrolizumab/quavonlimab trial (NCT04938817) in Smal | ||
|
2026-05-21 in 93 days |
PBM | Trial | Phase 2 | — | $2B | Primary completion for Psilocybin therapy trial (NCT07072728) in Adjustment Disorder | ||
|
2026-05-23 in 95 days |
PFE | Trial | Phase 2 | — | $8B | Primary completion for Multivalent Pneumococcal Vaccine - Formulation 1 trial (NCT06182124 | ||
|
2026-05-25 in 97 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for Topical corticosteroids trial (NCT06241118) in Dermatitis Atopic | ||
|
2026-05-25 in 97 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for Amlitelimab trial (NCT06241118) in Dermatitis Atopic | ||
|
2026-05-25 in 97 days |
UCBJY | Trial | Phase 3 | — | $8B | Primary completion for Bimekizumab trial (NCT04009499) in Psoriatic Arthritis | ||
|
2026-05-25 in 97 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for Topical tacrolimus or pimecrolimus trial (NCT06241118) in Dermatiti | ||
|
2026-05-25 in 97 days |
AZNCF | Trial | Phase 2 | — | $50B | Primary completion for AZD6234 trial (NCT06862791) in Obesity or Overweight | ||
|
2026-05-25 in 97 days |
AZN | Trial | Phase 2 | — | $25B | Primary completion for AZD9550 trial (NCT06862791) in Obesity or Overweight | ||
|
2026-05-27 in 99 days |
IPSEY | Trial | Phase 3 | — | $3B | Primary completion for Placebo trial (NCT04336722) in Biliary Atresia | ||
|
2026-05-27 in 99 days |
SNY | Trial | Phase 3 | — | $5B | Primary completion for RSVt Vaccine trial (NCT06252285) in RSV Immunisation | ||
|
2026-05-27 in 99 days |
MRNA | Trial | Phase 3 | — | $4B | Primary completion for mRNA-1345 trial (NCT06143046) in Respiratory Syncytial Virus | ||
|
2026-05-27 in 99 days |
AZNCF | Trial | Phase 2 | — | $8B | Primary completion for AZD6234 trial (NCT06851858) in Endocrinology | ||
|
2026-05-28 in 100 days |
SNY | Trial | Phase 2 | — | $5B | Primary completion for Pandemic flu H5 HA mRNA SD2 vaccine trial (NCT06907511) in Pandemic | ||
|
2026-05-29 in 101 days |
NVS | Trial | Phase 3 | — | $11B | Primary completion for Ribociclib trial (NCT03701334) in Early Breast Cancer | ||
|
2026-05-29 in 101 days |
AZNCF | Trial | Phase 3 | — | $20B | Primary completion for Benralizumab trial (NCT06465485) in Severe Eosinophilic Asthma | ||
|
2026-05-29 in 101 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Durvalumab trial (NCT03682068) in Unresectable Locally Advanced Uro | ||
|
2026-05-29 in 101 days |
DVAX | Trial | Phase 2 | — | $100M | Primary completion for rF1V-1018 trial (NCT07207408) in Prevention of Pneumonic Plague Res | ||
|
2026-05-29 in 101 days |
VRTX | Trial | Phase 2 | — | $15B | Primary completion for VX-264 trial (NCT05791201) in Type 1 Diabetes | ||
|
2026-05-29 in 101 days |
AAPG | Other | — | — | — | For cancer. Ascentage Pharma announced six abstracts from clinical studies of three cancer | ||
|
2026-05-30 in 102 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Alectinib trial (NCT03194893) in Neoplasms | ||
|
2026-05-30 in 102 days |
VNDA | Trial | Phase 3 | — | $300M | Primary completion for Tradipitant trial (NCT06138613) in Motion Sickness | ||
|
2026-05-30 in 102 days |
ANRO | Trial | Phase 2 | — | $8B | Primary completion for DR10624 Injection trial (NCT07024212) in MASLD | ||
|
2026-05-31 in 103 days |
TEVA | Trial | Phase 3 | — | $20B | Primary completion for Fp/ABS trial (NCT06664619) in Asthma | ||
|
2026-05-31 in 103 days |
RHHBY | Trial | Phase 3 | — | $7B | Primary completion for Lenalidomide trial (NCT04712097) in Relapsed or Refractory Follicul | ||
|
2026-05-31 in 103 days |
RHHBY | Trial | Phase 3 | — | $25B | Primary completion for Rituximab trial (NCT04712097) in Relapsed or Refractory Follicular | ||
|
2026-05-31 in 103 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Mosunetuzumab trial (NCT04712097) in Relapsed or Refractory Follicu | ||
|
2026-05-31 in 103 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Tociluzumab trial (NCT04712097) in Relapsed or Refractory Follicula | ||
|
2026-05-31 in 103 days |
STA | Trial | Phase 2 | — | $15B | Primary completion for Lenalidomide trial (NCT06087653) in Multiple Myeloma | ||
|
2026-05-31 in 103 days |
PFE | Trial | Phase 3 | — | $5B | Primary completion for disitamab vedotin trial (NCT06003231) in Carcinoma, Non-Small-Cell | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Belzutifan trial (NCT04626479) in Carcinoma, Renal Cell | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04626479) in Carcinoma, Renal Cell | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 2 | — | $15B | Primary completion for MK-4830 trial (NCT04626518) in Carcinoma, Renal Cell | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Pembrolizumab/Quavonlimab trial (NCT04626479) in Carcinoma, Renal C | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Lenvatinib trial (NCT04626479) in Carcinoma, Renal Cell | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 3 | — | $7B | Primary completion for Favezelimab/Pembrolizumab trial (NCT04626479) in Carcinoma, Renal C | ||
|
2026-05-31 in 103 days |
MRK | Trial | Phase 2 | — | $6B | Primary completion for Vibostolimab/Pembrolizumab trial (NCT04626479) in Carcinoma, Renal | ||
|
2026-05-31 in 103 days |
RHHBY | Trial | Phase 2 | — | $1B | Primary completion for Tominersen trial (NCT05686551) in Huntington Disease | ||
|
2026-05-31 in 103 days |
AAPG | Trial | Phase 2 | — | $300M | Primary completion for APG-2575 trial (NCT04496349) in T-Prolymphocytic Leukemia | ||
|
2026-05-31 in 103 days |
AAPG | Trial | Phase 2 | — | $8B | Primary completion for APG-115 trial (NCT04496349) in T-Prolymphocytic Leukemia | ||
|
2026-05-31 in 103 days |
OTSKF | Trial | Phase 2 | — | $4B | Primary completion for IV Decitabine trial (NCT06091267) in Myelodysplastic Syndromes | ||
|
2026-05-31 in 103 days |
SVA | Trial | Phase 2 | — | $2B | Primary completion for Low-dose experimental vaccine trial (NCT07400003) in Herpes Zoster | ||
|
2026-06-01 in 173 days |
MRUS | Trial Readout | 2 | — | $3B | JUN 1 2026 34 days 🔬 Trial Readout (zenocutuzumab) $MRUS Merus NV NRG1 fusion-positive NSC | ||
|
2026-06-01 in 173 days |
RHHBY | Trial Readout | 3 | — | $9B | JUN 1 2026 34 days 🔬 Trial Readout (giredestrant + everolimus — ...) $RHHBY Roche / Genent | ||
|
2026-06-01 in 173 days |
JNGHF | Trial | Phase 3 | — | $2B | Primary completion for SHR7280 tablets trial (NCT05442827) in Uterine Fibroids With Menorr | ||
|
2026-06-01 in 173 days |
ARDX | Trial | Phase 3 | — | $4B | Primary completion for Tenapanor 50 MG trial (NCT05643534) in Irritable Bowel Syndrome Wit | ||
|
2026-06-01 in 173 days |
HNSPF | Trial | Phase 3 | — | $10B | Primary completion for HS-20117 trial (NCT06417008) in Non-Squamous Non-Small Cell Lung Ca | ||
|
2026-06-01 in 173 days |
MOLN | Trial | Phase 3 | — | $300M | Primary completion for Short regimen of benznidazole trial (NCT04897516) in Chagas Disease | ||
|
2026-06-01 in 173 days |
OTSKF | Trial | Phase 3 | — | $15B | Primary completion for Centanafadine trial (NCT06973577) in ADHD | ||
|
2026-06-01 in 173 days |
PFE | Trial | Phase 3 | — | $4B | Primary completion for Cetuximab trial (NCT05217446) in Metastatic Colorectal Cancer | ||
|
2026-06-01 in 173 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for REGN7508 trial (NCT06299111) in Venous Thromboembolism | ||
|
2026-06-01 in 173 days |
REGN | Trial | Phase 2 | — | $8B | Primary completion for REGN9933 trial (NCT06299111) in Venous Thromboembolism | ||
|
2026-06-01 in 173 days |
MRTX | Trial | Phase 2 | — | $15B | Primary completion for Adagrasib oral dose of 400 mg twice daily tablets trial (NCT0560957 | ||
|
2026-06-01 in 173 days |
ARCT | Trial | Phase 2 | — | $200M | Primary completion for ARCT-810 trial (NCT06488313) in OTC Deficiency | ||
|
2026-06-01 in 173 days |
CASI | Trial | Phase 2 | — | $2B | Primary completion for CID-103 trial (NCT07017725) in Chronic Immune Thrombocytopenia | ||
|
2026-06-01 in 173 days |
ZNTL | Other | — | — | — | For Platinum-Resistant Ovarian Cancer. Zentalis Pharmaceuticals has received abstract acce | ||
|
2026-06-02 in 174 days |
NVO | Trial | Phase 3 | — | $35B | Primary completion for Tirzepatide trial (NCT06534411) in Diabetes Mellitus, Type 2 | ||
|
2026-06-02 in 174 days |
UCBJY | Trial | Phase 3 | — | $1B | Primary completion for zilucoplan (RA101495) trial (NCT04225871) in Generalized Myasthenia | ||
|
2026-06-02 in 174 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Durvalumab trial (NCT04550260) in Esophageal Squamous Cell Carcinom | ||
|
2026-06-02 in 174 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for cisplatin + fluorouracil trial (NCT04550260) in Esophageal Squamous | ||
|
2026-06-03 in 175 days |
CYTK | AdCom | — | 85% | $4B | JUN 3 2026 36 days 🏛️ AdCom MYQORZO (aficamten) $CYTK Cytokinetics Obstructive hypertrophi | ||
|
2026-06-03 in 175 days |
CYTK | AdCom | — | 85% | — | JUN 3 2026 36 days 🏛️ AdCom MYQORZO (aficamten) $CYTK Cytokinetics Obstructive hypertrophi | ||
|
2026-06-05 in 177 days |
ARVN | PDUFA | — | 85% | $10B | JUN 5 2026 38 days 💊 PDUFA (vepdegestrant (ARV-471)) $ARVN Arvinas / Pfizer · NDA ESR1-mut | ||
|
2026-06-05 in 177 days |
SNY | Trial | Phase 3 | — | $500M | Primary completion for MenACYW135 polysaccharide vaccine trial (NCT07135986) in Meningococ | ||
|
2026-06-05 in 177 days |
SNY | Trial | Phase 3 | — | $500M | Primary completion for MenACYW conjugate vaccine trial (NCT07135986) in Meningococcal Infe | ||
|
2026-06-05 in 177 days |
TAK | Trial | Phase 3 | — | $8B | Primary completion for Zasocitinib trial (NCT06973291) in Plaque Psoriasis | ||
|
2026-06-05 in 177 days |
IPSEY | Trial | Phase 3 | — | $3B | Primary completion for Botulinum toxin type A trial (NCT06047457) in Episodic Migraine | ||
|
2026-06-05 in 177 days |
ARVN | PDUFA | — | 85% | — | JUN 5 2026 38 days 💊 PDUFA (vepdegestrant (ARV-471)) $ARVN Arvinas / Pfizer · NDA ESR1-mut | ||
|
2026-06-07 in 179 days |
ARGX | PDUFA | Phase 3 | — | $500M | For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K | ||
|
2026-06-08 in 180 days |
ABBV | PDUFA | — | 90% | $6B | JUN 8 2026 41 days 💊 PDUFA (cendakimab) $ABBV AbbVie / Arena Pharma · NDA Eosinophilic eso | ||
|
2026-06-08 in 180 days |
RYTM | PDUFA | NDA | — | — | For Obesity caused by genetic deficiencies. NDA filing. Extracted from SEC filing: 8-K | ||
|
2026-06-08 in 180 days |
UCBJY | Trial | Phase 3 | — | $1B | Primary completion for rozanolixizumab trial (NCT06149559) in Generalized Myasthenia Gravi | ||
|
2026-06-08 in 180 days |
SNYNF | Trial | Phase 3 | — | $500M | Primary completion for Dupilumab trial (NCT06687980) in Lichen Simplex Chronicus | ||
|
2026-06-08 in 180 days |
REGN | Trial | Phase 3 | — | $2B | Primary completion for Placebo trial (NCT06161441) in Resectable Non-small Cell Lung Cance | ||
|
2026-06-08 in 180 days |
ABBV | PDUFA | — | 90% | — | JUN 8 2026 41 days 💊 PDUFA (cendakimab) $ABBV AbbVie / Arena Pharma · NDA Eosinophilic eso | ||
|
2026-06-09 in 181 days |
NVO | Trial | Phase 3 | — | $45B | Primary completion for Ziltivekimab B trial (NCT05021835) in Cardiovascular Risk | ||
|
2026-06-09 in 181 days |
NVS | Trial | Phase 2 | — | $2B | Primary completion for KAE609 (Cipargamin) trial (NCT05750628) in Uncomplicated Plasmodium | ||
|
2026-06-09 in 181 days |
NVS | Trial | Phase 2 | — | $2B | Primary completion for INE963 trial (NCT05750628) in Uncomplicated Plasmodium Falciparum M | ||
|
2026-06-11 in 183 days |
GSK | Trial | Phase 3 | — | $2B | Primary completion for BLU-5937 trial (NCT05600777) in Cough | ||
|
2026-06-11 in 183 days |
TKPHF | Trial | Phase 2 | — | $2B | Primary completion for TAK-755 trial (NCT05714969) in Thrombotic Thrombocytopenic Purpura | ||
|
2026-06-12 in 184 days |
AZN | Trial | Phase 2 | — | $8B | Primary completion for AZD7798 trial (NCT06450197) in Moderate to Severe Crohn's Disease | ||
|
2026-06-14 in 186 days |
GMAB | Trial | Phase 3 | — | $5B | Primary completion for Epcoritamab trial (NCT05660967) in Diffuse Large B-Cell Lymphoma | ||
|
2026-06-15 in 187 days |
CYTK | Trial Readout | 3 | — | $4B | JUN 15 2026 48 days 🔬 Trial Readout MYQORZO (aficamten — ACACIA-HCM) $CYTK Cytokinetics No | ||
|
2026-06-15 in 187 days |
COGT | Trial Readout | 2 | — | $4B | JUN 15 2026 48 days 🔬 Trial Readout (bezuclastinib) $COGT Cogent Biosciences Advanced syst | ||
|
2026-06-15 in 187 days |
AKBA | Trial | Phase 3 | — | $4B | Primary completion for Erythropoiesis-Stimulating Agent (ESA) trial (NCT06901505) in Anemi | ||
|
2026-06-15 in 187 days |
TLX | Trial | Phase 3 | — | $2B | Primary completion for 68Ga-PSMA-11 trial (NCT07052214) in PCA | ||
|
2026-06-15 in 187 days |
IONS | Trial | Phase 3 | — | $2B | Primary completion for ION363 trial (NCT04768972) in Amyotrophic Lateral Sclerosis | ||
|
2026-06-15 in 187 days |
AKBA | Trial | Phase 3 | — | $12B | Primary completion for Vadadustat trial (NCT06901505) in Anemia of Chronic Kidney Disease | ||
|
2026-06-15 in 187 days |
GNLX | Trial | Phase 3 | — | $4B | Primary completion for olvimulogene nanivacirepvec trial (NCT05281471) in Platinum-resista | ||
|
2026-06-15 in 187 days |
VNDA | Trial | Phase 3 | — | $8B | Primary completion for Tasimelteon trial (NCT04652882) in Sleep Wake Disorders | ||
|
2026-06-15 in 187 days |
CYTK | Trial | Phase 3 | — | $4B | Primary completion for Aficamten trial (NCT06081894) in Symptomatic Non-Obstructive Hypert | ||
|
2026-06-15 in 187 days |
POCI | Trial | Phase 3 | — | $2B | Primary completion for 1mg elsunersen trial (NCT07019922) in Epileptic Encephalopathy | ||
|
2026-06-15 in 187 days |
ARWR | Trial | Phase 3 | — | $3B | Primary completion for Plozasiran Injection trial (NCT06347016) in Severe Hypertriglycerid | ||
|
2026-06-15 in 187 days |
FOLD | Trial | Phase 3 | — | $400M | Primary completion for Miglustat trial (NCT03911505) in Pompe Disease (Late-onset) | ||
|
2026-06-15 in 187 days |
RNXT | Trial | Phase 3 | — | $2B | Primary completion for nab-paclitaxel trial (NCT03257033) in Locally Advanced Pancreatic C | ||
|
2026-06-15 in 187 days |
CGON | Trial | Phase 3 | — | $4B | Primary completion for Cretostimogene Grenadenorepvec trial (NCT06111235) in Non Muscle In | ||
|
2026-06-15 in 187 days |
FOLD | Trial | Phase 3 | — | $400M | Primary completion for Cipaglucosidase Alfa trial (NCT03911505) in Pompe Disease (Late-ons | ||
|
2026-06-15 in 187 days |
SKBBY | Trial | Phase 3 | — | $800M | Primary completion for BL-B01D1 trial (NCT06437509) in Extensive-stage Small-cell Lung Can | ||
|
2026-06-15 in 187 days |
SKBBY | Trial | Phase 3 | — | $18B | Primary completion for Eribulin trial (NCT06382142) in Triple-Negative Breast Cancer | ||
|
2026-06-15 in 187 days |
SKBBY | Trial | Phase 3 | — | $5B | Primary completion for Vinorelbine trial (NCT06382142) in Triple-Negative Breast Cancer | ||
|
2026-06-15 in 187 days |
ALKS | Trial | Phase 2 | — | $2B | Primary completion for ALKS 2680 trial (NCT06843590) in Idiopathic Hypersomnia | ||
|
2026-06-15 in 187 days |
SKBBY | Trial | Phase 2 | — | $4B | Primary completion for PD-1 monoclonal antibody trial (NCT06437509) in Extensive-stage Sma | ||
|
2026-06-15 in 187 days |
ARWR | Trial | Phase 2 | — | $18B | Primary completion for ARO-DIMERPA trial (NCT07223658) in Hyperlipidemia; Mixed | ||
|
2026-06-15 in 187 days |
JHPCY | Trial | Phase 2 | — | $2B | Primary completion for HRS-9190 trial (NCT07404579) in Neuromuscular Blockade | ||
|
2026-06-15 in 187 days |
BIVI | Trial | Phase 3 | — | $12B | Primary completion for NE3107 trial (NCT06847191) in Long COVID | ||
|
2026-06-15 in 187 days |
CLDX | Trial | Phase 3 | — | $400M | Primary completion for barzolvolimab trial (NCT06366750) in Prurigo Nodularis | ||
|
2026-06-15 in 187 days |
INCY | Trial | Phase 3 | — | $2B | Primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma | ||
|
2026-06-15 in 187 days |
SPRY | Trial | Phase 2 | — | $2B | Primary completion for 0.5 mg epinephrine trial (NCT06927999) in Urticaria Chronic | ||
|
2026-06-15 in 187 days |
JNGHF | Trial | Phase 2 | — | $15B | Primary completion for HRS-5041 tablets trial (NCT06568094) in Prostate Cancer | ||
|
2026-06-15 in 187 days |
FDMT | Trial | Phase 2 | — | $500M | Primary completion for 4D-125 IVT Injection trial (NCT04517149) in X-Linked Retinitis Pigm | ||
|
2026-06-15 in 187 days |
FDMT | Trial | Phase 2 | — | $1B | Primary completion for 4D-310 trial (NCT05629559) in Fabry Disease | ||
|
2026-06-15 in 187 days |
ALKS | Trial | Phase 3 | — | $15B | Primary completion for Placebo trial (NCT06843590) in Idiopathic Hypersomnia | ||
|
2026-06-15 in 187 days |
SGIOY | Trial | Phase 3 | — | $3B | Primary completion for Naldemedine trial (NCT05588323) in Opioid-Induced Constipation (OIC | ||
|
2026-06-15 in 187 days |
GRFS | Trial | Phase 2 | — | $6B | Primary completion for GRF312 5% trial (NCT07264517) in Dry Eye Disease | ||
|
2026-06-15 in 187 days |
ZBIO | Trial | Phase 3 | — | $400M | Primary completion for Obexelimab trial (NCT06559163) in Systemic Lupus Erythematosus | ||
|
2026-06-15 in 187 days |
JNGHF | Trial | Phase 2 | — | $8B | Primary completion for SHR- A1811 trial (NCT05896020) in Gynaecological Malignancies | ||
|
2026-06-15 in 187 days |
SYRE | Trial | Phase 2 | — | $8B | Primary completion for SPY001 trial (NCT07012395) in Ulcerative Colitis | ||
|
2026-06-15 in 187 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Tirzepatide trial (NCT06143956) in Obesity | ||
|
2026-06-15 in 187 days |
ARQT | Trial | Phase 2 | — | $8B | Primary completion for ARQ-151 cream 0.05% trial (NCT06998056) in Atopic Dermatitis (Eczem | ||
|
2026-06-15 in 187 days |
ADVB | Trial | Phase 2 | — | $8B | Primary completion for ABD-3001 trial (NCT05601726) in Acute Myeloid Leukemia, Adult | ||
|
2026-06-15 in 187 days |
INCY | Trial | Phase 2 | — | $12B | Primary completion for ICS-LABA trial (NCT05851443) in Moderate to Severe Asthma | ||
|
2026-06-15 in 187 days |
IMRX | Trial | Phase 2 | — | $2B | Primary completion for IMM-1-104 Monotherapy (Treatment Group A) trial (NCT05585320) in Ad | ||
|
2026-06-15 in 187 days |
CADL | Trial | Phase 3 | — | $15B | Primary completion for aglatimagene besadenovec + valacyclovir trial (NCT07332000) in Pros | ||
|
2026-06-15 in 187 days |
TVTX | Trial | Phase 3 | — | $200M | Primary completion for Pegtibatinase trial (NCT03406611) in Homocystinuria | ||
|
2026-06-15 in 187 days |
LLY | Trial | Phase 2 | — | $25B | Primary completion for LY3841136 trial (NCT06603571) in Obesity | ||
|
2026-06-15 in 187 days |
JNGHF | Trial | Phase 2 | — | $2B | Primary completion for STSA-1301 subcutaneous injection trial (NCT06929299) in Primary Imm | ||
|
2026-06-15 in 187 days |
SVA | Trial | Phase 2 | — | $2B | Primary completion for Oral hexavalent reassortant rotavirus attenuated live vaccine trial | ||
|
2026-06-15 in 187 days |
CODX | Trial | Phase 2 | — | $15B | Primary completion for BL-M07D1 trial (NCT06445400) in HER2-positive Breast Cancer | ||
|
2026-06-15 in 187 days |
HRTX | Trial | Phase 2 | — | $300M | Primary completion for B10 L-BPA Injection trial (NCT06668987) in Meningioma | ||
|
2026-06-15 in 187 days |
LLY | Trial | Phase 2 | — | $25B | Primary completion for LY3305677 trial (NCT06143956) in Obesity | ||
|
2026-06-15 in 187 days |
EWTX | Trial | Phase 2 | — | $4B | Primary completion for EDG-7500 trial (NCT06347159) in Hypertrophic Cardiomyopathy | ||
|
2026-06-15 in 187 days |
ARDX | Trial | Phase 3 | — | $2B | Primary completion for Tenapanor trial (NCT06553547) in Irritable Bowel Syndrome with Cons | ||
|
2026-06-15 in 187 days |
BIOE | Trial | Phase 2 | — | $2B | Primary completion for TCMCB07 trial (NCT06937177) in Cancer Weight Loss | ||
|
2026-06-15 in 187 days |
MIRM | Trial | Phase 2 | — | $1B | Primary completion for Volixibat trial (NCT04663308) in Primary Sclerosing Cholangitis | ||
|
2026-06-15 in 187 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Mirvetuximab Soravtansine trial (NCT06365853) in Recurrent Ovarian | ||
|
2026-06-15 in 187 days |
VSTM | Trial | Phase 2 | — | $15B | Primary completion for avutometinib and sotorasib trial (NCT05074810) in Non Small Cell Lu | ||
|
2026-06-15 in 187 days |
CLNN | Trial | Phase 2 | — | $2B | Primary completion for CNMAu8 trial (NCT05299658) in Amyotrophic Lateral Sclerosis | ||
|
2026-06-15 in 187 days |
JNGHF | Trial | Phase 2 | — | $15B | Primary completion for HRS-1167 tablets trial (NCT06568094) in Prostate Cancer | ||
|
2026-06-16 in 188 days |
SNY | PDUFA | Phase 3 | — | $8B | For hemophilia. BLA filing. Extracted from SEC filing: 6-K | ||
|
2026-06-16 in 188 days |
BNTX | Trial | Phase 3 | — | $15B | Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose tri | ||
|
2026-06-16 in 188 days |
NVS | Trial | Phase 3 | — | $8B | Primary completion for Pertuzumab trial (NCT04208178) in Advanced HER2+Breast Cancer | ||
|
2026-06-17 in 189 days |
GSK | Trial | Phase 3 | — | $2B | Primary completion for Placebo trial (NCT05600777) in Cough | ||
|
2026-06-17 in 189 days |
NVS | Trial | Phase 2 | — | $6B | Primary completion for 68Ga-PSMA-11 trial (NCT06004661) in Metastatic Castration-Resistant | ||
|
2026-06-17 in 189 days |
AZN | Trial | Phase 2 | — | $12B | Primary completion for AZD8421 trial (NCT06188520) in ER+ HER2- Advanced Breast Cancer | ||
|
2026-06-17 in 189 days |
NVS | Trial | Phase 3 | — | $2B | Primary completion for AAA617 trial (NCT06004661) in Metastatic Castration-Resistant Prost | ||
|
2026-06-17 in 189 days |
OCUL | Other | — | — | — | Ocular Therapeutix announced it will host an investor day event on June 17, 2026. This is | ||
|
2026-06-18 in 190 days |
IMCR | PDUFA | Phase 3 | — | $8B | For unresectable or metastatic uveal melanoma. BLA filing. Extracted from SEC filing: 8-K | ||
|
2026-06-18 in 190 days |
EVFM | PDUFA | NDA | — | — | For Prevention of pregnancy. NDA filing. Extracted from SEC filing: 8-K | ||
|
2026-06-19 in 191 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Tozorakimab trial (NCT05624450) in Viral Lung Infection and Acute R | ||
|
2026-06-22 in 194 days |
INCY | Trial | Phase 3 | — | $5B | Primary completion for itacitinib trial (NCT04640025) in Myelofibrosis | ||
|
2026-06-22 in 194 days |
CLRB | Trial | Phase 2 | — | $1B | Primary completion for Iopofosine I 131 single dose trial (NCT02952508) in Waldenstrom Mac | ||
|
2026-06-26 in 198 days |
IPSEY | Trial | Phase 3 | — | $300M | Primary completion for Odevixibat trial (NCT04336722) in Biliary Atresia | ||
|
2026-06-26 in 198 days |
IPSEY | Trial | Phase 3 | — | $1B | Primary completion for Elafibranor trial (NCT06383403) in Primary Biliary Cholangitis | ||
|
2026-06-27 in 199 days |
WVE | Trial | Phase 2 | — | $1B | Primary completion for WVE-N531 trial (NCT04906460) in Duchenne Muscular Dystrophy | ||
|
2026-06-28 in 200 days |
MNKD | PDUFA | Phase 3 | — | $8B | For Type 1 diabetes. NDA filing. Extracted from SEC filing: 8-K | ||
|
2026-06-29 in 201 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for Amlitelimab trial (NCT06407934) in Dermatitis Atopic | ||
|
2026-06-29 in 201 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level trial (NCT0 | ||
|
2026-06-29 in 201 days |
TVRD | Trial | Phase 2 | — | $4B | Primary completion for TTI-101 trial (NCT05440708) in Hepatocellular Carcinoma | ||
|
2026-06-30 in 202 days |
AZN | PDUFA | — | 85% | $12B | JUN 30 2026 63 days 💊 PDUFA (camizestrant (AZD9833)) $AZN AstraZeneca · NDA HR+/HER2- adva | ||
|
2026-06-30 in 202 days |
AZN | PDUFA | — | 92% | $8B | JUN 30 2026 63 days 💊 PDUFA Truqap (supplemental) (capivasertib (Truqap) + abir...) $AZN A | ||
|
2026-06-30 in 202 days |
MBRX | Trial Readout | 2B/3 | — | $2B | JUN 30 2026 63 days 🔬 Trial Readout (annamycin + cytarabine (AnnA...) $MBRX Moleculin Biot | ||
|
2026-06-30 in 202 days |
VRDN | PDUFA | — | 88% | $2B | JUN 30 2026 63 days 💊 PDUFA (veligrotug) $VRDN Viridian Therapeutics · BLA Thyroid eye dis | ||
|
2026-06-30 in 202 days |
RICFY | Trial | 2 | — | $300M | Top-line results from Phase 2 trial of pasireotide | ||
|
2026-06-30 in 202 days |
AVDL | Trial | 3 | — | $300M | Data from Phase 3 trial of LUMRYZ (REVITALYZ) | ||
|
2026-06-30 in 202 days |
WVE | Trial | 1 | — | $25B | Three-month follow-up data from 600 mg Cohort 4 Phase 1 trial of WVE-007 (INLIGHT) | ||
|
2026-06-30 in 202 days |
CGEM | Trial | 1 | — | $8B | Initial data from Phase 1 study of CLN-978 (OUTRACE) | ||
|
2026-06-30 in 202 days |
KOD | Trial | 3 | — | $6B | Topline data from Phase 3 trial of KSI-501(DAYBREAK) | ||
|
2026-06-30 in 202 days |
LPCN | Trial | 1 | — | $6B | Topline data from Phase 1 trial of uTREAT | ||
|
2026-06-30 in 202 days |
RNA | Trial | 3 | — | $2B | Topline safety and efficacy results from Phase 3 trial of LPCN 1154 (oral brexanolone) | ||
|
2026-06-30 in 202 days |
ASND | Trial | 3 | — | $300M | Topline data from Phase 3 trial of delpacibart etedesiran (HARBOR) | ||
|
2026-06-30 in 202 days |
NXTC | Trial | — | — | $800M | 78-week data from Phase II Trial of TransCon CNP in combination with TransCon hGH (COACH) | ||
|
2026-06-30 in 202 days |
AQST | Trial | 1 | — | $5B | Data from Phase 1 open-label dose escalation study of SIM0505 (CDH6 ADC) | ||
|
2026-06-30 in 202 days |
CADL | Trial | 1 | — | $1B | Data readout from second Phase 1 trial of AQST-108 | ||
|
2026-06-30 in 202 days |
RAPP | Trial | 3 | — | $15B | Follow-up clinical data from phase 3 trial of Aglatimagene besadenovec (CAN-2409) | ||
|
2026-06-30 in 202 days |
CHRS | Trial | 2a | — | $3B | 8-week follow-up results from Phase 2a trial of RAP-219 | ||
|
2026-06-30 in 202 days |
OCS | Trial | 1b | — | $3B | Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripali | ||
|
2026-06-30 in 202 days |
MIRM | Trial | 3 | — | $4B | Top-line data readout from Phase 3 trial of OCS-01 (DIAMOND) | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Enzalutamide trial (NCT05112965) in Neoplasms | ||
|
2026-06-30 in 202 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for carboplatin trial (NCT05911295) in Urothelial Carcinoma | ||
|
2026-06-30 in 202 days |
PFE | Trial | Phase 3 | — | $8B | Primary completion for gemcitabine trial (NCT05911295) in Urothelial Carcinoma | ||
|
2026-06-30 in 202 days |
TLX | Trial | Phase 3 | — | $4B | Primary completion for 89Zr-TLX250 PET/CT trial (NCT06750419) in Clear Cell Renal Cell Car | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $5B | Primary completion for Paclitaxel trial (NCT05112965) in Neoplasms | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT05112965) in Neoplasms | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Bevacizumab trial (NCT05112965) in Neoplasms | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Atezolizumab trial (NCT05047250) in Non-Small Cell Lung Cancer | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Lenvatinib trial (NCT04770896) in Unresectable Hepatocellular Carci | ||
|
2026-06-30 in 202 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Durvalumab trial (NCT05221840) in Non-Small Cell Lung Cancer | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Inavolisib trial (NCT05646862) in Breast Cancer | ||
|
2026-06-30 in 202 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for cisplatin trial (NCT05911295) in Urothelial Carcinoma | ||
|
2026-06-30 in 202 days |
SBFM | Trial | Phase 2 | — | $15B | Primary completion for Matching placebo trial (NCT07042126) in Dermatitis, Atopic | ||
|
2026-06-30 in 202 days |
LRVIY | Trial | Phase 3 | — | $2B | Primary completion for Moxifloxacin / Dexamethasone Ophthalmic Solution trial (NCT07305987 | ||
|
2026-06-30 in 202 days |
CELC | Trial | Phase 3 | — | $18B | Primary completion for Palbociclib trial (NCT05501886) in Breast Cancer | ||
|
2026-06-30 in 202 days |
JNJ | Trial | Phase 3 | — | $2B | Primary completion for JNJ-90301900 (NBTXR3) trial (NCT04892173) in Locally Advanced Head | ||
|
2026-06-30 in 202 days |
SBFM | Trial | Phase 3 | — | $15B | Primary completion for 611 trial (NCT07042126) in Dermatitis, Atopic | ||
|
2026-06-30 in 202 days |
OLMA | Trial | Phase 3 | — | $18B | Primary completion for Palazestrant trial (NCT06016738) in Breast Cancer | ||
|
2026-06-30 in 202 days |
KALV | Trial | Phase 3 | — | $2B | Primary completion for KVD900 600 mg trial (NCT05511922) in Hereditary Angioedema | ||
|
2026-06-30 in 202 days |
ZBIO | Trial | Phase 3 | — | $400M | Primary completion for Obexelimab trial (NCT05786573) in Warm Autoimmune Hemolytic Anemia | ||
|
2026-06-30 in 202 days |
KALV | Trial | Phase 3 | — | $2B | Primary completion for KVD900 300 mg trial (NCT05505916) in Hereditary Angioedema | ||
|
2026-06-30 in 202 days |
BGNE | Trial | Phase 3 | — | $5B | Primary completion for Pamiparib capsule trial (NCT03519230) in Ovarian Cancer | ||
|
2026-06-30 in 202 days |
PFE | Trial | Phase 3 | — | $5B | Primary completion for disitamab vedotin trial (NCT05911295) in Urothelial Carcinoma | ||
|
2026-06-30 in 202 days |
CELC | Trial | Phase 3 | — | — | Primary completion for Gedatolisib trial (NCT05501886) in Breast Cancer | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $7B | Primary completion for Entrectinib trial (NCT02650401) in Solid Tumors | ||
|
2026-06-30 in 202 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Sacituzumab tirumotecan trial (NCT06637423) in Non-Muscle Invasive | ||
|
2026-06-30 in 202 days |
AZNCF | Trial | Phase 2 | — | $15B | Primary completion for Oleclumab trial (NCT06606847) in Non-Small Cell Lung Cancer | ||
|
2026-06-30 in 202 days |
NVS | Trial | Phase 2 | — | $5B | Primary completion for 68Ga-FAP-2286 trial (NCT04939610) in Solid Tumor | ||
|
2026-06-30 in 202 days |
MDNAF | Trial | Phase 2 | — | $4B | Primary completion for MDNA11 trial (NCT05086692) in Advanced Solid Tumor | ||
|
2026-06-30 in 202 days |
LGVN | Trial | Phase 2 | — | $600M | Primary completion for Lomecel-B medicinal signaling cells trial (NCT04925024) in Hypoplas | ||
|
2026-06-30 in 202 days |
KYTX | PDUFA | — | — | — | Kyverna plans to file a U.S. NDA in H1 2026 for its CAR-T therapy in stiff person syndrome | ||
|
2026-06-30 in 202 days |
GNTA | Trial | Phase 2 | — | $2B | Primary completion for Temferon trial (NCT03866109) in Glioblastoma Multiforme | ||
|
2026-06-30 in 202 days |
MRTX | Trial | Phase 2 | — | $3B | Primary completion for MRTX0902 trial (NCT05578092) in Solid Tumor | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 2 | — | $8B | Primary completion for RO7247669 trial (NCT04140500) in Solid Tumors | ||
|
2026-06-30 in 202 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Giredestrant trial (NCT05634499) in Endometrial Cancer | ||
|
2026-06-30 in 202 days |
MRK | Trial | Phase 3 | — | $3B | Primary completion for Rescue medication trial (NCT06637423) in Non-Muscle Invasive Bladde | ||
|
2026-06-30 in 202 days |
MAIA | Trial | Phase 3 | — | $15B | Primary completion for 6-Thio-2'-Deoxyguanosine trial (NCT05208944) in Carcinoma, Non-Smal | ||
|
2026-06-30 in 202 days |
DYN | PDUFA | — | — | — | For Duchenne muscular dystrophy. Dyne Therapeutics plans to file for FDA approval of z-ros | ||
|
2026-06-30 in 202 days |
ENGN | Trial | Phase 2 | — | $2B | Primary completion for EG-70 (phase 1) trial (NCT04752722) in Superficial Bladder Cancer | ||
|
2026-06-30 in 202 days |
CGTX | Trial | Phase 2 | — | $1B | Primary completion for golexanolone trial (NCT07304843) in Primary Biliary Cholangitis (PB | ||
|
2026-06-30 in 202 days |
NVS | Trial | Phase 2 | — | $3B | Primary completion for Asciminib Pediatric formulation group trial (NCT04925479) in Myeloi | ||
|
2026-06-30 in 202 days |
AURA | Trial | Phase 3 | — | $300M | For bladder cancer. Aura Biosciences presented Phase 3 bel-sar data momentum at the TD Cow | ||
|
2026-06-30 in 202 days |
MRNA | Trial | Phase 2 | — | $2B | Primary completion for mRNA-1468 trial (NCT05701800) in Herpes Zoster | ||
|
2026-06-30 in 202 days |
MRTX | Trial | Phase 3 | — | $13B | Primary completion for MRTX849 trial (NCT05578092) in Solid Tumor | ||
|
2026-06-30 in 202 days |
DNTH | Trial | Phase 3 | — | $2B | Primary completion for DNTH103 trial (NCT06537999) in Multifocal Motor Neuropathy | ||
|
2026-06-30 in 202 days |
MRK | Trial | Phase 3 | — | $5B | Primary completion for Olaparib trial (NCT04123366) in Solid Tumors | ||
|
2026-06-30 in 202 days |
FCHS | Trial | — | — | — | BiopharmaDive identifies 10 clinical trials expected to deliver readouts in H1 2026 across | ||
|
2026-06-30 in 202 days |
AZN | PDUFA | — | 85% | — | JUN 30 2026 63 days 💊 PDUFA (camizestrant (AZD9833)) $AZN AstraZeneca · NDA HR+/HER2- adva | ||
|
2026-06-30 in 202 days |
VRDN | PDUFA | — | 88% | — | JUN 30 2026 63 days 💊 PDUFA (veligrotug) $VRDN Viridian Therapeutics · BLA Thyroid eye dis | ||
|
2026-07-01 in 273 days |
MBRX | Trial Readout | 2B/3 | — | $1B | JUL 1 2026 64 days 🔬 Trial Readout (annamycin (AnnAraC)) $MBRX Moleculin Biotech Relapsed/ | ||
|
2026-07-01 in 273 days |
GSK | Trial | Phase 3 | — | $500M | Primary completion for Investigational varicella vaccine trial (NCT06693895) in Chickenpox | ||
|
2026-07-01 in 273 days |
ALMS | Trial | Phase 3 | — | $12B | Primary completion for ESK-001 trial (NCT05966480) in SLE | ||
|
2026-07-01 in 273 days |
ANRO | Trial | Phase 3 | — | $22B | Primary completion for LM-302 trial (NCT05934331) in Malignant Neoplasms of Digestive Orga | ||
|
2026-07-01 in 273 days |
AZNCF | Trial | Phase 3 | — | $4B | Primary completion for Durvalumab trial (NCT06040099) in Hepatocellular Carcinoma (HCC) | ||
|
2026-07-02 in 274 days |
AMGN | Trial | Phase 2 | — | $2B | Primary completion for Docetaxel trial (NCT05094336) in Advanced MTAP-null Solid Tumors | ||
|
2026-07-02 in 274 days |
AMGN | Trial | Phase 2 | — | $3B | Primary completion for AMG 193 trial (NCT05094336) in Advanced MTAP-null Solid Tumors | ||
|
2026-07-06 in 278 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Cisplatin trial (NCT04380636) in Lung Neoplasms | ||
|
2026-07-06 in 278 days |
MRK | Trial | Phase 3 | — | $5B | Primary completion for Olaparib trial (NCT04380636) in Lung Neoplasms | ||
|
2026-07-06 in 278 days |
MRK | Trial | Phase 3 | — | $12B | Primary completion for Paclitaxel trial (NCT04380636) in Lung Neoplasms | ||
|
2026-07-06 in 278 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Carboplatin trial (NCT04380636) in Lung Neoplasms | ||
|
2026-07-06 in 278 days |
AZNCF | Trial | Phase 3 | — | $6B | Primary completion for Taxane trial (NCT04784715) in Breast Cancer; HER2-positive; Metasta | ||
|
2026-07-06 in 278 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Odronextamab trial (NCT03888105) in B-cell Non-Hodgkin Lymphoma (B- | ||
|
2026-07-06 in 278 days |
MRK | Trial | Phase 2 | — | $15B | Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointesti | ||
|
2026-07-07 in 279 days |
VERA | PDUFA | — | 88% | $8B | JUL 7 2026 70 days 💊 PDUFA (atacicept) $VERA Vera Therapeutics · BLA IgA nephropathy (IgAN | ||
|
2026-07-07 in 279 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Osimertinib trial (NCT06194448) in Lung Cancer | ||
|
2026-07-07 in 279 days |
VERA | PDUFA | — | 88% | — | JUL 7 2026 70 days 💊 PDUFA (atacicept) $VERA Vera Therapeutics · BLA IgA nephropathy (IgAN | ||
|
2026-07-08 in 280 days |
AZNCF | Trial | Phase 2 | — | $8B | Primary completion for AZD6234 trial (NCT06851858) in Endocrinology | ||
|
2026-07-09 in 281 days |
PHAR | Trial | Phase 3 | — | $500M | Primary completion for Leniolisib trial (NCT05693129) in APDS | ||
|
2026-07-09 in 281 days |
NVS | Trial | Phase 3 | — | $2B | Primary completion for Iptacopan trial (NCT04889430) in Atypical Hemolytic Uremic Syndrome | ||
|
2026-07-10 in 282 days |
SWTX | PDUFA | — | 93% | $2B | JUL 10 2026 73 days 💊 PDUFA (mirdametinib) $SWTX SpringWorks Therapeutics · NDA NF1-associ | ||
|
2026-07-10 in 282 days |
SNY | Trial | Phase 2 | — | $8B | Primary completion for SAR441344 IV trial (NCT05039840) in Systemic Lupus Erythematosus | ||
|
2026-07-10 in 282 days |
SWTX | PDUFA | — | 93% | — | JUL 10 2026 73 days 💊 PDUFA (mirdametinib) $SWTX SpringWorks Therapeutics · NDA NF1-associ | ||
|
2026-07-13 in 285 days |
PFE | Trial | Phase 3 | — | $6B | Primary completion for PF-06821497 trial (NCT06551324) in Metastatic Castrate Resistant Pr | ||
|
2026-07-13 in 285 days |
INCY | Trial | Phase 3 | — | $400M | Primary completion for Vehicle Cream trial (NCT06548360) in NonSegmental Vitiligo | ||
|
2026-07-13 in 285 days |
INCY | Trial | Phase 3 | — | $5B | Primary completion for Ruxolitinib trial (NCT06832618) in Atopic Dermatitis | ||
|
2026-07-13 in 285 days |
RHHBY | Trial | Phase 3 | — | $2B | Primary completion for Placebo trial (NCT06863961) in Atopic Dermatitis | ||
|
2026-07-13 in 285 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Afimkibart trial (NCT06863961) in Atopic Dermatitis | ||
|
2026-07-15 in 287 days |
SNGX | Trial | Phase 3 | — | $2B | Primary completion for Hypericin trial (NCT06470451) in CTCL/ Mycosis Fungoides | ||
|
2026-07-15 in 287 days |
SVA | Trial | Phase 3 | — | $1B | Primary completion for PROVARIX trial (NCT07475000) in Varicella (Chickenpox) | ||
|
2026-07-15 in 287 days |
VRDN | Trial | Phase 3 | — | $2B | Primary completion for VRDN-003 trial (NCT07155668) in Thyroid Eye Disease | ||
|
2026-07-15 in 287 days |
ABBV | Trial | Phase 3 | — | $300M | Primary completion for Adalimumab trial (NCT05814627) in Rheumatoid Arthritis | ||
|
2026-07-15 in 287 days |
BHVN | Trial | Phase 3 | — | $5B | Primary completion for BHV-7000 trial (NCT06425159) in Generalized Epilepsy | ||
|
2026-07-15 in 287 days |
LXRX | Trial | Phase 3 | — | $55B | Primary completion for Sotagliflozin trial (NCT06481891) in Obstructive Cardiomyopathy, Hy | ||
|
2026-07-15 in 287 days |
SKBBY | Trial | Phase 3 | — | $5B | Primary completion for Nab-paclitaxel trial (NCT06279364) in Triple Negative Breast Cancer | ||
|
2026-07-15 in 287 days |
SKBBY | Trial | Phase 3 | — | $6B | Primary completion for Paclitaxel trial (NCT06279364) in Triple Negative Breast Cancer | ||
|
2026-07-15 in 287 days |
SKBBY | Trial | Phase 3 | — | $8B | Primary completion for SI-B001 trial (NCT05943795) in Non-small Cell Lung Adenocarcinoma | ||
|
2026-07-15 in 287 days |
SNGX | Trial | Phase 3 | — | $1B | Primary completion for Placebo trial (NCT06470451) in CTCL/ Mycosis Fungoides | ||
|
2026-07-15 in 287 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for SKB264 trial (NCT06279364) in Triple Negative Breast Cancer | ||
|
2026-07-15 in 287 days |
CHHE | Trial | Phase 3 | — | $6B | Primary completion for IAH0968 trial (NCT06504732) in Stomach Neoplasms | ||
|
2026-07-15 in 287 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Upadacitinib trial (NCT05814627) in Rheumatoid Arthritis | ||
|
2026-07-15 in 287 days |
ONC | Trial | Phase 3 | — | $19B | Primary completion for Tislelizumab trial (NCT04164199) in Advanced Malignancies | ||
|
2026-07-15 in 287 days |
RARE | Trial | Phase 3 | — | $300M | Primary completion for GTX-102 trial (NCT06617429) in Angelman Syndrome | ||
|
2026-07-15 in 287 days |
LXRX | Trial | Phase 3 | — | $800M | Primary completion for Placebo trial (NCT06481891) in Obstructive Cardiomyopathy, Hypertro | ||
|
2026-07-15 in 287 days |
POCI | Trial | Phase 3 | — | $200M | Primary completion for 1.0mg/kg/day PRAX-562 trial (NCT07010471) in Developmental and Epil | ||
|
2026-07-15 in 287 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Bimatoprost SR trial (NCT03891446) in Open-Angle Glaucoma | ||
|
2026-07-15 in 287 days |
HRMY | Trial | Phase 3 | — | $300M | Primary completion for Pitolisant tablet trial (NCT06366464) in Prader-Willi Syndrome | ||
|
2026-07-15 in 287 days |
GSK | Trial | Phase 2 | — | $20B | Primary completion for GSK5784283 trial (NCT06748053) in Asthma | ||
|
2026-07-15 in 287 days |
ALPN | Trial | Phase 3 | — | $900M | Primary completion for povetacicept trial (NCT05757570) in Immune Thrombocytopenia | ||
|
2026-07-15 in 287 days |
SWTX | Trial | Phase 2 | — | $300M | Primary completion for Nirogacestat trial (NCT05348356) in Ovarian Granulosa-Stromal Tumor | ||
|
2026-07-15 in 287 days |
GILD | Trial | Phase 3 | — | $5B | Primary completion for Lenacapavir Tablet trial (NCT06101329) in Pre-Exposure Prophylaxis | ||
|
2026-07-15 in 287 days |
GILD | Trial | Phase 3 | — | $2B | Primary completion for Lenacapavir Injection trial (NCT06101329) in Pre-Exposure Prophylax | ||
|
2026-07-15 in 287 days |
GSK | Trial | Phase 3 | — | $31B | Primary completion for Paclitaxel trial (NCT06317311) in Carcinoma | ||
|
2026-07-15 in 287 days |
GSK | Trial | Phase 2 | — | $600M | Primary completion for Carboplatin trial (NCT06317311) in Carcinoma | ||
|
2026-07-15 in 287 days |
GSK | Trial | Phase 3 | — | $4B | Primary completion for Dostarlimab trial (NCT06317311) in Carcinoma | ||
|
2026-07-15 in 287 days |
SION | Trial | Phase 2 | — | $6B | Primary completion for SION-719 trial (NCT07108153) in Cystic Fibrosis (CF) | ||
|
2026-07-15 in 287 days |
DWTX | Trial | Phase 2 | — | $1B | Primary completion for Halneuron trial (NCT06848348) in Chemotherapy Induced Neuropathic P | ||
|
2026-07-15 in 287 days |
EVMN | Trial | Phase 2 | — | $3B | Primary completion for EVO756 trial (NCT07150845) in Atoptic Dermatitis | ||
|
2026-07-15 in 287 days |
RXRX | Trial | Phase 2 | — | $200M | Primary completion for REC-4881 trial (NCT05552755) in Familial Adenomatous Polyposis | ||
|
2026-07-15 in 287 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Telisotuzumab vedotin trial (NCT03539536) in Non-small Cell Lung Ca | ||
|
2026-07-15 in 287 days |
ARWR | Trial | Phase 2 | — | $25B | Primary completion for ARO-ALK7 trial (NCT06937203) in Obesity | ||
|
2026-07-15 in 287 days |
BIO | Trial | Phase 2 | — | $25B | Primary completion for VRB-101 trial (NCT07281937) in Obesity | ||
|
2026-07-15 in 287 days |
GILD | Trial | Phase 2 | — | $2B | Primary completion for Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) trial (NCT06101 | ||
|
2026-07-15 in 287 days |
JHPCY | Trial | Phase 2 | — | $500M | Primary completion for Tegileridine Fumarate lnjection trial (NCT07372924) in Abirritation | ||
|
2026-07-15 in 287 days |
CODX | Trial | Phase 2 | — | $15B | Primary completion for PD-1 Monoclonal Antibody trial (NCT06475300) in Non-small Cell Lung | ||
|
2026-07-15 in 287 days |
CODX | Trial | Phase 3 | — | $4B | Primary completion for BL-B01D1 trial (NCT06475300) in Non-small Cell Lung Cancer | ||
|
2026-07-15 in 287 days |
COAG | Trial | Phase 2 | — | $300M | Primary completion for Sutacimig trial (NCT07347249) in Congenital Factor VII Deficiency | ||
|
2026-07-15 in 287 days |
DCPH | Trial | Phase 3 | — | $2B | Primary completion for Vimseltinib trial (NCT03069469) in Advanced Malignant Neoplasm | ||
|
2026-07-15 in 287 days |
GPCR | Trial | Phase 2 | — | $50B | Primary completion for Aleniglipron trial (NCT06693843) in Obesity, Overweight, or Chronic | ||
|
2026-07-16 in 288 days |
TKPHF | Trial | Phase 2 | — | $300M | Primary completion for TAK-360 trial (NCT06812078) in Idiopathic Hypersomnia | ||
|
2026-07-17 in 289 days |
CELC | PDUFA | — | 90% | $1B | JUL 17 2026 80 days 💊 PDUFA (gedatolisib) $CELC Celcuity · NDA HR+/HER2-/PIK3CA wild-type | ||
|
2026-07-17 in 289 days |
TEVA | Trial | Phase 3 | — | $20B | Primary completion for TEV-56248 trial (NCT06052267) in Asthma | ||
|
2026-07-17 in 289 days |
CELC | PDUFA | — | 90% | — | JUL 17 2026 80 days 💊 PDUFA (gedatolisib) $CELC Celcuity · NDA HR+/HER2-/PIK3CA wild-type | ||
|
2026-07-20 in 292 days |
PTGX | Trial Readout | 3 | — | $500M | JUL 20 2026 83 days 🔬 Trial Readout (rusfertide) $PTGX Protagonist Therapeutics Polycythem | ||
|
2026-07-21 in 293 days |
AMYT | Trial | Phase 3 | — | $400M | Primary completion for metreleptin trial (NCT05164341) in Partial Lipodystrophy | ||
|
2026-07-21 in 293 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Palbociclib trial (NCT05468697) in Renal Cell Carcinoma | ||
|
2026-07-21 in 293 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Belzutifan trial (NCT05468697) in Renal Cell Carcinoma | ||
|
2026-07-22 in 294 days |
INCY | Trial | Phase 2 | — | $5B | Primary completion for INCB099280 trial (NCT05879822) in Advanced Solid Tumor | ||
|
2026-07-23 in 295 days |
BNTX | Trial | Phase 3 | — | $15B | Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose tri | ||
|
2026-07-23 in 295 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04123366) in Solid Tumors | ||
|
2026-07-23 in 295 days |
REGN | Trial | Phase 2 | — | $500M | Primary completion for REGN7544 trial (NCT06608901) in Sepsis-Induced Hypotension | ||
|
2026-07-23 in 295 days |
REGN | Trial | Phase 2 | — | $2B | Primary completion for PB trial (NCT06608901) in Sepsis-Induced Hypotension | ||
|
2026-07-24 in 296 days |
AZN | Trial | Phase 3 | — | $55B | Primary completion for Placebo trial (NCT06151964) in Overweight and Obesity | ||
|
2026-07-24 in 296 days |
AZN | Trial | Phase 2 | — | $25B | Primary completion for AZD9550 trial (NCT06151964) in Overweight and Obesity | ||
|
2026-07-25 in 297 days |
BIIB | PDUFA | — | 92% | $15B | JUL 25 2026 88 days 💊 PDUFA Leqembi (lecanemab) $BIIB Eisai / Biogen · sNDA Subcutaneous f | ||
|
2026-07-25 in 297 days |
BIIB | PDUFA | — | 92% | — | JUL 25 2026 88 days 💊 PDUFA Leqembi (lecanemab) $BIIB Eisai / Biogen · sNDA Subcutaneous f | ||
|
2026-07-26 in 298 days |
NVAX | Trial | Phase 3 | — | $15B | Primary completion for CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvan | ||
|
2026-07-27 in 299 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Olaparib trial (NCT04884360) in Ovarian Cancer | ||
|
2026-07-28 in 300 days |
UCBJY | Trial | Phase 3 | — | $8B | Primary completion for Bimekizumab trial (NCT04436640) in Axial Spondyloarthritis | ||
|
2026-07-29 in 301 days |
NVO | PDUFA | — | 80% | $1B | JUL 29 2026 92 days 💊 PDUFA (denecimig (Mim8)) $NVO Novo Nordisk · BLA Hemophilia A (with | ||
|
2026-07-29 in 301 days |
NVS | Trial | Phase 2 | — | $5B | Primary completion for JDQ443 trial (NCT05358249) in KRAS G12C Mutant Solid Tumors | ||
|
2026-07-29 in 301 days |
NVO | PDUFA | — | 80% | — | JUL 29 2026 92 days 💊 PDUFA (denecimig (Mim8)) $NVO Novo Nordisk · BLA Hemophilia A (with | ||
|
2026-07-30 in 302 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for ritonavir trial (NCT05261139) in COVID-19 | ||
|
2026-07-30 in 302 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for nirmatrelvir trial (NCT05261139) in COVID-19 | ||
|
2026-07-30 in 302 days |
SBFM | Trial | Phase 3 | — | $2B | Primary completion for SSGJ-707 trial (NCT06980272) in Advanced Non-Small Cell Lung Cancer | ||
|
2026-07-30 in 302 days |
SBFM | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT06980272) in Advanced Non-Small Cell Lung C | ||
|
2026-07-30 in 302 days |
QNRX | Trial | Phase 3 | — | $200M | Primary completion for QRX003, 4% Lotion trial (NCT06953466) in Netherton Syndrome | ||
|
2026-07-30 in 302 days |
MRNA | Trial | Phase 3 | — | $4B | Primary completion for mRNA-1345 trial (NCT06067230) in Respiratory Syncytial Virus | ||
|
2026-07-30 in 302 days |
JNGHF | Trial | Phase 3 | — | $4B | Primary completion for TACE+Camrelizumab+Apatinib mesylate trial (NCT05320692) in Hepatoce | ||
|
2026-07-30 in 302 days |
BIO | Trial | Phase 2 | — | $2B | Primary completion for Recombinant Human Proteoglycan 4 trial (NCT07118241) in Sjögren's S | ||
|
2026-07-30 in 302 days |
JNGHF | Trial | Phase 3 | — | $3B | Primary completion for JSKN003 trial (NCT05744427) in Advanced Solid Tumor | ||
|
2026-07-30 in 302 days |
MRTX | Trial | Phase 3 | — | $15B | Primary completion for Adagrasib trial (NCT05853575) in Advanced Cancer | ||
|
2026-07-31 in 303 days |
BNTX | Trial | Phase 3 | — | $15B | Primary completion for BNT162b2 Vaccine trial (NCT07300839) in COVID-19 | ||
|
2026-07-31 in 303 days |
BNTX | Trial | Phase 3 | — | $6B | Primary completion for Placebo trial (NCT07300839) in COVID-19 | ||
|
2026-07-31 in 303 days |
BNTX | Trial | Phase 3 | — | $15B | Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19 | ||
|
2026-07-31 in 303 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT06698042) in Lung Cancer | ||
|
2026-07-31 in 303 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for BCG trial (NCT03711032) in High-risk Non-muscle Invasive Bladder Ca | ||
|
2026-07-31 in 303 days |
JAZZ | Trial | Phase 3 | — | $8B | Primary completion for Tislelizumab trial (NCT05152147) in Gastric Neoplasms | ||
|
2026-07-31 in 303 days |
BIIB | Trial | Phase 3 | — | $1B | Primary completion for Nusinersen trial (NCT04729907) in Muscular Atrophy, Spinal | ||
|
2026-07-31 in 303 days |
WXI | Trial | Phase 3 | — | $55B | Primary completion for Semaglutide trial (NCT07064486) in Type 2 Diabetes (T2DM) | ||
|
2026-07-31 in 303 days |
WXI | Trial | Phase 3 | — | $25B | Primary completion for BGM0504 trial (NCT07064486) in Type 2 Diabetes (T2DM) | ||
|
2026-07-31 in 303 days |
JAZZ | Trial | Phase 3 | — | $15B | Primary completion for Zanidatamab trial (NCT05152147) in Gastric Neoplasms | ||
|
2026-07-31 in 303 days |
JNGHF | Trial | Phase 3 | — | $4B | Primary completion for Rivoceranib (Apatinib) trial (NCT04639180) in Hepatocellular Carcin | ||
|
2026-07-31 in 303 days |
JAZZ | Trial | Phase 2 | — | $8B | Primary completion for Capecitabine trial (NCT05152147) in Gastric Neoplasms | ||
|
2026-07-31 in 303 days |
JNGHF | Trial | Phase 3 | — | $6B | Primary completion for Camrelizumab trial (NCT04639180) in Hepatocellular Carcinoma (HCC) | ||
|
2026-07-31 in 303 days |
LLY | Other | — | — | — | For Obesity. The FDA has requested that Eli Lilly submit cardiovascular and liver safety d | ||
|
2026-07-31 in 303 days |
BIOE | Trial | Phase 2 | — | $12B | Primary completion for JMT202 injection trial (NCT07140809) in Hypertriglyceridemia | ||
|
2026-07-31 in 303 days |
HNSPF | Trial | Phase 3 | — | $2B | Primary completion for HS-20093 trial (NCT06112704) in Advanced Solid Tumor | ||
|
2026-07-31 in 303 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Dapagliflozin trial (NCT06942910) in Chronic Kidney Disease With Hi | ||
|
2026-07-31 in 303 days |
RHHBY | Trial | Phase 2 | — | $8B | Primary completion for ZN-A-1041 trial (NCT05593094) in Advanced Solid Tumors | ||
|
2026-07-31 in 303 days |
RHHBY | Trial | Phase 2 | — | $8B | Primary completion for Axitinib trial (NCT05805501) in Renal Cell Carcinoma | ||
|
2026-07-31 in 303 days |
AZN | Trial | Phase 3 | — | $5B | Primary completion for Zibotentan/Dapagliflozin trial (NCT06942910) in Chronic Kidney Dise | ||
|
2026-07-31 in 303 days |
BCYC | Trial | Phase 2 | — | $6B | Primary completion for BT5528 trial (NCT04180371) in Advanced Solid Tumor Historically Kno | ||
|
2026-07-31 in 303 days |
BIOE | Trial | Phase 2 | — | $8B | Primary completion for NECVAX-NEO1 trial (NCT06631079) in Solid Tumor | ||
|
2026-07-31 in 303 days |
ALPMY | Trial | Phase 2 | — | — | Primary completion for oxaliplatin trial (NCT03505320) in Pharmacokinetics of Zolbetuximab | ||
|
2026-07-31 in 303 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Tiragolumab trial (NCT05805501) in Renal Cell Carcinoma | ||
|
2026-07-31 in 303 days |
RHHBY | Trial | Phase 2 | — | $5B | Primary completion for Tobemstomig trial (NCT05805501) in Renal Cell Carcinoma | ||
|
2026-07-31 in 303 days |
ALPMY | Trial | Phase 3 | — | $2B | Primary completion for zolbetuximab trial (NCT03505320) in Pharmacokinetics of Zolbetuxima | ||
|
2026-08-01 in 373 days |
BMRN | Trial | Phase 3 | — | $150M | Primary completion for Placebo trial (NCT06455059) in Hypochondroplasia | ||
|
2026-08-01 in 373 days |
BMRN | Trial | Phase 3 | — | $300M | Primary completion for Vosoritide trial (NCT06455059) in Hypochondroplasia | ||
|
2026-08-01 in 373 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for SC Tulisokibart trial (NCT06052059) in Ulcerative Colitis | ||
|
2026-08-01 in 373 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for IV Tulisokibart trial (NCT06052059) in Ulcerative Colitis | ||
|
2026-08-01 in 373 days |
CBDY | PDUFA | NDA | — | $400M | For Recurrent Respiratory Papillomatosis (RRP). BLA filing. AI-extracted from news: INOVIO | ||
|
2026-08-01 in 373 days |
RHHBY | Trial | Phase 2 | — | $10B | Primary completion for Zifibancimig trial (NCT04567303) in Macular Degeneration | ||
|
2026-08-01 in 373 days |
BBOT | Trial | Phase 2 | — | $7B | Primary completion for BBT-207 trial (NCT05920135) in EGFR Mutant Advanced Non-Small Cell | ||
|
2026-08-01 in 373 days |
MRNA | PDUFA | Phase 3 | — | $8B | For Influenza vaccine. FDA reversed its Refusal-to-File decision on Moderna's mRNA-1010 fl | ||
|
2026-08-01 in 373 days |
MRNA | Trial | Phase 2 | — | $800M | Primary completion for mRNA-1647 trial (NCT05683457) in Cytomegalovirus Infection | ||
|
2026-08-03 in 375 days |
DSKYF | Trial | Phase 3 | — | $16B | Primary completion for T-DXd trial (NCT06174987) in Advanced Cancer | ||
|
2026-08-04 in 376 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for Amlitelimab trial (NCT06557772) in Coeliac Disease | ||
|
2026-08-05 in 377 days |
SNYNF | Trial | Phase 3 | — | $20B | Primary completion for Amlitelimab trial (NCT06557772) in Coeliac Disease | ||
|
2026-08-05 in 377 days |
MRNA | PDUFA | Phase 3 | — | $15B | For influenza. The FDA reversed its earlier Refusal-to-File decision and agreed to review | ||
|
2026-08-05 in 377 days |
VRNA | Trial | Phase 2 | — | $15B | Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmon | ||
|
2026-08-06 in 378 days |
AZN | Trial | Phase 2 | — | $50B | Primary completion for AZD6234 trial (NCT07017179) in Obesity/Overweight | ||
|
2026-08-07 in 379 days |
UCBJY | Trial | Phase 3 | — | $8B | Primary completion for Bimekizumab trial (NCT04436640) in Axial Spondyloarthritis | ||
|
2026-08-07 in 379 days |
SNY | Trial | Phase 3 | — | $2B | Primary completion for Mometasone furoate nasal spray (MFNS) trial (NCT06691113) in Chroni | ||
|
2026-08-07 in 379 days |
SNY | Trial | Phase 3 | — | $15B | Primary completion for Itepekimab (SAR440340) trial (NCT06691113) in Chronic Rhinosinusiti | ||
|
2026-08-08 in 380 days |
SNY | Trial | Phase 3 | — | $800M | Primary completion for Yellow fever vaccine (live) trial (NCT07103148) in Yellow Fever Imm | ||
|
2026-08-08 in 380 days |
SNY | Trial | Phase 3 | — | $800M | Primary completion for Measles, combinations with mumps and rubella, live attenuated trial | ||
|
2026-08-10 in 382 days |
INCY | Trial | Phase 3 | — | $300M | Primary completion for Ruxolitinib Cream trial (NCT06548360) in NonSegmental Vitiligo | ||
|
2026-08-13 in 385 days |
ZEAL | Trial | Phase 2 | — | $25B | Primary completion for Petrelintide trial (NCT06926842) in Overweight | ||
|
2026-08-13 in 385 days |
JSPR | Trial | Phase 2 | — | $3B | Primary completion for Briquilimab trial (NCT06736262) in Urticaria Chronic | ||
|
2026-08-14 in 386 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for Nexium 20mg trial (NCT05267613) in Erosive Esophagitis | ||
|
2026-08-15 in 387 days |
IMVT | Trial Readout | 3 | — | $2B | AUG 15 2026 109 days 🔬 Trial Readout (batoclimab) $IMVT Immunovant Thyroid eye disease (TE | ||
|
2026-08-15 in 387 days |
HELP | Trial | Phase 3 | — | $15B | Primary completion for CYB003 trial (NCT06564818) in Major Depressive Disorder | ||
|
2026-08-15 in 387 days |
JAZZ | Trial | Phase 3 | — | $300M | Primary completion for Dordaviprone (ONC201) trial (NCT05580562) in H3 K27M | ||
|
2026-08-15 in 387 days |
SNYNF | Trial | Phase 3 | — | $8B | Primary completion for Fitusiran trial (NCT03974113) in Hemophilia | ||
|
2026-08-15 in 387 days |
PHVS | Trial | Phase 3 | — | $2B | Primary completion for Deucrictibant trial (NCT06669754) in Hereditary Angioedema (HAE) | ||
|
2026-08-15 in 387 days |
ENSCW | Trial | Phase 3 | — | $3B | Primary completion for PF614 capsule trial (NCT06602271) in Postoperative Pain, Acute | ||
|
2026-08-15 in 387 days |
GRFS | Trial | Phase 3 | — | $2B | Primary completion for Alpha-1 MP trial (NCT01983241) in Pulmonary Emphysema in Alpha-1 PI | ||
|
2026-08-15 in 387 days |
ENSCW | Trial | Phase 2 | — | $6B | Primary completion for Placebo trial (NCT06602271) in Postoperative Pain, Acute | ||
|
2026-08-15 in 387 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Upadacitinib 15mg Dose trial (NCT06389136) in Atopic Dermatitis | ||
|
2026-08-15 in 387 days |
SBFM | Trial | Phase 3 | — | $2B | Primary completion for Lerotinib trial (NCT04415853) in Esophageal Cancer | ||
|
2026-08-15 in 387 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Venetoclax trial (NCT03539744) in Multiple Myeloma | ||
|
2026-08-15 in 387 days |
LLY | Trial | Phase 3 | — | $25B | Primary completion for Retatrutide trial (NCT06260722) in Diabetes Mellitus, Type 2 | ||
|
2026-08-15 in 387 days |
KOD | Trial | Phase 3 | — | $6B | Primary completion for Aflibercept trial (NCT06556368) in Wet Age-related Macular Degenera | ||
|
2026-08-15 in 387 days |
LLY | Trial | Phase 3 | — | $55B | Primary completion for Semaglutide trial (NCT06260722) in Diabetes Mellitus, Type 2 | ||
|
2026-08-15 in 387 days |
IMVT | Trial | Phase 3 | — | $2B | Primary completion for Batoclimab trial (NCT05517447) in Thyroid Eye Disease | ||
|
2026-08-15 in 387 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Pomalidomide trial (NCT03539744) in Multiple Myeloma | ||
|
2026-08-15 in 387 days |
SLGL | Trial | Phase 3 | — | $200M | Primary completion for Patidegib Topical Gel trial (NCT06050122) in Gorlin Syndrome | ||
|
2026-08-15 in 387 days |
KPTI | Trial | Phase 3 | — | $8B | Primary completion for Selinexor trial (NCT05611931) in Endometrial Cancer | ||
|
2026-08-15 in 387 days |
BJDX | Trial | Phase 3 | — | $500M | Primary completion for Brelovitug 300 mg trial (NCT07298330) in Chronic Hepatitis D Infect | ||
|
2026-08-15 in 387 days |
EYPT | Trial | Phase 3 | — | $6B | Primary completion for Aflibercept (2.0 mg) trial (NCT06668064) in Wet Age Related Macular | ||
|
2026-08-15 in 387 days |
RNA | Trial | Phase 3 | — | $400M | Primary completion for AOC 1001 (del-desiran) trial (NCT06411288) in DM1 | ||
|
2026-08-15 in 387 days |
XENE | Trial | Phase 3 | — | $15B | Primary completion for Azetukalner trial (NCT06775379) in Major Depressive Disorder | ||
|
2026-08-15 in 387 days |
PCRX | Trial | Phase 3 | — | $2B | Primary completion for ZILRETTA trial (NCT06269705) in Glenohumeral Osteoarthritis | ||
|
2026-08-15 in 387 days |
EYPT | Trial | Phase 3 | — | $4B | Primary completion for EYP-1901 trial (NCT06668064) in Wet Age Related Macular Degeneratio | ||
|
2026-08-15 in 387 days |
KOD | Trial | Phase 3 | — | $6B | Primary completion for Tarcocimab tedromer trial (NCT06556368) in Wet Age-related Macular | ||
|
2026-08-15 in 387 days |
ACRS | Trial | Phase 2 | — | $8B | Primary completion for ATI-045 trial (NCT07011706) in Atopic Dermatitis | ||
|
2026-08-15 in 387 days |
ARGX | Trial | Phase 2 | — | $2B | Primary completion for ARGX-119 trial (NCT06441682) in Amyotrophic Lateral Sclerosis | ||
|
2026-08-15 in 387 days |
GILD | Trial | Phase 3 | — | $6B | Primary completion for Zimberelimab trial (NCT06727565) in Head and Neck Squamous Cell Car | ||
|
2026-08-15 in 387 days |
CRIS | Trial | Phase 2 | — | $8B | Primary completion for Ibrutinib trial (NCT03328078) in Relapsed Hematologic Malignancy | ||
|
2026-08-15 in 387 days |
LLY | Trial | Phase 2 | — | $8B | Primary completion for Mazdutide trial (NCT06817356) in Alcohol Use Disorder | ||
|
2026-08-15 in 387 days |
ACRS | Trial | Phase 2 | — | $3B | Primary completion for Placebo trial (NCT07011706) in Atopic Dermatitis | ||
|
2026-08-15 in 387 days |
MANE | Trial | Phase 3 | — | $3B | Primary completion for VDPHL01 trial (NCT06527365) in Androgenetic Alopecia | ||
|
2026-08-15 in 387 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for Ranibizumab trial (NCT04514653) in Neovascular Age-Related Macular | ||
|
2026-08-15 in 387 days |
KYTX | Trial | Phase 3 | — | $900M | Primary completion for Standard lymphodepletion regimen trial (NCT05938725) in Lupus Nephr | ||
|
2026-08-15 in 387 days |
MPLT | Trial | Phase 2 | — | $12B | Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia | ||
|
2026-08-15 in 387 days |
RIGL | Trial | Phase 2 | — | $1B | Primary completion for R906289 Monosodium (R289 Na) trial (NCT05308264) in Low Risk Myelod | ||
|
2026-08-15 in 387 days |
CORT | Trial | Phase 3 | — | $5B | Primary completion for Relacorilant 150 mg once daily (QD) trial (NCT06906341) in Ovarian | ||
|
2026-08-15 in 387 days |
PMVP | Trial | Phase 2 | — | $6B | Primary completion for rezatapopt trial (NCT04585750) in Advanced Solid Tumor | ||
|
2026-08-15 in 387 days |
GILD | Trial | Phase 3 | — | $15B | Primary completion for Domvanalimab trial (NCT06727565) in Head and Neck Squamous Cell Car | ||
|
2026-08-15 in 387 days |
ADVB | Trial | Phase 2 | — | — | Primary completion for Vodobatinib (K0706) capsules trial (NCT02629692) in Healthy (For Pa | ||
|
2026-08-15 in 387 days |
CPHI | Trial | Phase 2 | — | $45B | Primary completion for ASC30 tablets trial (NCT07321678) in T2DM (Type 2 Diabetes Mellitus | ||
|
2026-08-15 in 387 days |
SBFM | Trial | Phase 2 | — | $8B | Primary completion for Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody I | ||
|
2026-08-15 in 387 days |
CORT | Trial | Phase 3 | — | $4B | Primary completion for Nab-paclitaxel 80 mg/m^2 trial (NCT06906341) in Ovarian Cancer | ||
|
2026-08-15 in 387 days |
DCPH | Trial | Phase 2 | — | $4B | Primary completion for DCC-3084 trial (NCT06287463) in Advanced Solid Tumor | ||
|
2026-08-15 in 387 days |
BCYC | Trial | Phase 2 | — | $6B | Primary completion for Nivolumab trial (NCT04180371) in Advanced Solid Tumor Historically | ||
|
2026-08-15 in 387 days |
ANRO | Trial | Phase 2 | — | $15B | Primary completion for Placebo trial (NCT06656416) in Bipolar Disorder I or II With a Majo | ||
|
2026-08-15 in 387 days |
PEPG | Trial | Phase 2 | — | $300M | Primary completion for PGN-EDODM1 trial (NCT06667453) in Myotonic Dystrophy 1 | ||
|
2026-08-15 in 387 days |
ANRO | Trial | Phase 2 | — | $10B | Primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Maj | ||
|
2026-08-15 in 387 days |
IPIX | Trial | Phase 2 | — | $2B | Primary completion for S095029 trial (NCT06116136) in MSI-H/dMMR Gastroesophageal-junction | ||
|
2026-08-15 in 387 days |
CRIS | Trial | Phase 2 | — | $8B | Primary completion for Emavusertib trial (NCT03328078) in Relapsed Hematologic Malignancy | ||
|
2026-08-15 in 387 days |
SKBBY | Trial | Phase 2 | — | $15B | Primary completion for Osimertinib Mesylate Tablets trial (NCT06498986) in Non-small Cell | ||
|
2026-08-15 in 387 days |
SKBBY | Trial | Phase 3 | — | $800M | Primary completion for BL-B01D1 trial (NCT06498986) in Non-small Cell Lung Cancer | ||
|
2026-08-15 in 387 days |
IGC | Trial | Phase 2 | — | $15B | Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease | ||
|
2026-08-17 in 389 days |
PRAX | PDUFA | — | 90% | $1B | AUG 17 2026 111 days 💊 PDUFA (ulixacaltamide (PRAX-944)) $PRAX Praxis Precision Medicines | ||
|
2026-08-17 in 389 days |
PFE | Trial | Phase 2 | — | $12B | Primary completion for BAT trial (NCT05639647) in Gram-negative Bacterial Infections | ||
|
2026-08-17 in 389 days |
PFE | Trial | Phase 3 | — | $1B | Primary completion for ATM-AVI trial (NCT05639647) in Gram-negative Bacterial Infections | ||
|
2026-08-17 in 389 days |
PRAX | PDUFA | — | 90% | — | AUG 17 2026 111 days 💊 PDUFA (ulixacaltamide (PRAX-944)) $PRAX Praxis Precision Medicines | ||
|
2026-08-18 in 390 days |
BIO | Trial | Phase 3 | — | $5B | Primary completion for FDA018-ADC trial (NCT06519370) in Triple Negative Breast Cancer | ||
|
2026-08-18 in 390 days |
MRK | Trial | Phase 2 | — | $15B | Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointesti | ||
|
2026-08-19 in 391 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for etoposide trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-08-19 in 391 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for pemetrexed trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-08-19 in 391 days |
MRK | Trial | Phase 3 | — | $12B | Primary completion for pembrolizumab/vibostolimab trial (NCT05298423) in Carcinoma, Non-Sm | ||
|
2026-08-19 in 391 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Cisplatin trial (NCT04634877) in Endometrial Neoplasms | ||
|
2026-08-19 in 391 days |
AZN | Trial | Phase 3 | — | $8B | Primary completion for 5-Fluorouracil trial (NCT05489211) in Endometrial Cancer | ||
|
2026-08-19 in 391 days |
AZN | Trial | Phase 3 | — | $8B | Primary completion for Carboplatin trial (NCT05489211) in Endometrial Cancer | ||
|
2026-08-19 in 391 days |
AZN | Trial | Phase 2 | — | $4B | Primary completion for Leucovorin LV trial (NCT05489211) in Endometrial Cancer | ||
|
2026-08-19 in 391 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Volrustomig trial (NCT05489211) in Endometrial Cancer | ||
|
2026-08-19 in 391 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Capecitabine trial (NCT05489211) in Endometrial Cancer | ||
|
2026-08-19 in 391 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Datopotamab deruxtecan (Dato-DXd) trial (NCT05489211) in Endometria | ||
|
2026-08-19 in 391 days |
REGN | Trial | Phase 2 | — | $6B | Primary completion for REGN7075 trial (NCT04626635) in Advanced Solid Tumors | ||
|
2026-08-20 in 392 days |
KALV | AdCom | — | 85% | $1B | AUG 20 2026 114 days 🏛️ AdCom (donidalorsen) $KALV KalVista Pharmaceuticals Hereditary ang | ||
|
2026-08-20 in 392 days |
REGN | PDUFA | Phase 3 | — | $400M | For Fibrodysplasia Ossificans Progressiva (FOP). BLA filing. AI-extracted from news: Garet | ||
|
2026-08-20 in 392 days |
ARGX | PDUFA | Phase 3 | — | $1B | For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K | ||
|
2026-08-20 in 392 days |
AZNCF | Trial | Phase 2 | — | $8B | Primary completion for AZD7798 trial (NCT06681324) in Crohn's Disease | ||
|
2026-08-20 in 392 days |
TAK | Trial | Phase 2 | — | $300M | Primary completion for TAK-360 trial (NCT06952699) in Narcolepsy Type 2 | ||
|
2026-08-20 in 392 days |
KALV | AdCom | — | 85% | — | AUG 20 2026 114 days 🏛️ AdCom (donidalorsen) $KALV KalVista Pharmaceuticals Hereditary ang | ||
|
2026-08-21 in 393 days |
NVO | Trial | Phase 3 | — | $35B | Primary completion for Oral semaglutide trial (NCT07271251) in Type 2 Diabetes | ||
|
2026-08-21 in 393 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT06797869) in | ||
|
2026-08-22 in 394 days |
CAPR | PDUFA | — | 67% | $1B | AUG 22 2026 116 days 💊 PDUFA (deramiocel) $CAPR Capricor Therapeutics · BLA Duchenne muscu | ||
|
2026-08-22 in 394 days |
CAPR | PDUFA | — | 67% | — | AUG 22 2026 116 days 💊 PDUFA (deramiocel) $CAPR Capricor Therapeutics · BLA Duchenne muscu | ||
|
2026-08-23 in 395 days |
PFE | Trial | Phase 2 | — | $18B | Primary completion for PF-07220060 + PF-07104091 combination dose escalation trial (NCT052 | ||
|
2026-08-24 in 396 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for AZD9833 trial (NCT04711252) in ER-Positive HER2-Negative Breast Can | ||
|
2026-08-24 in 396 days |
UCBJY | Trial | Phase 3 | — | $15B | Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy | ||
|
2026-08-24 in 396 days |
RHHBY | Trial | Phase 3 | — | $25B | Primary completion for RO7204239 trial (NCT06965413) in Obesity | ||
|
2026-08-25 in 397 days |
JAZZ | PDUFA | NDA | — | — | SBLA filing. Extracted from: Jazz Pharmaceuticals Announces FDA Acceptance and Priority Re | ||
|
2026-08-25 in 397 days |
DRUG | PDUFA | NDA | — | — | SBLA filing. Extracted from news: Jazz Pharmaceuticals Announces FDA Acceptance and Priori | ||
|
2026-08-25 in 397 days |
RHHBY | PDUFA | Phase 2 | — | $15B | NDA filing. AI-extracted from news: FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdom | ||
|
2026-08-25 in 397 days |
SNY | Trial | Phase 2 | — | $2B | Primary completion for Rilzabrutinib dose 1 trial (NCT06984627) in Graves' Disease | ||
|
2026-08-27 in 399 days |
CLTS | Trial | Phase 2 | — | $15B | Primary completion for Lutetium (177Lu) rhPSMA-10.1 Injection trial (NCT05413850) in Prost | ||
|
2026-08-28 in 400 days |
AZN | Trial | Phase 2 | — | $15B | Primary completion for AZD2936 trial (NCT04995523) in Non-Small-Cell Lung Carcinoma | ||
|
2026-08-28 in 400 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Carboplatin trial (NCT06624059) in Non-Small Cell Lung Cancer | ||
|
2026-08-28 in 400 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT06624059) in Non-Small Cell Lung Cancer | ||
|
2026-08-28 in 400 days |
IPSEY | Trial | Phase 2 | — | $500M | Primary completion for Elafibranor 80 mg trial (NCT05627362) in Primary Sclerosing Cholang | ||
|
2026-08-28 in 400 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Alectinib trial (NCT06624059) in Non-Small Cell Lung Cancer | ||
|
2026-08-28 in 400 days |
RHHBY | Trial | Phase 3 | — | $1B | Primary completion for Cisplatin trial (NCT06624059) in Non-Small Cell Lung Cancer | ||
|
2026-08-30 in 402 days |
TAK | Trial | Phase 3 | — | $2B | Primary completion for Tetravalent Dengue Vaccine (TDV) trial (NCT07047521) in Dengue Feve | ||
|
2026-08-30 in 402 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for Elranatamab trial (NCT06152575) in Multiple Myeloma | ||
|
2026-08-30 in 402 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for Elotuzumab trial (NCT06152575) in Multiple Myeloma | ||
|
2026-08-30 in 402 days |
IMNN | Trial | Phase 2 | — | $5B | Primary completion for Paclitaxel trial (NCT05739981) in Ovarian Cancer | ||
|
2026-08-31 in 403 days |
BAYRY | Trial | Phase 3 | — | $2B | Primary completion for BAY3723113 trial (NCT07023341) in Obstructive Hypertrophic Cardiomy | ||
|
2026-08-31 in 403 days |
GALDY | Trial | Phase 3 | — | $400M | Primary completion for Nemolizumab trial (NCT03989206) in Moderate-to-Severe Atopic Dermat | ||
|
2026-08-31 in 403 days |
DSKYF | Trial | Phase 3 | — | $3B | Primary completion for Ramucirumab trial (NCT04704934) in Gastric Cancer, Adenocarcinoma | ||
|
2026-08-31 in 403 days |
ALPMY | Trial | Phase 3 | — | $3B | Primary completion for Tamoxifen trial (NCT06440967) in Hot Flashes | ||
|
2026-08-31 in 403 days |
ALPMY | Trial | Phase 3 | — | $3B | Primary completion for Fezolinetant trial (NCT06440967) in Hot Flashes | ||
|
2026-08-31 in 403 days |
RHHBY | Trial | Phase 3 | — | $800M | Primary completion for Sefaxersen (RO7434656) trial (NCT05797610) in Primary IgA Nephropat | ||
|
2026-08-31 in 403 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for Wujia Yizhi granules trial (NCT06534723) in Alzheimer's Dementia | ||
|
2026-08-31 in 403 days |
HNPHY | Trial | Phase 3 | — | $6B | Primary completion for HS-20093 trial (NCT06935409) in Osteosarcoma | ||
|
2026-08-31 in 403 days |
HNPHY | Trial | Phase 3 | — | $400M | Primary completion for Gemcitabine combined with docetaxel trial (NCT06935409) in Osteosar | ||
|
2026-08-31 in 403 days |
ALPMY | Trial | Phase 2 | — | $8B | Primary completion for nab-paclitaxel trial (NCT03816163) in Pancreatic Cancer | ||
|
2026-08-31 in 403 days |
VSTM | Trial | Phase 2 | — | $8B | Primary completion for avutometinib (VS-6766) and defactinib in combination with gemcitabi | ||
|
2026-08-31 in 403 days |
IPSEY | Trial | Phase 3 | — | $2B | Primary completion for IPN10200 trial (NCT04821089) in Moderate to Severe Upper Facial Lin | ||
|
2026-08-31 in 403 days |
IPSEY | Trial | Phase 2 | — | $3B | Primary completion for Dysport trial (NCT04821089) in Moderate to Severe Upper Facial Line | ||
|
2026-08-31 in 403 days |
4151.T | Trial | Phase 2 | — | $4B | Primary completion for Aflibercept Injection trial (NCT06116916) in Diabetic Macular Edema | ||
|
2026-08-31 in 403 days |
SNY | Trial | Phase 3 | — | $2B | Primary completion for Belumosudil trial (NCT05567406) in Chronic Graft Versus Host Diseas | ||
|
2026-08-31 in 403 days |
4151.T | Trial | Phase 2 | — | $8B | Primary completion for KHK4951 trial (NCT06116890) in Neovascular Age-Related Macular Dege | ||
|
2026-08-31 in 403 days |
ALPMY | Trial | Phase 3 | — | $2B | Primary completion for zolbetuximab trial (NCT03816163) in Pancreatic Cancer | ||
|
2026-08-31 in 403 days |
SBFM | Trial | Phase 2 | — | $8B | Primary completion for SSGJ-706 trial (NCT07171606) in First-line Advanced NSCLC Patients | ||
|
2026-09-01 in 473 days |
BCYC | Trial Readout | 2 | — | $1B | SEP 1 2026 126 days 🔬 Trial Readout (BT8009) $BCYC Bicycle Therapeutics Metastatic urothel | ||
|
2026-09-01 in 473 days |
AZN | Trial Readout | 3 | — | $8B | SEP 1 2026 126 days 🔬 Trial Readout (camizestrant — SERENA-4) $AZN AstraZeneca HR+/HER2- a | ||
|
2026-09-01 in 473 days |
INCY | Trial | Phase 3 | — | $5B | Primary completion for Tafasitamab trial (NCT04824092) in Diffuse Large B-cell Lymphoma | ||
|
2026-09-01 in 473 days |
INCY | Trial | Phase 3 | — | $3B | Primary completion for Prednisone trial (NCT04824092) in Diffuse Large B-cell Lymphoma | ||
|
2026-09-01 in 473 days |
INCY | Trial | Phase 3 | — | $5B | Primary completion for Cyclophosphamide trial (NCT04824092) in Diffuse Large B-cell Lympho | ||
|
2026-09-01 in 473 days |
INCY | Trial | Phase 3 | — | $4B | Primary completion for Lenalidomide trial (NCT04824092) in Diffuse Large B-cell Lymphoma | ||
|
2026-09-01 in 473 days |
TGTX | Trial | Phase 3 | — | $9B | Primary completion for Ublituximab trial (NCT05877963) in Relapsing Multiple Sclerosis | ||
|
2026-09-01 in 473 days |
SNY | PDUFA | NDA | — | — | For Diabetes. NDA filing. Extracted from SEC filing: 6-K | ||
|
2026-09-01 in 473 days |
NVO | Trial | Phase 2 | — | $35B | Primary completion for NNC0519-0130 trial (NCT06717698) in Chronic Kidney Disease | ||
|
2026-09-01 in 473 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for Semaglutide trial (NCT06717698) in Chronic Kidney Disease | ||
|
2026-09-01 in 473 days |
PFE | Trial | Phase 3 | — | $18B | Primary completion for ARV-471 trial (NCT05548127) in Breast Cancer | ||
|
2026-09-02 in 474 days |
CFOO | PDUFA | NDA | — | $3B | For pediatric solid tumors. NDA filing. AI-extracted from news: InnoCare’s next-generation | ||
|
2026-09-02 in 474 days |
AMGN | Trial | Phase 3 | — | $2B | Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS) | ||
|
2026-09-02 in 474 days |
TAK | PDUFA | NDA | — | $2B | For Polycythemia Vera. NDA filing. AI-extracted from news: Takeda and Protagonist Announce | ||
|
2026-09-02 in 474 days |
PFE | Trial | Phase 2 | — | $3B | Primary completion for PF-07868489 trial (NCT06137742) in Pulmonary Arterial Hypertension | ||
|
2026-09-03 in 475 days |
UCBJY | Trial | Phase 3 | — | $400M | Primary completion for fenfluramine trial (NCT06118255) in Dravet Syndrome | ||
|
2026-09-03 in 475 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk | ||
|
2026-09-03 in 475 days |
NVO | Other | — | — | — | For diabetes/obesity. Aspen Pharmacare expects to receive Canadian regulatory approval for | ||
|
2026-09-05 in 477 days |
HLUYY | Trial | Phase 3 | — | $400M | Primary completion for Eptinezumab trial (NCT04965675) in Chronic Migraine in Children | ||
|
2026-09-06 in 478 days |
ICPT | Trial | Phase 2 | — | $2B | Primary completion for INT-787 trial (NCT05639543) in Alcohol Associated Hepatitis | ||
|
2026-09-06 in 478 days |
ICPT | Trial | Phase 3 | — | $3B | Primary completion for Placebo trial (NCT05639543) in Alcohol Associated Hepatitis | ||
|
2026-09-07 in 479 days |
NVS | Trial | Phase 2 | — | $1B | Primary completion for EYU688 trial (NCT06006559) in Dengue | ||
|
2026-09-09 in 481 days |
NVSEF | Trial | Phase 2 | — | $8B | Primary completion for YTB323 trial (NCT05798117) in Systemic Lupus Erythematosus | ||
|
2026-09-15 in 487 days |
GERN | Trial Readout | 3 | — | $2B | SEP 15 2026 140 days 🔬 Trial Readout Rytelo (imetelstat (Rytelo) — IMpact...) $GERN Geron | ||
|
2026-09-15 in 487 days |
ALNY | PDUFA | — | 90% | $4B | SEP 15 2026 140 days 💊 PDUFA (zilebesiran) $ALNY Alnylam Pharmaceuticals · NDA Hypertensio | ||
|
2026-09-15 in 487 days |
ITCI | Trial | Phase 3 | — | $15B | Primary completion for Lumateperone trial (NCT05850689) in Major Depressive Disorder | ||
|
2026-09-15 in 487 days |
MRK | Trial | Phase 3 | — | $12B | Primary completion for Paclitaxel trial (NCT04634877) in Endometrial Neoplasms | ||
|
2026-09-15 in 487 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04634877) in Endometrial Neoplasms | ||
|
2026-09-15 in 487 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Carboplatin trial (NCT04634877) in Endometrial Neoplasms | ||
|
2026-09-15 in 487 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Docetaxel trial (NCT04634877) in Endometrial Neoplasms | ||
|
2026-09-15 in 487 days |
AVIR | Trial | Phase 3 | — | $8B | Primary completion for Bemnifosbuvir-Ruzasvir (BEM/RZR) trial (NCT06868264) in HEPATITIS C | ||
|
2026-09-15 in 487 days |
BIOE | Trial | Phase 3 | — | $2B | Primary completion for Recombinant humanized anti-PD-1 monoclonal antibody injection trial | ||
|
2026-09-15 in 487 days |
ALKS | Trial | Phase 3 | — | $12B | Primary completion for OLZ/SAM trial (NCT05303064) in Schizophrenia | ||
|
2026-09-15 in 487 days |
JNGHF | Trial | Phase 3 | — | $8B | Primary completion for STSP-0601 for Injection trial (NCT06922045) in Hemophilia | ||
|
2026-09-15 in 487 days |
ARGX | Trial | Phase 3 | — | $1B | Primary completion for Empasiprubart trial (NCT06742190) in Multifocal Motor Neuropathy (M | ||
|
2026-09-15 in 487 days |
SUPN | Trial | Phase 3 | — | $6B | Primary completion for SPN-812 trial (NCT02736656) in Attention-Deficit/Hyperactivity Diso | ||
|
2026-09-15 in 487 days |
LLY | Trial | Phase 3 | — | $3B | Primary completion for LY3650150 trial (NCT06339008) in Perennial Allergic Rhinitis (PAR) | ||
|
2026-09-15 in 487 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Risankizumab trial (NCT06100744) in Juvenile Psoriatic Arthritis | ||
|
2026-09-15 in 487 days |
ARGX | Trial | Phase 3 | — | $300M | Primary completion for IVIG (Intravenous Immunoglobulin) trial (NCT06742190) in Multifocal | ||
|
2026-09-15 in 487 days |
NVS | Trial | Phase 3 | — | $12B | Primary completion for Alpelisib trial (NCT05038735) in Breast Cancer | ||
|
2026-09-15 in 487 days |
NVS | Trial | Phase 3 | — | $18B | Primary completion for Fulvestrant trial (NCT05038735) in Breast Cancer | ||
|
2026-09-15 in 487 days |
ALKS | Trial | Phase 3 | — | $12B | Primary completion for Olanzapine trial (NCT05303064) in Schizophrenia | ||
|
2026-09-15 in 487 days |
ABBV | Trial | Phase 3 | — | $300M | Primary completion for Adalimumab trial (NCT06100744) in Juvenile Psoriatic Arthritis | ||
|
2026-09-15 in 487 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Cisplatin (as radiosensitizer) trial (NCT04634877) in Endometrial N | ||
|
2026-09-15 in 487 days |
IRON | Trial | Phase 3 | — | $300M | Primary completion for DISC-1459 trial (NCT06910358) in Erythropoietic Protoporphyria (EPP | ||
|
2026-09-15 in 487 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Tirzepatide trial (NCT05536804) in Overweight | ||
|
2026-09-15 in 487 days |
CORT | Trial | Phase 2 | — | $3B | Primary completion for Nenocorilant 200 mg trial (NCT07276373) in Neoplasms | ||
|
2026-09-15 in 487 days |
ZURA | Trial | Phase 2 | — | $1B | Primary completion for Tibulizumab Dose A trial (NCT06993610) in Hidradenitis Suppurativa | ||
|
2026-09-15 in 487 days |
AGMB | Trial | Phase 2 | — | $3B | Primary completion for AGMB-129 trial (NCT05843578) in Fibrostenotic Crohn's Disease | ||
|
2026-09-15 in 487 days |
SNDX | Trial | Phase 2 | — | $2B | Primary completion for Axatilimab trial (NCT06132256) in Idiopathic Pulmonary Fibrosis | ||
|
2026-09-15 in 487 days |
GILD | Trial | Phase 3 | — | $1B | Primary completion for Placebo trial (NCT02932150) in Chronic Hepatitis B | ||
|
2026-09-15 in 487 days |
VRNA | Trial | Phase 2 | — | $2B | Primary completion for Nebulized Ensifentrine Suspension; 3 mg trial (NCT06559150) in Non- | ||
|
2026-09-15 in 487 days |
EWTX | Trial | Phase 2 | — | $800M | Primary completion for Sevasemten 10 mg trial (NCT05291091) in Becker Muscular Dystrophy | ||
|
2026-09-15 in 487 days |
GILD | Trial | Phase 3 | — | $4B | Primary completion for TAF trial (NCT02932150) in Chronic Hepatitis B | ||
|
2026-09-15 in 487 days |
VNDA | Trial | Phase 2 | — | $6B | Primary completion for VSJ-110 trial (NCT07179055) in Dry Eye | ||
|
2026-09-15 in 487 days |
GALDY | Trial | Phase 3 | — | $400M | Primary completion for nemolizumab trial (NCT07074977) in Chronic Pruritus of Unknown Orig | ||
|
2026-09-15 in 487 days |
SLN | Trial | Phase 2 | — | $1B | Primary completion for Placebo trial (NCT05499013) in Polycythemia Vera | ||
|
2026-09-15 in 487 days |
NAMS | Trial | Phase 2 | — | $500M | Primary completion for Obicetrapib 10mg trial (NCT06982508) in Antioxidant Absorption | ||
|
2026-09-15 in 487 days |
ORIC | Trial | Phase 2 | — | $5B | Primary completion for ORIC-114 trial (NCT05315700) in Solid Tumors | ||
|
2026-09-15 in 487 days |
MOLN | Trial | Phase 2 | — | $15B | Primary completion for PMD-026 trial (NCT04115306) in Metastatic Breast Cancer | ||
|
2026-09-15 in 487 days |
ORKA | Trial | Phase 2 | — | $12B | Primary completion for ORKA-001 Induction Dose trial (NCT07090330) in Plaque Psoriasis | ||
|
2026-09-15 in 487 days |
LLY | Trial | Phase 2 | — | $3B | Primary completion for LY3537021 trial (NCT07169851) in Nausea | ||
|
2026-09-15 in 487 days |
SLN | Trial | Phase 2 | — | $2B | Primary completion for SLN124 trial (NCT05499013) in Polycythemia Vera | ||
|
2026-09-15 in 487 days |
MGNX | Trial | Phase 2 | — | $8B | Primary completion for lorigerlimab trial (NCT05848011) in Androgen-Independent Prostatic | ||
|
2026-09-15 in 487 days |
HLUYY | Trial | Phase 2 | — | $400M | Primary completion for Lu AG13909 trial (NCT05669950) in Congenital Adrenal Hyperplasia | ||
|
2026-09-15 in 487 days |
BIO | Trial | Phase 2 | — | $800M | Primary completion for rhPRG4 450ug/ml trial (NCT07118254) in Ocular Graft Versus Host Dis | ||
|
2026-09-15 in 487 days |
VERA | Trial | Phase 3 | — | $2B | Primary completion for Atacicept trial (NCT07020923) in IgA Nephropathy (IgAN) | ||
|
2026-09-15 in 487 days |
MAZE | Trial | Phase 2 | — | $2B | Primary completion for MZE829 trial (NCT06830629) in Proteinuric Kidney Disease | ||
|
2026-09-15 in 487 days |
SKBBY | Trial | Phase 2 | — | $8B | Primary completion for PRT-064040 nasal spray trial (NCT07304518) in Migraine | ||
|
2026-09-15 in 487 days |
SBFM | Trial | Phase 3 | — | $20B | Primary completion for 610 trial (NCT06680947) in Asthma | ||
|
2026-09-15 in 487 days |
VNDA | Trial | Phase 2 | — | $1B | Primary completion for Trichostatin A trial (NCT07065773) in Onychomycosis of Toenail | ||
|
2026-09-15 in 487 days |
BIO | Trial | Phase 2 | — | $2B | Primary completion for TOUR006 - 20 MG trial (NCT06088979) in Thyroid Eye Disease | ||
|
2026-09-15 in 487 days |
PCSA | Trial | Phase 2 | — | $18B | Primary completion for PCS6422 and capecitabine trial (NCT06568692) in Breast Cancer | ||
|
2026-09-15 in 487 days |
SVA | Trial | Phase 2 | — | $8B | Primary completion for Sinovac PCV24 trial (NCT07300644) in Pneumococcal Infectious Diseas | ||
|
2026-09-15 in 487 days |
GILD | Trial | Phase 2 | — | $15B | Primary completion for Sacituzumab Govitecan-hziy (SG) trial (NCT05186974) in Non-small Ce | ||
|
2026-09-15 in 487 days |
KPTI | Trial | Phase 3 | — | $8B | Primary completion for Selinexor trial (NCT04562870) in Myelofibrosis | ||
|
2026-09-15 in 487 days |
BHVN | Trial | Phase 3 | — | $25B | Primary completion for Taldefgrobep Alfa trial (NCT07281495) in Obesity | ||
|
2026-09-15 in 487 days |
WVE | Trial | Phase 2 | — | $800M | Primary completion for WVE-006 trial (NCT06405633) in Alpha-1 Antitrypsin Deficiency | ||
|
2026-09-15 in 487 days |
CORT | Trial | Phase 2 | — | $2B | Primary completion for Dazucorilant 300 mg trial (NCT05407324) in Amyotrophic Lateral Scle | ||
|
2026-09-15 in 487 days |
DSGN | Trial | Phase 2 | — | $500M | Primary completion for DT-168 trial (NCT07024693) in Fuchs Endothelial Corneal Dystrophy | ||
|
2026-09-15 in 487 days |
CORT | Trial | Phase 2 | — | $8B | Primary completion for Miricorilant (Cohort A) trial (NCT06108219) in Nonalcoholic Steatoh | ||
|
2026-09-15 in 487 days |
CYTK | Trial | Phase 2 | — | $15B | Primary completion for CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) trial (NCT06793371) | ||
|
2026-09-15 in 487 days |
IRON | Trial | Phase 2 | — | $2B | Primary completion for DISC-0974 trial (NCT05320198) in Myelofibrosis; Anemia | ||
|
2026-09-15 in 487 days |
TEVA | Trial | Phase 2 | — | $2B | Primary completion for TEV-53408 trial (NCT06807463) in Celiac Disease | ||
|
2026-09-15 in 487 days |
ALNY | PDUFA | — | 90% | — | SEP 15 2026 140 days 💊 PDUFA (zilebesiran) $ALNY Alnylam Pharmaceuticals · NDA Hypertensio | ||
|
2026-09-17 in 489 days |
SNY | Trial | Phase 3 | — | $400M | Primary completion for Azithromycin trial (NCT06082037) in Lung Transplant Rejection | ||
|
2026-09-17 in 489 days |
SNY | Trial | Phase 3 | — | $2B | Primary completion for Belumosudil trial (NCT06082037) in Lung Transplant Rejection | ||
|
2026-09-17 in 489 days |
VRTX | Trial | Phase 3 | — | $15B | Primary completion for Biological/Vaccine trial (NCT06832410) in Type 1 Diabetes | ||
|
2026-09-17 in 489 days |
GSK | Trial | Phase 2 | — | $6B | Primary completion for Flu mRNA (Formulation B1) trial (NCT07204964) in Influenza, Human | ||
|
2026-09-18 in 490 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Nemtabrutinib trial (NCT03162536) in Lymphoma, B-Cell | ||
|
2026-09-18 in 490 days |
TKPHF | Trial | Phase 3 | — | $8B | Primary completion for TAK-279 trial (NCT06233461) in Crohn's Disease | ||
|
2026-09-21 in 493 days |
CRDL | Trial | Phase 3 | — | $1B | Primary completion for CardiolRx trial (NCT06708299) in Recurrent Pericarditis | ||
|
2026-09-21 in 493 days |
NVS | Trial | Phase 2 | — | $2B | Primary completion for VHB937 trial (NCT06643481) in Amyotrophic Lateral Sclerosis (ALS) | ||
|
2026-09-21 in 493 days |
PFE | Trial | Phase 2 | — | $20B | Primary completion for PF-07275315 trial (NCT05995964) in Atopic Dermatitis | ||
|
2026-09-22 in 494 days |
ONC | Trial | Phase 3 | — | $2B | Primary completion for Sonrotoclax trial (NCT05952037) in Waldenstrom Macroglobulinemia | ||
|
2026-09-22 in 494 days |
ONC | Trial | Phase 3 | — | $900M | Primary completion for Zanubrutinib trial (NCT05952037) in Waldenstrom Macroglobulinemia | ||
|
2026-09-23 in 495 days |
PFE | Trial | Phase 3 | — | $800M | Primary completion for PF-07220060 trial (NCT04557449) in Liposarcoma | ||
|
2026-09-23 in 495 days |
PFE | Trial | Phase 3 | — | $100M | Primary completion for Midazolam trial (NCT04557449) in Liposarcoma | ||
|
2026-09-27 in 499 days |
PRAX | PDUFA | — | 93% | $1B | SEP 27 2026 152 days 💊 PDUFA (relutrigine) $PRAX Praxis Precision Medicines · NDA SCN2A- a | ||
|
2026-09-27 in 499 days |
CBDY | PDUFA | NDA | — | — | For patients with cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements who have r | ||
|
2026-09-27 in 499 days |
PRAX | PDUFA | — | 93% | — | SEP 27 2026 152 days 💊 PDUFA (relutrigine) $PRAX Praxis Precision Medicines · NDA SCN2A- a | ||
|
2026-09-28 in 500 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Inavolisib trial (NCT05894239) in Metastatic Breast Cancer | ||
|
2026-09-28 in 500 days |
OCGN | Trial | Phase 3 | — | $300M | Primary completion for OCU410ST trial (NCT05956626) in Stargardt Disease | ||
|
2026-09-28 in 500 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Phesgo trial (NCT05894239) in Metastatic Breast Cancer | ||
|
2026-09-28 in 500 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Optional Endocrine Therapy of Investigator's Choice trial (NCT05894 | ||
|
2026-09-28 in 500 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Taxane-based Chemotherapy trial (NCT05894239) in Metastatic Breast | ||
|
2026-09-28 in 500 days |
RHHBY | Trial | Phase 3 | — | $2B | Primary completion for Placebo trial (NCT05894239) in Metastatic Breast Cancer | ||
|
2026-09-28 in 500 days |
INCY | Trial | Phase 2 | — | $2B | Primary completion for INCB099280 trial (NCT05888844) in Cutaneous Squamous Cell Carcinoma | ||
|
2026-09-28 in 500 days |
AZN | Trial | Phase 2 | — | $3B | Primary completion for AZD0901 trial (NCT07143604) in Gastric Cancer | ||
|
2026-09-30 in 502 days |
ROIV | PDUFA | — | 93% | $2B | SEP 30 2026 155 days 💊 PDUFA (brepocitinib) $ROIV Priovant Therapeutics / Roivant Sciences | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT06417814) in Metastatic Non-small Cell Lung Ca | ||
|
2026-09-30 in 502 days |
HNSPF | Trial | Phase 3 | — | $4B | Primary completion for Topotecan trial (NCT06498479) in Small Cell Lung Cancer | ||
|
2026-09-30 in 502 days |
HNSPF | Trial | Phase 3 | — | $8B | Primary completion for HS-20093 trial (NCT06498479) in Small Cell Lung Cancer | ||
|
2026-09-30 in 502 days |
RYTM | Trial | Phase 3 | — | $15B | Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity | ||
|
2026-09-30 in 502 days |
BIO | Trial | Phase 3 | — | $6B | Primary completion for JMT101 trial (NCT06735391) in Locally Advanced or Metastatic Non-sq | ||
|
2026-09-30 in 502 days |
BIIB | Trial | Phase 3 | — | $4B | Primary completion for Litifilimab trial (NCT05531565) in Subacute Cutaneous Lupus Erythem | ||
|
2026-09-30 in 502 days |
AMYT | Trial | Phase 3 | — | $400M | Primary completion for Metreleptin trial (NCT06502990) in Generalized Lipodystrophy | ||
|
2026-09-30 in 502 days |
ISCO | Trial | Phase 3 | — | $2B | Primary completion for NaBen® trial (NCT03094429) in Refractory Schizophrenia | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $2B | Primary completion for Cisplatin trial (NCT06417814) in Metastatic Non-small Cell Lung Can | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $8B | Primary completion for Carboplatin trial (NCT06417814) in Metastatic Non-small Cell Lung C | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $18B | Primary completion for Dato-DXd trial (NCT06417814) in Metastatic Non-small Cell Lung Canc | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Osimertinib trial (NCT06417814) in Metastatic Non-small Cell Lung C | ||
|
2026-09-30 in 502 days |
VNDA | PDUFA | NDA | — | — | For Non-24-hour sleep-wake disorder in the blind. sNDA filing. Extracted from SEC filing: | ||
|
2026-09-30 in 502 days |
GSK | Trial | Phase 2 | — | $15B | Primary completion for GSK4527226 trial (NCT06079190) in Alzheimer's Disease | ||
|
2026-09-30 in 502 days |
TAK | Trial | Phase 3 | — | $12B | Primary completion for TAK-279 trial (NCT06254950) in Ulcerative Colitis | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $5B | Primary completion for Glofitamab trial (NCT03533283) in Non-Hodgkins Lymphoma | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Vincristine trial (NCT04980222) in Lymphoma | ||
|
2026-09-30 in 502 days |
BMRN | Trial | Phase 2 | — | $1B | Primary completion for BMN 351 trial (NCT06280209) in Duchenne Muscular Dystrophy | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $400M | Primary completion for Crovalimab trial (NCT03157635) in Paroxysmal Hemoglobinuria, Noctur | ||
|
2026-09-30 in 502 days |
BIO | Trial | Phase 2 | — | $7B | Primary completion for JIN-A02 trial (NCT05394831) in EGFR Mutant Advanced Non-small Cell | ||
|
2026-09-30 in 502 days |
TPTX | Trial | Phase 2 | — | $4B | Primary completion for Oral repotrectinib (TPX-0005) trial (NCT04094610) in Locally Advanc | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $28B | Primary completion for Rosuvastatin trial (NCT07218900) in Dyslipidaemia | ||
|
2026-09-30 in 502 days |
BIOE | Trial | Phase 2 | — | $8B | Primary completion for Fruquintinib trial (NCT07235293) in Colorectal Cancer | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Doxorubicin trial (NCT04980222) in Lymphoma | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $500M | Primary completion for Satralizumab trial (NCT06450639) in Duchenne Muscular Dystrophy | ||
|
2026-09-30 in 502 days |
AZN | Trial | Phase 3 | — | $4B | Primary completion for AZD0780 trial (NCT07218900) in Dyslipidaemia | ||
|
2026-09-30 in 502 days |
GNTA | Trial | Phase 2 | — | $4B | Primary completion for Pembrolizumab trial (NCT06716853) in Clear Cell RCC | ||
|
2026-09-30 in 502 days |
DSKYF | Trial | Phase 2 | — | $15B | Primary completion for Carboplatin trial (NCT06362252) in Extensive Stage-small Cell Lung | ||
|
2026-09-30 in 502 days |
DSKYF | Trial | Phase 3 | — | $2B | Primary completion for Ifinatamab deruxtecan trial (NCT06362252) in Extensive Stage-small | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Prednisone trial (NCT04980222) in Lymphoma | ||
|
2026-09-30 in 502 days |
RHHBY | Trial | Phase 3 | — | $25B | Primary completion for Tocilizumab trial (NCT03533283) in Non-Hodgkins Lymphoma | ||
|
2026-09-30 in 502 days |
QURE | Trial | Phase 2 | — | $2B | Primary completion for AMT-162 trial (NCT06100276) in Amyotrophic Lateral Sclerosis | ||
|
2026-09-30 in 502 days |
SYRE | Trial | — | — | — | Spyre's ulcerative colitis program is progressing, with rheumatoid arthritis data expected | ||
|
2026-09-30 in 502 days |
ROIV | PDUFA | — | 93% | — | SEP 30 2026 155 days 💊 PDUFA (brepocitinib) $ROIV Priovant Therapeutics / Roivant Sciences | ||
|
2026-10-01 in 573 days |
REGN | PDUFA | — | 93% | $2B | OCT 1 2026 156 days 💊 PDUFA (pozelimab) $REGN Regeneron · BLA VEXAS syndrome (complement C | ||
|
2026-10-01 in 573 days |
ARGX | Trial | Phase 3 | — | $1B | Primary completion for Efgartigimod PH20 SC trial (NCT06392386) in Generalized Myasthenia | ||
|
2026-10-01 in 573 days |
GSK | PDUFA | NDA | — | $2B | For chronic graft-versus-host disease. NDA filing. Extracted from SEC filing: 6-K | ||
|
2026-10-01 in 573 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure | ||
|
2026-10-01 in 573 days |
COCP | Trial | Phase 2 | — | $500M | Primary completion for CDI-988 trial (NCT07198139) in Norovirus | ||
|
2026-10-01 in 573 days |
NVS | Trial | Phase 3 | — | $2B | Primary completion for Iptacopan (LNP023) trial (NCT05230537) in Age-Related Macular Degen | ||
|
2026-10-01 in 573 days |
REGN | PDUFA | — | 93% | — | OCT 1 2026 156 days 💊 PDUFA (pozelimab) $REGN Regeneron · BLA VEXAS syndrome (complement C | ||
|
2026-10-02 in 574 days |
TKPHF | Trial | Phase 3 | — | $2B | Primary completion for TAK-861 trial (NCT07363720) in Narcolepsy Type 1 (NT1) | ||
|
2026-10-05 in 577 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure | ||
|
2026-10-05 in 577 days |
MRNA | Trial | Phase 2 | — | $1B | Primary completion for mRNA-1189 trial (NCT05164094) in Epstein-Barr Virus Infection | ||
|
2026-10-05 in 577 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Afimkibart trial (NCT06863961) in Atopic Dermatitis | ||
|
2026-10-06 in 578 days |
AZN | Trial | Phase 3 | — | $20B | Primary completion for Benralizumab trial (NCT06512883) in Eosinophilic Granulomatosis Wit | ||
|
2026-10-07 in 579 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Dupilumab trial (NCT02612454) in Atopic Dermatitis | ||
|
2026-10-07 in 579 days |
RARE | PDUFA | Phase 3 | — | $200M | For Sanfilippo Syndrome Type A (MPS IIIA). BLA filing. AI-extracted from news: Ultragenyx | ||
|
2026-10-08 in 580 days |
PFE | Trial | Phase 3 | — | $4B | Primary completion for Rimegepant trial (NCT06616194) in Migraine | ||
|
2026-10-09 in 581 days |
INCY | Trial | Phase 3 | — | $400M | Primary completion for Vehicle Cream trial (NCT06959225) in Hidradenitis Suppurativa | ||
|
2026-10-09 in 581 days |
INCY | Trial | Phase 3 | — | $300M | Primary completion for Ruxolitinib Cream trial (NCT06959225) in Hidradenitis Suppurativa | ||
|
2026-10-09 in 581 days |
AZN | Trial | Phase 2 | — | $3B | Primary completion for AZD7760 trial (NCT06749457) in Staphylococcus Aureus | ||
|
2026-10-09 in 581 days |
TECX | Trial | Phase 2 | — | $4B | Primary completion for TX000045- Dose A trial (NCT06616974) in Pulmonary Hypertension | ||
|
2026-10-13 in 585 days |
BIOE | Trial | Phase 3 | — | $12B | Primary completion for JSKN003 trial (NCT06846437) in Unrespectable Locally Advanced and o | ||
|
2026-10-13 in 585 days |
GSK | Trial | Phase 2 | — | $8B | Primary completion for Cobolimab trial (NCT06521567) in Melanoma | ||
|
2026-10-14 in 586 days |
GSK | Trial | Phase 3 | — | $2B | Primary completion for Momelotinib trial (NCT06517875) in Primary Myelofibrosis | ||
|
2026-10-14 in 586 days |
GSK | Trial | Phase 2 | — | $2B | Primary completion for Luspatercept trial (NCT06517875) in Primary Myelofibrosis | ||
|
2026-10-15 in 587 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for LY3537982 trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-10-15 in 587 days |
XENE | Trial | Phase 3 | — | $4B | Primary completion for XEN1101 trial (NCT05716100) in Focal Onset Seizures | ||
|
2026-10-15 in 587 days |
TENX | Trial | Phase 3 | — | $4B | Primary completion for TNX-103 trial (NCT05983250) in Pulmonary Hypertension | ||
|
2026-10-15 in 587 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Aflibercept (EYLEA®) trial (NCT05407636) in AMD | ||
|
2026-10-15 in 587 days |
EYPT | Trial | Phase 3 | — | $6B | Primary completion for Aflibercept (2.0 mg) trial (NCT06683742) in Wet Age Related Macular | ||
|
2026-10-15 in 587 days |
HUMA | Trial | Phase 3 | — | $10B | Primary completion for Acellular Tissue Engineered Vessel (ATEV) trial (NCT05908084) in En | ||
|
2026-10-15 in 587 days |
MESO | Trial | Phase 3 | — | $2B | Primary completion for Rexlemestrocel-L + HA mixture trial (NCT06325566) in Degenerative D | ||
|
2026-10-15 in 587 days |
EYPT | Trial | Phase 3 | — | $4B | Primary completion for EYP-1901 trial (NCT06683742) in Wet Age Related Macular Degeneratio | ||
|
2026-10-15 in 587 days |
CLDX | Trial | Phase 3 | — | $400M | Primary completion for Barzolvolimab trial (NCT06727552) in Atopic Dermatitis | ||
|
2026-10-15 in 587 days |
MIRM | Trial | Phase 3 | — | $300M | Primary completion for Maralixibat trial (NCT06553768) in Cholestatic Liver Disease (Excep | ||
|
2026-10-15 in 587 days |
SBFM | Trial | Phase 3 | — | $3B | Primary completion for Clascoterone trial (NCT06403501) in Acne Vulgaris | ||
|
2026-10-15 in 587 days |
LLY | Trial | Phase 3 | — | $25B | Primary completion for Retatrutide trial (NCT06297603) in Type 2 Diabetes | ||
|
2026-10-15 in 587 days |
LLY | Trial | Phase 3 | — | $18B | Primary completion for Carboplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-10-15 in 587 days |
CODX | Trial | Phase 3 | — | $12B | Primary completion for tapinarof cream, 1% trial (NCT05172726) in Plaque Psoriasis | ||
|
2026-10-15 in 587 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-10-15 in 587 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Cisplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-10-15 in 587 days |
URGN | Trial | Phase 3 | — | $2B | Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carci | ||
|
2026-10-15 in 587 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-10-15 in 587 days |
VNDA | Trial | Phase 3 | — | $12B | Primary completion for iloperidone trial (NCT07090161) in Hypertension | ||
|
2026-10-15 in 587 days |
SKBBY | Trial | Phase 2 | — | $2B | Primary completion for BL-B01D1 for Injection trial (NCT06598787) in Recurrent Glioblastom | ||
|
2026-10-15 in 587 days |
GPCR | Trial | Phase 2 | — | $50B | Primary completion for Aleniglipron trial (NCT07400588) in Obese | ||
|
2026-10-15 in 587 days |
BIO | Trial | Phase 2 | — | $8B | Primary completion for TRIV-509 trial (NCT07167758) in Atopic Dermatitis | ||
|
2026-10-15 in 587 days |
SUPN | Trial | Phase 2 | — | $3B | Primary completion for SPN-817 trial (NCT06798896) in Focal Onset Seizures | ||
|
2026-10-15 in 587 days |
PHAR | Trial | Phase 3 | — | $500M | Primary completion for Leniolisib trial (NCT06897358) in Common Variable Immunodeficiency | ||
|
2026-10-15 in 587 days |
GILD | Trial | Phase 3 | — | $28B | Primary completion for Optimized Background Regimen (OBR) trial (NCT06749054) in HIV-1-inf | ||
|
2026-10-15 in 587 days |
GILD | Trial | Phase 3 | — | $28B | Primary completion for Oral Lenacapavir trial (NCT06749054) in HIV-1-infection | ||
|
2026-10-15 in 587 days |
GILD | Trial | Phase 3 | — | $5B | Primary completion for Sacituzumab Govitecan-hziy trial (NCT05119907) in Solid Tumor | ||
|
2026-10-15 in 587 days |
RAPP | Trial | Phase 2 | — | $3B | Primary completion for RAP-219 trial (NCT07046494) in Bipolar 1 Disorder | ||
|
2026-10-15 in 587 days |
ABOS | Trial | Phase 2 | — | $15B | Primary completion for sabirnetug trial (NCT06335173) in Alzheimer Disease | ||
|
2026-10-15 in 587 days |
IMCR | Trial | Phase 3 | — | $3B | Primary completion for Brenetafusp trial (NCT04262466) in Select Advanced Solid Tumors | ||
|
2026-10-15 in 587 days |
IPIX | Trial | Phase 2 | — | $15B | Primary completion for GI-101 trial (NCT04977453) in Advanced Solid Tumor | ||
|
2026-10-15 in 587 days |
MPLT | Trial | Phase 2 | — | $2B | Primary completion for ML-004 (IR)/(ER) tablet trial (NCT05081245) in Autism Spectrum Diso | ||
|
2026-10-15 in 587 days |
SKBBY | Trial | Phase 3 | — | $2B | Primary completion for BL-M07D1 trial (NCT06423885) in HER2-positive Gastric or Gastroesop | ||
|
2026-10-15 in 587 days |
SKBBY | Trial | Phase 2 | — | $4B | Primary completion for PD-1 monoclonal antibody trial (NCT06423885) in HER2-positive Gastr | ||
|
2026-10-15 in 587 days |
RNA | Trial | Phase 2 | — | $400M | Primary completion for AOC 1020 trial (NCT05747924) in FSHD | ||
|
2026-10-15 in 587 days |
CRNX | Trial | Phase 3 | — | $400M | Primary completion for atumelnant trial (NCT05804669) in Cushing Syndrome | ||
|
2026-10-16 in 588 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Atezolizumab trial (NCT03533283) in Non-Hodgkins Lymphoma | ||
|
2026-10-16 in 588 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Polatuzumab Vedotin trial (NCT03533283) in Non-Hodgkins Lymphoma | ||
|
2026-10-16 in 588 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Obinutuzumab trial (NCT03533283) in Non-Hodgkins Lymphoma | ||
|
2026-10-16 in 588 days |
RHHBY | Trial | Phase 2 | — | $9B | Primary completion for 89Zr-Df-IAB22M2C trial (NCT03533283) in Non-Hodgkins Lymphoma | ||
|
2026-10-17 in 589 days |
VTRS | PDUFA | — | — | — | For Presbyopia. Viatris announced FDA acceptance of a supplemental New Drug Application fo | ||
|
2026-10-18 in 590 days |
BGNE | Trial | Phase 2 | — | $25B | Primary completion for BGB-45035 trial (NCT07100938) in Rheumatoid Arthritis | ||
|
2026-10-19 in 591 days |
INCY | Trial | Phase 3 | — | $2B | Primary completion for Povorcitinib trial (NCT06516965) in Prurigo Nodularis | ||
|
2026-10-19 in 591 days |
PFE | Trial | Phase 2 | — | $8B | Primary completion for PF-07264660 trial (NCT05995964) in Atopic Dermatitis | ||
|
2026-10-19 in 591 days |
AMGN | Trial | Phase 3 | — | $20B | Primary completion for Rocatinlimab trial (NCT06376045) in Asthma | ||
|
2026-10-20 in 592 days |
KALV | PDUFA | — | 93% | $2B | OCT 20 2026 175 days 💊 PDUFA (donidalorsen) $KALV KalVista Pharmaceuticals · NDA Hereditar | ||
|
2026-10-20 in 592 days |
OTSKF | Trial | Phase 3 | — | $12B | Primary completion for SEP-363856 trial (NCT06894212) in Schizophrenia | ||
|
2026-10-20 in 592 days |
BIIB | Trial | Phase 3 | — | $8B | Primary completion for Placebo trial (NCT05531565) in Subacute Cutaneous Lupus Erythematos | ||
|
2026-10-20 in 592 days |
KALV | PDUFA | — | 93% | — | OCT 20 2026 175 days 💊 PDUFA (donidalorsen) $KALV KalVista Pharmaceuticals · NDA Hereditar | ||
|
2026-10-22 in 594 days |
AMGN | Trial | Phase 3 | — | $2B | Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS) | ||
|
2026-10-23 in 595 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Durvalumab trial (NCT06040099) in Hepatocellular Carcinoma (HCC) | ||
|
2026-10-26 in 598 days |
NVS | Trial | Phase 3 | — | $18B | Primary completion for Inclisiran sodium 300 mg trial (NCT05360446) in Coronary Artery Dis | ||
|
2026-10-26 in 598 days |
GALDY | Trial | Phase 3 | — | $400M | Primary completion for Nemolizumab trial (NCT04204616) in Prurigo Nodularis | ||
|
2026-10-26 in 598 days |
IPSEY | Trial | Phase 2 | — | $4B | Primary completion for Cabozantinib trial (NCT06341712) in Osteosarcoma | ||
|
2026-10-27 in 599 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Volrustomig trial (NCT05775159) in Hepatocellular Carcinoma | ||
|
2026-10-27 in 599 days |
AZN | Trial | Phase 2 | — | $4B | Primary completion for Lenvatinib trial (NCT05775159) in Hepatocellular Carcinoma | ||
|
2026-10-28 in 600 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Belzutifan trial (NCT05239728) in Carcinoma, Renal Cell | ||
|
2026-10-29 in 601 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Belzutifan trial (NCT04736706) in Carcinoma, Renal Cell | ||
|
2026-10-29 in 601 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Lenvatinib trial (NCT04736706) in Carcinoma, Renal Cell | ||
|
2026-10-29 in 601 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04736706) in Carcinoma, Renal Cell | ||
|
2026-10-29 in 601 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Pembrolizumab/Quavonlimab trial (NCT04736706) in Carcinoma, Renal C | ||
|
2026-10-29 in 601 days |
MRK | PDUFA | Phase 2 | — | $12B | For Adults with Active Psoriatic Arthritis If the sBLA is approved. sbla filing. AI-extra | ||
|
2026-10-30 in 602 days |
CYTK | PDUFA | — | 92% | $8B | OCT 30 2026 185 days 💊 PDUFA MYQORZO (supplemental) (aficamten (MAPLE-HCM sNDA)) $CYTK Cyt | ||
|
2026-10-30 in 602 days |
VRTX | Trial | Phase 3 | — | $6B | Primary completion for VX-121/TEZ/D-IVA trial (NCT05444257) in Cystic Fibrosis | ||
|
2026-10-30 in 602 days |
AMGN | Trial | Phase 3 | — | $20B | Primary completion for Rocatinlimab trial (NCT06527404) in Prurigo Nodularis | ||
|
2026-10-30 in 602 days |
BNTX | Trial | Phase 3 | — | $15B | Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19 | ||
|
2026-10-30 in 602 days |
SNYNF | Trial | Phase 2 | — | $2B | Primary completion for venglustat (GZ402671) trial (NCT02843035) in Gaucher Disease Type 1 | ||
|
2026-10-30 in 602 days |
INBX | Trial | Phase 2 | — | $13B | Primary completion for INBRX-106 - Hexavalent OX40 agonist antibody trial (NCT04198766) in | ||
|
2026-10-30 in 602 days |
CYTK | PDUFA | — | 92% | — | OCT 30 2026 185 days 💊 PDUFA MYQORZO (supplemental) (aficamten (MAPLE-HCM sNDA)) $CYTK Cyt | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Carboplatin trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Gemcitabine trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $1B | Primary completion for Cisplatin trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Docetaxel trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
AZN | Trial | Phase 3 | — | $18B | Primary completion for Fulvestrant trial (NCT06635447) in Breast Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Bevacizumab trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Cobimetinib trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Entrectinib trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Atezolizumab trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Alectinib trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Vemurafenib trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Divarasib trial (NCT03178552) in Non-Small Cell Lung Cancer | ||
|
2026-10-31 in 603 days |
AZN | Trial | Phase 3 | — | $5B | Primary completion for Capivasertib trial (NCT06635447) in Breast Cancer | ||
|
2026-10-31 in 603 days |
TKPHF | Trial | Phase 3 | — | $8B | Primary completion for TAK-788 trial (NCT04129502) in Advanced/Metastatic Non-Small Cell L | ||
|
2026-10-31 in 603 days |
IPIX | Trial | Phase 3 | — | $4B | Primary completion for Cenerimod trial (NCT05648500) in Lupus Erythematosus, Systemic | ||
|
2026-10-31 in 603 days |
IMMP | Trial | Phase 3 | — | $18B | Primary completion for eftilagimod alpha trial (NCT05747794) in Breast Carcinoma | ||
|
2026-10-31 in 603 days |
ZEAL | Trial | Phase 3 | — | $800M | Primary completion for glepaglutide trial (NCT03905707) in Short Bowel Syndrome | ||
|
2026-10-31 in 603 days |
TEVA | Trial | Phase 3 | — | $20B | Primary completion for TEV-56248 trial (NCT06052267) in Asthma | ||
|
2026-10-31 in 603 days |
SRPT | Trial | Phase 3 | — | $1B | Primary completion for Eteplirsen trial (NCT03992430) in Muscular Dystrophy, Duchenne | ||
|
2026-10-31 in 603 days |
ANNX | Trial | Phase 3 | — | $4B | Primary completion for Vonaprument trial (NCT06510816) in Geographic Atrophy | ||
|
2026-10-31 in 603 days |
JNGHF | Trial | Phase 3 | — | $12B | Primary completion for SHR6390 trial (NCT04842617) in Hormone Receptor Positive,Human Epid | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 2 | — | $8B | Primary completion for Tiragolumab trial (NCT05805501) in Renal Cell Carcinoma | ||
|
2026-10-31 in 603 days |
JSPR | Trial | Phase 2 | — | $3B | Primary completion for Briquilimab trial (NCT06162728) in Chronic Spontaneous Urticaria | ||
|
2026-10-31 in 603 days |
ACRV | Trial | Phase 2 | — | $3B | Primary completion for ACR-368 trial (NCT05548296) in Endometrial Adenocarcinoma | ||
|
2026-10-31 in 603 days |
RYTM | Trial | Phase 3 | — | $15B | Primary completion for Setmelanotide trial (NCT06772597) in Prader-Willi Syndrome | ||
|
2026-10-31 in 603 days |
TAK | Trial | Phase 2 | — | $15B | Primary completion for TAK-788 trial (NCT02716116) in Carcinoma, Non-Small-Cell Lung | ||
|
2026-10-31 in 603 days |
SYRE | Trial | Phase 2 | — | $25B | Primary completion for SPY002-072 trial (NCT07148414) in Rheumatoid Arthritis | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Nab-Paclitaxel trial (NCT05852691) in Breast Cancer | ||
|
2026-10-31 in 603 days |
ADAG | Trial | Phase 2 | — | $15B | Primary completion for ADG126 trial (NCT05405595) in Advanced/Metastatic Solid Tumors | ||
|
2026-10-31 in 603 days |
RHHBY | Trial | Phase 2 | — | $5B | Primary completion for Tobemstomig trial (NCT05852691) in Breast Cancer | ||
|
2026-11-01 in 673 days |
BMY | Trial | Phase 3 | — | $8B | Primary completion for KarXT trial (NCT06951698) in Bipolar-I Disorder With Mania or Mania | ||
|
2026-11-01 in 673 days |
SRRK | Trial | Phase 3 | — | $2B | Primary completion for Apitegromab trial (NCT05626855) in Spinal Muscular Atrophy | ||
|
2026-11-01 in 673 days |
OTSKF | Trial | Phase 3 | — | $1B | Primary completion for JNT-517 Tablet trial (NCT06971731) in Phenylketonuria | ||
|
2026-11-01 in 673 days |
SMMT | PDUFA | Phase 3 | — | $8B | Extracted from: Summit gets November PDUFA date for its PD-1xVEGF bispecific | ||
|
2026-11-01 in 673 days |
CRBP | Trial | Phase 2 | — | $14B | Primary completion for CRB-601 monoclonal antibody trial (NCT06603844) in Solid Tumor | ||
|
2026-11-01 in 673 days |
BIOE | Trial | Phase 2 | — | $200M | Primary completion for BBP-418 trial (NCT04800874) in LGMD2I | ||
|
2026-11-02 in 674 days |
GSK | Trial | Phase 3 | — | $4B | Primary completion for Dostarlimab trial (NCT05723562) in Neoplasms, Rectal | ||
|
2026-11-03 in 675 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Placebo trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma | ||
|
2026-11-03 in 675 days |
REGN | Trial | Phase 3 | — | $1B | Primary completion for Cemiplimab trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma | ||
|
2026-11-03 in 675 days |
BAYRY | Trial | Phase 2 | — | $5B | Primary completion for BAY2599023 (DTX201) trial (NCT03588299) in Hemophilia A | ||
|
2026-11-05 in 677 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for Fitusiran trial (NCT03754790) in Hemophilia | ||
|
2026-11-06 in 678 days |
MRK | Trial | Phase 2 | — | $7B | Primary completion for pembrolizumab trial (NCT03407144) in Hodgkin Lymphoma | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Lenvatinib trial (NCT05319730) in Esophageal Squamous Cell Carcinom | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Sacituzumab tirumotecan trial (NCT05319730) in Esophageal Squamous | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 3 | — | $12B | Primary completion for Paclitaxel trial (NCT05319730) in Esophageal Squamous Cell Carcinom | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 2 | — | $2B | Primary completion for Antihistamine trial (NCT05319730) in Esophageal Squamous Cell Carci | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT05319730) in Esophageal Squamous Cell Carci | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Supportive care measures trial (NCT05319730) in Esophageal Squamous | ||
|
2026-11-07 in 679 days |
MRK | Trial | Phase 2 | — | $15B | Primary completion for MK-4830 trial (NCT05319730) in Esophageal Squamous Cell Carcinoma | ||
|
2026-11-09 in 681 days |
BIO | Trial | Phase 2 | — | $14B | Primary completion for BAT8010 for Injection trial (NCT06376136) in Advanced Solid Tumors | ||
|
2026-11-10 in 682 days |
ALNY | PDUFA | — | 90% | $4B | NOV 10 2026 196 days 💊 PDUFA (elebsiran) $ALNY Alnylam / Roche · NDA Hepatitis B virus (HB | ||
|
2026-11-10 in 682 days |
ANRO | Trial | Phase 3 | — | $4B | Primary completion for Apatinib trial (NCT06351020) in Locally Advanced or Metastatic GC a | ||
|
2026-11-10 in 682 days |
ANRO | Trial | Phase 3 | — | $4B | Primary completion for LM-302 trial (NCT06351020) in Locally Advanced or Metastatic GC and | ||
|
2026-11-10 in 682 days |
ALNY | PDUFA | — | 90% | — | NOV 10 2026 196 days 💊 PDUFA (elebsiran) $ALNY Alnylam / Roche · NDA Hepatitis B virus (HB | ||
|
2026-11-12 in 684 days |
RHHBY | Trial | Phase 3 | — | $28B | Primary completion for Ocrelizumab trial (NCT03523858) in Progressive Multiple Sclerosis ( | ||
|
2026-11-13 in 685 days |
GSK | Trial | Phase 3 | — | $4B | Primary completion for Niraparib trial (NCT04641247) in Ovarian Neoplasms | ||
|
2026-11-13 in 685 days |
AZN | Trial | Phase 2 | — | $4B | Primary completion for AZD0486 trial (NCT06137118) in B-cell Acute Lymphoblastic Leukemia | ||
|
2026-11-15 in 687 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for capecitabine trial (NCT06118333) in Nasopharyngeal Carcinoma | ||
|
2026-11-15 in 687 days |
SKBBY | Trial | Phase 3 | — | $1B | Primary completion for gemcitabine trial (NCT06118333) in Nasopharyngeal Carcinoma | ||
|
2026-11-15 in 687 days |
LLY | Trial | Phase 3 | — | $8B | Primary completion for Lasmiditan trial (NCT04396236) in Migraine | ||
|
2026-11-15 in 687 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Tirzepatide trial (NCT06662383) in Obesity | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 3 | — | $6B | Primary completion for ABBV-444 trial (NCT07284381) in Dry Eye Disease | ||
|
2026-11-15 in 687 days |
MCUJF | Trial | Phase 3 | — | $100M | Primary completion for Pyridoxal Phosphate trial (NCT04706013) in Pyridox(am)Ine 5'-Phosph | ||
|
2026-11-15 in 687 days |
LLY | Trial | Phase 3 | — | $25B | Primary completion for Orforglipron trial (NCT06649045) in OSA | ||
|
2026-11-15 in 687 days |
CRVS | Trial | Phase 3 | — | $800M | Primary completion for Soquelitinib trial (NCT06561048) in Peripheral T-Cell Lymphoma, Not | ||
|
2026-11-15 in 687 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for SKB264 trial (NCT06448312) in Non-Small Cell Lung Cancer | ||
|
2026-11-15 in 687 days |
MNMD | Trial | Phase 3 | — | $8B | Primary completion for MM120 (LSD D-Tartrate) trial (NCT06809595) in Generalized Anxiety D | ||
|
2026-11-15 in 687 days |
NAMS | Trial | Phase 3 | — | $18B | Primary completion for Obicetrapib trial (NCT05202509) in Atherosclerotic Cardiovascular D | ||
|
2026-11-15 in 687 days |
SKBBY | Trial | Phase 3 | — | $800M | Primary completion for BL-B01D1 trial (NCT06382129) in Non-small Cell Lung Cancer | ||
|
2026-11-15 in 687 days |
ONC | Trial | Phase 3 | — | $2B | Primary completion for Sonrotoclax trial (NCT04973605) in Relapsed/Refractory Multiple Mye | ||
|
2026-11-15 in 687 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Elebsiran trial (NCT07142811) in Viral Hepatitis | ||
|
2026-11-15 in 687 days |
ATOS | Trial | Phase 2 | — | $18B | Primary completion for (Z)-endoxifen trial (NCT05607004) in Breast Neoplasms | ||
|
2026-11-15 in 687 days |
APTOF | Trial | Phase 2 | — | $2B | Primary completion for Tuspetinib trial (NCT03850574) in Leukemia, Myeloid, Acute | ||
|
2026-11-15 in 687 days |
APGE | Trial | Phase 2 | — | $8B | Primary completion for APG777 trial (NCT06395948) in Atopic Dermatitis | ||
|
2026-11-15 in 687 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Tobevibart trial (NCT07142811) in Viral Hepatitis | ||
|
2026-11-15 in 687 days |
BEIGF | Trial | Phase 2 | — | $4B | Primary completion for Zanubrutinib trial (NCT06637501) in Chronic Lymphocytic Leukemia | ||
|
2026-11-15 in 687 days |
ZURA | Trial | Phase 2 | — | $1B | Primary completion for Tibulizumab Dose A trial (NCT06993610) in Hidradenitis Suppurativa | ||
|
2026-11-15 in 687 days |
BNTX | Trial | Phase 2 | — | $2B | Primary completion for RO7198457 intravenous (IV) trial (NCT04486378) in Colorectal Cancer | ||
|
2026-11-15 in 687 days |
ONC | Trial | Phase 2 | — | $6B | Primary completion for Dexamethasone trial (NCT04973605) in Relapsed/Refractory Multiple M | ||
|
2026-11-15 in 687 days |
VXRT | Trial | Phase 2 | — | $15B | Primary completion for VXA-CoV2-3.1 trial (NCT06672055) in SARS-CoV2 | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Livmoniplimab trial (NCT05822752) in Hepatocellular Carcinoma | ||
|
2026-11-15 in 687 days |
PHAR | Trial | Phase 3 | — | $500M | Primary completion for Leniolisib trial (NCT06549114) in Primary Immunodeficiency Disorder | ||
|
2026-11-15 in 687 days |
ARGX | Trial | Phase 3 | — | $1B | Primary completion for Empasiprubart IV trial (NCT06284954) in Dermatomyositis | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Mirvetuximab soravtansine trial (NCT05456685) in High Grade Ovarian | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for Carboplatin trial (NCT05456685) in High Grade Ovarian Cancer | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 2 | — | $4B | Primary completion for Lenvatinib trial (NCT05822752) in Hepatocellular Carcinoma | ||
|
2026-11-15 in 687 days |
JNGHF | Trial | Phase 2 | — | $9B | Primary completion for SHR-A1811 combined with Pyrotinib. trial (NCT06015048) in HER2-expr | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 3 | — | $3B | Primary completion for Budigalimab trial (NCT05822752) in Hepatocellular Carcinoma | ||
|
2026-11-15 in 687 days |
MNKD | Trial | Phase 2 | — | $15B | Primary completion for Basal insulin trial (NCT07224321) in Type 1 Diabetes Mellitus | ||
|
2026-11-15 in 687 days |
MNKD | Trial | Phase 3 | — | $55B | Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for ABBV-932 trial (NCT06846320) in Generalized Anxiety Disorder (GAD) | ||
|
2026-11-15 in 687 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Bulevirtide trial (NCT07142811) in Viral Hepatitis | ||
|
2026-11-15 in 687 days |
SKBBY | Trial | Phase 3 | — | $8B | Primary completion for SI-B001 trial (NCT06668961) in Head and Neck Squamous Cell Carcinom | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Obinutuzumab trial (NCT04895436) in Chronic Lymphocytic Leukemia (C | ||
|
2026-11-15 in 687 days |
LLY | Trial | Phase 2 | — | $35B | Primary completion for LY3938577 trial (NCT07215312) in Diabetes Mellitus, Type 2 | ||
|
2026-11-15 in 687 days |
BGNE | Trial | Phase 2 | — | $6B | Primary completion for Tislelizumab (BGB-A317) trial (NCT03736889) in MSI-H/dMMR Solid Tum | ||
|
2026-11-15 in 687 days |
LLY | Trial | Phase 2 | — | $18B | Primary completion for MORF-057 trial (NCT06226883) in Inflammatory Bowel Diseases | ||
|
2026-11-15 in 687 days |
JHPCY | Trial | Phase 2 | — | $2B | Primary completion for Bupivacaine Liposome Injection trial (NCT06529432) in Local Analges | ||
|
2026-11-15 in 687 days |
SKBBY | Trial | Phase 2 | — | $2B | Primary completion for SI-B003 trial (NCT06668961) in Head and Neck Squamous Cell Carcinom | ||
|
2026-11-15 in 687 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Venetoclax trial (NCT04895436) in Chronic Lymphocytic Leukemia (CLL | ||
|
2026-11-15 in 687 days |
TYRA | Trial | Phase 2 | — | $2B | Primary completion for TYRA-300 trial (NCT05544552) in Locally Advanced Urothelial Carcino | ||
|
2026-11-15 in 687 days |
NAMS | Trial | Phase 2 | — | $18B | Primary completion for obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks trial ( | ||
|
2026-11-15 in 687 days |
ONC | Trial | Phase 3 | — | $8B | Primary completion for BGB-16673 trial (NCT05006716) in B-cell Malignancy | ||
|
2026-11-15 in 687 days |
ELTX | Trial | Phase 2 | — | $6B | Primary completion for ELI-002 7P trial (NCT05726864) in Pancreatic Ductal Adenocarcinoma | ||
|
2026-11-15 in 687 days |
CRDF | Trial | Phase 2 | — | $8B | Primary completion for FOLFOX trial (NCT06106308) in Metastatic Colorectal Cancer | ||
|
2026-11-15 in 687 days |
CRDF | Trial | Phase 2 | — | $8B | Primary completion for Onvansertib trial (NCT06106308) in Metastatic Colorectal Cancer | ||
|
2026-11-15 in 687 days |
KPRX | Trial | Phase 2 | — | $4B | Primary completion for KIO-104 trial (NCT06825702) in Macular Edema | ||
|
2026-11-16 in 688 days |
UCBJY | Trial | Phase 3 | — | $1B | Primary completion for Zilucoplan trial (NCT06055959) in Generalized Myasthenia Gravis | ||
|
2026-11-16 in 688 days |
MRK | Trial | Phase 3 | — | $1B | Primary completion for Tulisokibart trial (NCT06956235) in Hidradenitis Suppurativa | ||
|
2026-11-17 in 689 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Volrustomig trial (NCT06079671) in Locally Advanced Cervical Cancer | ||
|
2026-11-19 in 691 days |
RHHBY | Trial | Phase 2 | — | $15B | Primary completion for RO7269162 trial (NCT06402838) in Alzheimer's Disease | ||
|
2026-11-19 in 691 days |
NVS | Trial | Phase 2 | — | $15B | Primary completion for 225Ac-PSMA-R2 trial (NCT05983198) in Prostate Cancer | ||
|
2026-11-23 in 695 days |
NVO | Trial | Phase 3 | — | $50B | Primary completion for Insulin aspart trial (NCT07076199) in Diabetes Mellitus, Type 1 | ||
|
2026-11-23 in 695 days |
NVO | Trial | Phase 3 | — | $50B | Primary completion for Insulin glargine trial (NCT07076199) in Diabetes Mellitus, Type 1 | ||
|
2026-11-23 in 695 days |
NVO | Trial | Phase 3 | — | $35B | Primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1 | ||
|
2026-11-24 in 696 days |
AZN | Trial | Phase 2 | — | $8B | Primary completion for AZD0754 trial (NCT06267729) in Metastatic Prostate Cancer | ||
|
2026-11-27 in 699 days |
RHHBY | Trial | Phase 2 | — | $55B | Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus | ||
|
2026-11-29 in 701 days |
PFE | Trial | Phase 3 | — | $4B | Primary completion for Rimegepant trial (NCT06641466) in Menstrual Migraine | ||
|
2026-11-30 in 702 days |
RNAC | Trial | Phase 3 | — | $2B | Primary completion for Decartes-08 trial (NCT06799247) in Myasthaenia Gravis | ||
|
2026-11-30 in 702 days |
QNCX | Trial | Phase 3 | — | $200M | Primary completion for Dexamethasone sodium phosphate trial (NCT06664853) in Ataxia Telang | ||
|
2026-11-30 in 702 days |
SNY | Trial | Phase 3 | — | $3B | Primary completion for rilzabrutinib trial (NCT07216079) in Immune Thrombocytopenia | ||
|
2026-11-30 in 702 days |
IMCR | Trial | Phase 2 | — | $800M | Primary completion for IMC-R117C trial (NCT06840119) in Cancer | ||
|
2026-11-30 in 702 days |
AZN | Trial | Phase 3 | — | $4B | Primary completion for Tremelimumab trial (NCT07081633) in Hepatocellular Carcinoma | ||
|
2026-11-30 in 702 days |
BIO | Trial | Phase 2 | — | $8B | Primary completion for JMT108 trial (NCT07280832) in Unresectable Locally Advanced or Meta | ||
|
2026-11-30 in 702 days |
AZN | Trial | Phase 3 | — | $15B | Primary completion for Durvalumab trial (NCT07081633) in Hepatocellular Carcinoma | ||
|
2026-11-30 in 702 days |
RHHBY | Trial | Phase 3 | — | $1B | Primary completion for Risdiplam trial (NCT05808764) in Muscular Atrophy, Spinal | ||
|
2026-11-30 in 702 days |
NVSEF | Trial | Phase 2 | — | $2B | Primary completion for JDQ443 trial (NCT05358249) in KRAS G12C Mutant Solid Tumors | ||
|
2026-11-30 in 702 days |
NVSEF | Trial | Phase 3 | — | $2B | Primary completion for trametinib trial (NCT05358249) in KRAS G12C Mutant Solid Tumors | ||
|
2026-11-30 in 702 days |
NVSEF | Trial | Phase 3 | — | $18B | Primary completion for Ribociclib trial (NCT05358249) in KRAS G12C Mutant Solid Tumors | ||
|
2026-11-30 in 702 days |
NVSEF | Trial | Phase 2 | — | $5B | Primary completion for cetuximab trial (NCT05358249) in KRAS G12C Mutant Solid Tumors | ||
|
2026-11-30 in 702 days |
MRNA | Trial | Phase 2 | — | $800M | Primary completion for mRNA-3745 trial (NCT05095727) in Glycogen Storage Disease | ||
|
2026-11-30 in 702 days |
AURA | Trial | Phase 2 | — | $800M | Primary completion for AU-011 trial (NCT06643884) in Eye Cancer | ||
|
2026-11-30 in 702 days |
BAYRY | Trial | Phase 2 | — | $15B | Primary completion for BAY2927088_formulation A trial (NCT05099172) in Advanced Non-small | ||
|
2026-11-30 in 702 days |
VTRS | Trial | Phase 2 | — | $12B | Primary completion for MR-130A-01 contraceptive transdermal patch, containing norelgestrom | ||
|
2026-11-30 in 702 days |
SNY | Trial | Phase 2 | — | $15B | Primary completion for Isatuximab intravenous (IV) trial (NCT05669989) in Plasma Cell Myel | ||
|
2026-12-01 in 773 days |
ARGX | Trial | Phase 3 | — | $1B | Primary completion for EFG PH20 SC trial (NCT05523167) in Active Idiopathic Inflammatory M | ||
|
2026-12-01 in 773 days |
SNY | Trial | Phase 3 | — | $8B | Primary completion for PCV21 trial (NCT06838000) in Pneumococcal Infections | ||
|
2026-12-01 in 773 days |
SNY | Trial | Phase 3 | — | $15B | Primary completion for Itepekimab (SAR440340) trial (NCT06208306) in Chronic Obstructive P | ||
|
2026-12-01 in 773 days |
BIIB | Trial | Phase 3 | — | $900M | Primary completion for Felzartamab trial (NCT06685757) in Antibody-mediated Rejection | ||
|
2026-12-01 in 773 days |
BIIB | Trial | Phase 3 | — | $8B | Primary completion for Placebo trial (NCT06685757) in Antibody-mediated Rejection | ||
|
2026-12-01 in 773 days |
VNDA | Trial | Phase 3 | — | $300M | Primary completion for Tradipitant trial (NCT07446439) in Nausea and Vomiting | ||
|
2026-12-01 in 773 days |
ACLX | PDUFA | NDA | — | — | Extracted from: Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition | ||
|
2026-12-01 in 773 days |
ZNTL | Trial | Phase 2 | — | $8B | Primary completion for azenosertib trial (NCT05128825) in High-Grade Serous Ovarian, Fallo | ||
|
2026-12-01 in 773 days |
RNAC | Trial | Phase 2 | — | $8B | Primary completion for Descartes-08 trial (NCT07089121) in Childhood-onset Systemic Lupus | ||
|
2026-12-01 in 773 days |
ALMS | Trial | Phase 3 | — | $12B | Primary completion for ESK-001 trial (NCT05739435) in Plaque Psoriasis | ||
|
2026-12-01 in 773 days |
SNY | Trial | Phase 2 | — | $5B | Primary completion for Pandemic flu H5 HA mRNA SD2 vaccine trial (NCT06907511) in Pandemic | ||
|
2026-12-01 in 773 days |
JAZZ | Trial | Phase 2 | — | $200M | Primary completion for Lurbinectedin trial (NCT05734066) in Refractory Ewing Sarcoma | ||
|
2026-12-01 in 773 days |
NVO | Trial | Phase 2 | — | $15B | Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight | ||
|
2026-12-01 in 773 days |
MRK | PDUFA | Phase 3 | — | $8B | For Renal cell carcinoma (RCC). Exelixis presented data on Zanzalintinib for renal cell ca | ||
|
2026-12-01 in 773 days |
UPB | Other | — | — | — | Upstream Bio announced participation in upcoming December 2026 investor conferences. No sp | ||
|
2026-12-02 in 774 days |
PFE | Trial | Phase 3 | — | $18B | Primary completion for Enzalutamide trial (NCT06629779) in Metastatic Castration-Resistant | ||
|
2026-12-02 in 774 days |
PFE | Trial | Phase 3 | — | $6B | Primary completion for PF-06821497 trial (NCT06629779) in Metastatic Castration-Resistant | ||
|
2026-12-03 in 775 days |
ESALY | Trial | Phase 2 | — | $15B | Primary completion for E2814 trial (NCT06602258) in Alzheimer's Disease | ||
|
2026-12-03 in 775 days |
ESALY | Trial | Phase 3 | — | $8B | Primary completion for Lecanemab trial (NCT06602258) in Alzheimer's Disease | ||
|
2026-12-05 in 777 days |
VRTX | PDUFA | — | 92% | $2B | DEC 5 2026 221 days 💊 PDUFA Journavx (suzetrigine) $VRTX Vertex Pharmaceuticals · sNDA Mod | ||
|
2026-12-05 in 777 days |
VRTX | PDUFA | — | 92% | — | DEC 5 2026 221 days 💊 PDUFA Journavx (suzetrigine) $VRTX Vertex Pharmaceuticals · sNDA Mod | ||
|
2026-12-06 in 778 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for ibuzatrelvir trial (NCT07013474) in COVID-19 Infection | ||
|
2026-12-09 in 781 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Capecitabine trial (NCT07069712) in Gastroesophageal Adenocarcinoma | ||
|
2026-12-09 in 781 days |
AZN | Trial | Phase 2 | — | $3B | Primary completion for AZD0901 trial (NCT07069712) in Gastroesophageal Adenocarcinoma | ||
|
2026-12-11 in 783 days |
PFE | Trial | Phase 3 | — | $5B | Primary completion for disitamab vedotin trial (NCT04879329) in Urothelial Carcinoma | ||
|
2026-12-14 in 786 days |
AMGN | Trial | Phase 3 | — | $6B | Primary completion for ABP 234 trial (NCT06430866) in Early-stage Non-squamous Non-small C | ||
|
2026-12-15 in 787 days |
AXSM | Trial | Phase 3 | — | $3B | Primary completion for Solriamfetol 150 mg trial (NCT06568367) in Excessive Sleepiness | ||
|
2026-12-15 in 787 days |
ABBV | Trial | Phase 3 | — | $12B | Primary completion for Placebo trial (NCT05843643) in Systemic Lupus Erythematosus | ||
|
2026-12-15 in 787 days |
ABBV | Trial | Phase 3 | — | $1B | Primary completion for Lutikizumab trial (NCT06468228) in Hidradenitis Suppurativa | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 3 | — | $4B | Primary completion for Topotecan trial (NCT06500026) in Small Cell Lung Cancer | ||
|
2026-12-15 in 787 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Ranibizumab (LUCENTIS®) trial (NCT04704921) in AMD | ||
|
2026-12-15 in 787 days |
MDGL | Trial | Phase 3 | — | $12B | Primary completion for Resmetirom trial (NCT05500222) in NASH | ||
|
2026-12-15 in 787 days |
IONS | Trial | Phase 3 | — | $2B | Primary completion for Donidalorsen trial (NCT05392114) in Hereditary Angioedema | ||
|
2026-12-15 in 787 days |
CODX | Trial | Phase 3 | — | $15B | Primary completion for SKB264 trial (NCT06711900) in Non-Small Cell Lung Cancer | ||
|
2026-12-15 in 787 days |
OCS | Trial | Phase 3 | — | $6B | Primary completion for licaminlimab trial (NCT07548632) in Dry Eye Disease (DED) | ||
|
2026-12-15 in 787 days |
AVIR | Trial | Phase 3 | — | $8B | Primary completion for Bemnifosbuvir-Ruzasvir trial (NCT07037277) in HEPATITIS C VIRUS CHR | ||
|
2026-12-15 in 787 days |
CODX | Trial | Phase 3 | — | $15B | Primary completion for pemetrexed trial (NCT06711900) in Non-Small Cell Lung Cancer | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for Docetaxel trial (NCT06382129) in Non-small Cell Lung Cancer | ||
|
2026-12-15 in 787 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Bulevirtide trial (NCT07128550) in Viral Hepatitis | ||
|
2026-12-15 in 787 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Tobevibart trial (NCT07128550) in Viral Hepatitis | ||
|
2026-12-15 in 787 days |
IPSEY | Trial | Phase 3 | — | $2B | Primary completion for IPN10200 trial (NCT07427797) in Moderate to Severe Glabellar Lines | ||
|
2026-12-15 in 787 days |
MDWD | Trial | Phase 3 | — | $2B | Primary completion for EscharEx (EX-03) trial (NCT06568627) in Venous Leg Ulcer (VLU) | ||
|
2026-12-15 in 787 days |
CLCS | Trial | Phase 3 | — | $6B | Primary completion for Immuncell-LC trial (NCT04969731) in Pancreatic Ductal Adenocarcinom | ||
|
2026-12-15 in 787 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Upadacitinib trial (NCT05843643) in Systemic Lupus Erythematosus | ||
|
2026-12-15 in 787 days |
CLCS | Trial | Phase 3 | — | $6B | Primary completion for Gemcitabine trial (NCT04969731) in Pancreatic Ductal Adenocarcinoma | ||
|
2026-12-15 in 787 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Elebsiran trial (NCT07128550) in Viral Hepatitis | ||
|
2026-12-15 in 787 days |
BHVN | Trial | Phase 3 | — | $5B | Primary completion for BHV-7000 trial (NCT06132893) in Focal Epilepsy | ||
|
2026-12-15 in 787 days |
KOD | Trial | Phase 3 | — | $2B | Primary completion for KSI-101 trial (NCT06996080) in Macular Edema Secondary to Inflammat | ||
|
2026-12-15 in 787 days |
KRYS | Trial | Phase 3 | — | $300M | Primary completion for KB803 trial (NCT07016750) in Dystrophic Epidermolysis Bullosa | ||
|
2026-12-15 in 787 days |
WXI | Trial | Phase 3 | — | $6B | Primary completion for Mesenchymal Stem Cells trial (NCT06570291) in Knee Osteoarthritis | ||
|
2026-12-15 in 787 days |
MANE | Trial | Phase 3 | — | $3B | Primary completion for VDPHL01 trial (NCT06972264) in Androgenetic Alopecia | ||
|
2026-12-15 in 787 days |
NAMS | Trial | Phase 3 | — | $15B | Primary completion for obicetrapib 10 mg + ezetimibe 10 mg FDC daily trial (NCT06305559) i | ||
|
2026-12-15 in 787 days |
DMAC | Trial | Phase 3 | — | $8B | Primary completion for Recombinant human tissue kallikrein trial (NCT05065216) in Acute St | ||
|
2026-12-15 in 787 days |
LLY | Trial | Phase 3 | — | $25B | Primary completion for Retatrutide trial (NCT06662383) in Obesity | ||
|
2026-12-15 in 787 days |
JNGHF | Trial | Phase 3 | — | $2B | Primary completion for Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide tri | ||
|
2026-12-15 in 787 days |
GILD | Trial | Phase 3 | — | $15B | Primary completion for Sacituzumab Govitecan-hziy trial (NCT04639986) in Metastatic Breast | ||
|
2026-12-15 in 787 days |
AXSM | Trial | Phase 3 | — | $2B | Primary completion for Solriamfetol 300 mg trial (NCT06568367) in Excessive Sleepiness | ||
|
2026-12-15 in 787 days |
GLSI | Trial | Phase 3 | — | $18B | Primary completion for GLSI-100 trial (NCT05232916) in Breast Cancer | ||
|
2026-12-15 in 787 days |
VNDA | Trial | Phase 3 | — | $2B | Primary completion for VQW-765 trial (NCT07221578) in Social Anxiety Disorder (SAD) | ||
|
2026-12-15 in 787 days |
IXHL | Trial | Phase 3 | — | — | Primary completion for IHL-42X Low Dose trial (NCT06146101) in Obstructive Sleep Apnea | ||
|
2026-12-15 in 787 days |
BIO | Trial | Phase 2 | — | $300M | Primary completion for DR-01 trial (NCT05475925) in LGLL - Large Granular Lymphocytic Leuk | ||
|
2026-12-15 in 787 days |
DSGN | Trial | Phase 2 | — | $300M | Primary completion for DT-216P2 trial (NCT06874010) in Friedreich Ataxia | ||
|
2026-12-15 in 787 days |
GILD | Trial | Phase 2 | — | $15B | Primary completion for anitocabtagene-autoleucel trial (NCT05396885) in Multiple Myeloma | ||
|
2026-12-15 in 787 days |
EIKN | Trial | Phase 3 | — | $8B | Primary completion for EIK1001 trial (NCT06246110) in NSCLC | ||
|
2026-12-15 in 787 days |
ABBV | Trial | Phase 2 | — | $6B | Primary completion for ABBV-400 trial (NCT06107413) in Unresectable Metastatic Colorectal | ||
|
2026-12-15 in 787 days |
VMAR | Trial | Phase 2 | — | $8B | Primary completion for SHJ002 trial (NCT06579287) in Myopia, Progressive | ||
|
2026-12-15 in 787 days |
VRNA | Trial | Phase 3 | — | $15B | Primary completion for Ensifentrine trial (NCT05270525) in COPD | ||
|
2026-12-15 in 787 days |
ARWR | Trial | Phase 2 | — | $400M | Primary completion for ARO-DUX4 for Injection trial (NCT06131983) in Facio-Scapulo-Humeral | ||
|
2026-12-15 in 787 days |
EXAS | Trial | Phase 2 | — | $2B | Primary completion for Modified FOLFIRINOX trial (NCT06850623) in Locally Advanced Pancrea | ||
|
2026-12-15 in 787 days |
EPRX | Trial | Phase 2 | — | $2B | Primary completion for EP-104GI trial (NCT05608681) in Eosinophilic Esophagitis | ||
|
2026-12-15 in 787 days |
JHPCY | Trial | Phase 2 | — | $15B | Primary completion for SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 trial (NCT05482568) in A | ||
|
2026-12-15 in 787 days |
TRAW | Trial | Phase 2 | — | $6B | Primary completion for TRX-100 trial (NCT07371650) in Influenza | ||
|
2026-12-15 in 787 days |
KRYS | Trial | Phase 2 | — | $600M | Primary completion for KB801 trial (NCT06999733) in Neurotrophic Keratitis | ||
|
2026-12-15 in 787 days |
CODX | Trial | Phase 2 | — | $15B | Primary completion for BL-M07D1 trial (NCT06131450) in Gynecological Malignancies | ||
|
2026-12-15 in 787 days |
EIKN | Trial | Phase 2 | — | $18B | Primary completion for Paclitaxel trial (NCT06246110) in NSCLC | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 2 | — | $12B | Primary completion for GNC-035 trial (NCT06066203) in Non-hodgkin's Lymphoma | ||
|
2026-12-15 in 787 days |
AVLN | Trial | Phase 2 | — | $8B | Primary completion for AP02 trial (NCT07194382) in Idiopathic Pulmonary Fibrosis (IPF) | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 2 | — | $3B | Primary completion for Envafolimab+Lenvatinib trial (NCT05112991) in Advanced Endometrial | ||
|
2026-12-15 in 787 days |
ZLAB | Trial | Phase 3 | — | $12B | Primary completion for ZL-1310 trial (NCT06885281) in Solid Tumors | ||
|
2026-12-15 in 787 days |
LLY | Trial | Phase 2 | — | $12B | Primary completion for Pirtobrutinib trial (NCT06721013) in Immune Thrombocytopenia (ITP) | ||
|
2026-12-15 in 787 days |
ABVX | Trial | Phase 2 | — | $8B | Primary completion for Obefazimod trial (NCT06456593) in Moderately to Severely Active Cro | ||
|
2026-12-15 in 787 days |
ALZN | Trial | Phase 2 | — | $8B | Primary completion for Lithium carbonate trial (NCT07540338) in Bipolar I Disorder | ||
|
2026-12-15 in 787 days |
ALZN | Trial | Phase 2 | — | $15B | Primary completion for AL001 trial (NCT07540338) in Bipolar I Disorder | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 2 | — | $3B | Primary completion for Lenvatinib + Envafolimab trial (NCT05024214) in Solid Tumors | ||
|
2026-12-15 in 787 days |
LLY | Trial | Phase 2 | — | $55B | Primary completion for LY3457263 trial (NCT06897475) in Type 2 Diabetes | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 2 | — | $100M | Primary completion for Test product: HYP-2090PTSA trial (NCT06243354) in Safety | ||
|
2026-12-15 in 787 days |
OMER | Trial | Phase 2 | — | $2B | Primary completion for OMS906 study drug trial (NCT06298955) in Paroxysmal Nocturnal Hemog | ||
|
2026-12-15 in 787 days |
PHAT | Trial | Phase 3 | — | $3B | Primary completion for Vonoprazan trial (NCT06851559) in Eosinophilic Esophagitis | ||
|
2026-12-15 in 787 days |
CODX | Trial | Phase 2 | — | $5B | Primary completion for SI-B003 trial (NCT05965856) in Urothelial Carcinoma | ||
|
2026-12-15 in 787 days |
ANRO | Trial | Phase 2 | — | $15B | Primary completion for Placebo trial (NCT05922878) in Major Depressive Disorder | ||
|
2026-12-15 in 787 days |
CODX | Trial | Phase 3 | — | $4B | Primary completion for BL-B01D1 trial (NCT05924841) in Small Cell Lung Cancer | ||
|
2026-12-15 in 787 days |
SBFMW | Trial | Phase 2 | — | $2B | Primary completion for HEC585 dose A trial (NCT05139719) in Progressive Fibrosing Intersti | ||
|
2026-12-15 in 787 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for Eluxadoline trial (NCT03339128) in Irritable Bowel Syndrome | ||
|
2026-12-15 in 787 days |
CODX | Trial | Phase 2 | — | $15B | Primary completion for PD-1 Monoclonal Antibody trial (NCT06008054) in Esophageal Cancer | ||
|
2026-12-15 in 787 days |
BEAM | Trial | Phase 2 | — | $2B | Primary completion for BEAM-201 trial (NCT05885464) in Lymphoblastic Lymphoma | ||
|
2026-12-15 in 787 days |
DNLI | Trial | Phase 2 | — | $1B | Primary completion for DNL593 trial (NCT05262023) in Frontotemporal Dementia | ||
|
2026-12-15 in 787 days |
FDMT | Trial | Phase 2 | — | $6B | Primary completion for 4D-710 trial (NCT05248230) in Cystic Fibrosis Lung | ||
|
2026-12-15 in 787 days |
ARWR | Trial | Phase 2 | — | $300M | Primary completion for ARO-DM1 Intravenous (IV) Infusion trial (NCT06138743) in Myotonic D | ||
|
2026-12-15 in 787 days |
ANRO | Trial | Phase 2 | — | $15B | Primary completion for ALTO-300 trial (NCT05922878) in Major Depressive Disorder | ||
|
2026-12-15 in 787 days |
OCUL | Trial | Phase 2 | — | $300M | Primary completion for d-MAPPS trial (NCT06852768) in oGHVD | ||
|
2026-12-15 in 787 days |
KRRO | Trial | Phase 2 | — | $800M | Primary completion for KRRO-110 trial (NCT06677307) in Alpha-1 Anti-trypsin Deficiency | ||
|
2026-12-15 in 787 days |
SKBBY | Trial | Phase 2 | — | $5B | Primary completion for GNC-038 trial (NCT05623982) in Non-hodgkin's Lymphoma | ||
|
2026-12-15 in 787 days |
ZURA | Trial | Phase 2 | — | $1B | Primary completion for Tibulizumab trial (NCT06843239) in Systemic Sclerosis (SSc) | ||
|
2026-12-15 in 787 days |
GEHC | Trial | Phase 2 | — | $15B | Primary completion for Regadenoson trial (NCT04604782) in Myocardial Ischemia | ||
|
2026-12-15 in 787 days |
ASND | Trial | Phase 2 | — | $2B | Primary completion for Navepegritide trial (NCT06732895) in Achondroplasia | ||
|
2026-12-16 in 788 days |
RHHBY | Trial | Phase 3 | — | $500M | Primary completion for Satralizumab trial (NCT05503264) in NMDAR Autoimmune Encephalitis | ||
|
2026-12-16 in 788 days |
BIO | Trial | Phase 3 | — | $6B | Primary completion for KN026 trial (NCT06747338) in Early or Locally Advanced HER2-positiv | ||
|
2026-12-16 in 788 days |
MRK | Trial | Phase 2 | — | $4B | Primary completion for Posaconazole IV 6 mg/kg trial (NCT04665037) in Invasive Fungal Infe | ||
|
2026-12-17 in 789 days |
IPSEY | Trial | Phase 3 | — | $1B | Primary completion for Elafibranor trial (NCT06730061) in Primary Biliary Cholangitis | ||
|
2026-12-17 in 789 days |
SNY | Trial | Phase 2 | — | $8B | Primary completion for SAR442970 trial (NCT06958536) in Crohn's Disease | ||
|
2026-12-18 in 790 days |
KDNY | Trial | Phase 3 | — | $2B | Primary completion for Atrasentan trial (NCT04573478) in IgA Nephropathy | ||
|
2026-12-18 in 790 days |
RHHBY | PDUFA | NDA | — | — | For adult patients with oestrogen receptor (ER)-positive. Extracted from news: FDA accepts | ||
|
2026-12-18 in 790 days |
ADVB | PDUFA | NDA | — | — | For adult patients with oestrogen receptor (ER)-positive. Extracted from: FDA accepts New | ||
|
2026-12-18 in 790 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for MEDI0618 trial (NCT06602479) in Migraine | ||
|
2026-12-18 in 790 days |
RHHBY | Trial | Phase 2 | — | $5B | Primary completion for Tobemstomig trial (NCT05852691) in Breast Cancer | ||
|
2026-12-18 in 790 days |
ABBV | Trial | Phase 3 | — | $12B | Primary completion for Placebo trial (NCT03339128) in Irritable Bowel Syndrome | ||
|
2026-12-21 in 793 days |
UCBJY | Trial | Phase 3 | — | $8B | Primary completion for Bimekizumab trial (NCT06921850) in Hidradenitis Suppurativa | ||
|
2026-12-22 in 794 days |
ADVM | Trial | Phase 3 | — | $8B | Primary completion for Aflibercept trial (NCT06856577) in Neovascular Age-Related Macular | ||
|
2026-12-22 in 794 days |
VRTX | Trial | Phase 2 | — | $300M | Primary completion for VX-670 trial (NCT06185764) in Myotonic Dystrophy Type 1 (DM1) | ||
|
2026-12-23 in 795 days |
SNY | Trial | Phase 3 | — | $28B | Primary completion for MRI contrast-enhancing agents trial (NCT06141486) in Multiple Scler | ||
|
2026-12-23 in 795 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Enfortumab vedotin (EV) trial (NCT04700124) in Bladder Cancer | ||
|
2026-12-23 in 795 days |
BIOE | Trial | Phase 3 | — | $8B | Primary completion for JOINTSTEM trial (NCT04427930) in Knee Osteoarthritis | ||
|
2026-12-23 in 795 days |
SNY | Trial | Phase 3 | — | $15B | Primary completion for Frexalimab trial (NCT06141486) in Multiple Sclerosis | ||
|
2026-12-23 in 795 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04700124) in Bladder Cancer | ||
|
2026-12-23 in 795 days |
SNYNF | Trial | Phase 2 | — | $2B | Primary completion for frexalimab trial (NCT06500702) in Focal Segmental Glomerulosclerosi | ||
|
2026-12-23 in 795 days |
VRTX | Trial | Phase 3 | — | $6B | Primary completion for IVA trial (NCT05668741) in Cystic Fibrosis | ||
|
2026-12-23 in 795 days |
VRTX | Trial | Phase 2 | — | $6B | Primary completion for VX-522 mRNA therapy trial (NCT05668741) in Cystic Fibrosis | ||
|
2026-12-24 in 796 days |
NVS | Trial | Phase 3 | — | $12B | Primary completion for Ofatumumab approved dose trial (NCT06869785) in Relapsing Multiple | ||
|
2026-12-25 in 797 days |
IPIX | Trial | Phase 3 | — | $2B | Primary completion for Gemcitabine hydrochloride and albumin binding paclitaxel trial (NCT | ||
|
2026-12-25 in 797 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for Semaglutide trial (NCT03811561) in Diabetes Mellitus, Type 2 | ||
|
2026-12-25 in 797 days |
PFE | Trial | Phase 3 | — | $3B | Primary completion for Ritlecitinib 50 mg trial (NCT07219615) in Chronic Spontaneous Urtic | ||
|
2026-12-26 in 798 days |
INCY | Trial | Phase 3 | — | $2B | Primary completion for Povorcitinib trial (NCT06212999) in Hidradenitis Suppurativa (HS) | ||
|
2026-12-27 in 799 days |
IDIA | PDUFA | NDA | — | $1B | BLA submitted. AI-extracted from: CG Oncology Conference: Credo Posts 75.5% CR in BOND-003 | ||
|
2026-12-27 in 799 days |
CNTA | PDUFA | NDA | — | $15B | For epilepsy. NDA submitted. AI-extracted from: Praxis tees up another approval filing; Ge | ||
|
2026-12-28 in 800 days |
NVS | Trial | Phase 3 | — | $2B | Primary completion for Iptacopan trial (NCT06517758) in Generalized Myasthenia Gravis | ||
|
2026-12-28 in 800 days |
MRK | Trial | Phase 2 | — | $6B | Primary completion for Ramucirumab trial (NCT06445972) in Gastroesophageal Junction | ||
|
2026-12-30 in 802 days |
CLCS | Trial | Phase 3 | — | $12B | Primary completion for JointStem trial (NCT04368806) in Osteoarthritis, Knee | ||
|
2026-12-30 in 802 days |
IVA | Trial | Phase 3 | — | $12B | Primary completion for IVA337 trial (NCT04849728) in NASH - Nonalcoholic Steatohepatitis | ||
|
2026-12-30 in 802 days |
JNGHF | Trial | Phase 3 | — | $5B | Primary completion for Vicagrel trial (NCT06577519) in Acute Coronary Syndrome (ACS) Under | ||
|
2026-12-30 in 802 days |
PFE | Trial | Phase 3 | — | $18B | Primary completion for ARV-471 (PF-07850327) trial (NCT05909397) in Breast Cancer | ||
|
2026-12-30 in 802 days |
JNGHF | Trial | Phase 3 | — | $4B | Primary completion for VC004 Capsules trial (NCT06658353) in Locally Advanced Solid Tumor | ||
|
2026-12-30 in 802 days |
SAIC | Trial | Phase 3 | — | $2B | Primary completion for MY008211A tablets trial (NCT06933914) in Paroxysmal Nocturnal Hemog | ||
|
2026-12-30 in 802 days |
OTSKF | Trial | Phase 3 | — | $2B | Primary completion for Sibeprenlimab 400 mg trial (NCT05248646) in Immunoglobulin A Nephro | ||
|
2026-12-30 in 802 days |
SKBBY | Trial | Phase 2 | — | $14B | Primary completion for KN035 trial (NCT03667170) in Solid Tumor | ||
|
2026-12-30 in 802 days |
PBMWW | Trial | Phase 2 | — | $2B | Primary completion for Psilocybin therapy trial (NCT07072728) in Adjustment Disorder | ||
|
2026-12-30 in 802 days |
NTHI | Trial | Phase 2 | — | $400M | Primary completion for NEO100 trial (NCT05023018) in Residual, Progressive or Recurrent Gr | ||
|
2026-12-30 in 802 days |
VRTX | Trial | Phase 2 | — | $2B | Primary completion for Inaxaplin trial (NCT06794996) in Proteinuric Kidney Disease | ||
|
2026-12-30 in 802 days |
BIO | Trial | Phase 2 | — | $2B | Primary completion for autologous dendritic cells trial (NCT04115761) in GBM | ||
|
2026-12-30 in 802 days |
BIO | Trial | Phase 2 | — | $12B | Primary completion for LB1410 trial (NCT06468358) in Solid Tumor | ||
|
2026-12-30 in 802 days |
SGIOY | Trial | Phase 2 | — | $4B | Primary completion for S-337395 trial (NCT07214571) in Respiratory Syncytial Virus Infecti | ||
|
2026-12-30 in 802 days |
AMGN | Trial | Phase 3 | — | $4B | Primary completion for Tarlatamab trial (NCT05060016) in Relapsed/Refractory Small Cell Lu | ||
|
2026-12-30 in 802 days |
NVS | Trial | Phase 3 | — | $2B | Primary completion for Iptacopan trial (NCT06388941) in Anti-Neutrophil Cytoplasm Antibodi | ||
|
2026-12-30 in 802 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for Docetaxel trial (NCT05631262) in Selected Subjects With Advanced So | ||
|
2026-12-30 in 802 days |
SKBBY | Trial | Phase 3 | — | $15B | Primary completion for SKB264 trial (NCT05631262) in Selected Subjects With Advanced Solid | ||
|
2026-12-30 in 802 days |
PFE | Trial | Phase 3 | — | $12B | Primary completion for ARV-471 trial (NCT05573555) in Breast Cancer | ||
|
2026-12-30 in 802 days |
SUPN | Trial | Phase 2 | — | $2B | Primary completion for BIS-001ER trial (NCT03474770) in Focal Impaired Awareness Seizures | ||
|
2026-12-30 in 802 days |
SLS | Trial | Phase 2 | — | $12B | Primary completion for SLS009 trial (NCT04588922) in Hematologic Malignancies | ||
|
2026-12-30 in 802 days |
SGHT | Trial | Phase 2 | — | $300M | Primary completion for BS01 trial (NCT04278131) in Retinitis Pigmentosa | ||
|
2026-12-30 in 802 days |
PFE | Trial | Phase 3 | — | $18B | Primary completion for Ribociclib trial (NCT05573555) in Breast Cancer | ||
|
2026-12-31 in 803 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Elebsiran trial (NCT06903338) in Viral Hepatitis | ||
|
2026-12-31 in 803 days |
PFE | Trial | Phase 3 | — | $15B | Primary completion for Lenalidomide trial (NCT04404283) in Diffuse Large B-cell Lymphoma | ||
|
2026-12-31 in 803 days |
FOLD | Trial | Phase 3 | — | $1B | Primary completion for migalastat HCl 150 mg trial (NCT04020055) in Fabry Disease | ||
|
2026-12-31 in 803 days |
TAK | Trial | Phase 3 | — | $800M | Primary completion for Maribavir trial (NCT06439342) in Cytomegalovirus (CMV) | ||
|
2026-12-31 in 803 days |
JNGHF | Trial | Phase 3 | — | $15B | Primary completion for SHR-A1811 trial (NCT05424835) in HER2-Positive, Unresectable and/or | ||
|
2026-12-31 in 803 days |
LRVIY | Trial | Phase 3 | — | $8B | Primary completion for Etoricoxib + Betamethasone fixed dose trial (NCT06863701) in Gout A | ||
|
2026-12-31 in 803 days |
JNGHF | Trial | Phase 3 | — | $6B | Primary completion for Pyrotinib in combination with Capecitabine. trial (NCT05424835) in | ||
|
2026-12-31 in 803 days |
GALDY | Trial | Phase 3 | — | $3B | Primary completion for Vehicle Cream trial (NCT07186413) in Acne Vulgaris | ||
|
2026-12-31 in 803 days |
SGEN | Trial | Phase 3 | — | $8B | Primary completion for brentuximab vedotin trial (NCT04609566) in Melanoma | ||
|
2026-12-31 in 803 days |
INSM | Trial | Phase 3 | — | $4B | Primary completion for Treprostinil Palmitil trial (NCT05649748) in Pulmonary Arterial Hyp | ||
|
2026-12-31 in 803 days |
ANNX | Trial | Phase 3 | — | $1B | Primary completion for Tanruprubart trial (NCT07020819) in Guillain-Barre Syndrome | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Pertuzumab trial (NCT02320435) in Solid Tumors | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 3 | — | $18B | Primary completion for Trastuzumab trial (NCT02320435) in Solid Tumors | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 3 | — | $15B | Primary completion for Inavolisib trial (NCT05894239) in Metastatic Breast Cancer | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 3 | — | $2B | Primary completion for Other Combination Anti-Cancer Therapies trial (NCT02320435) in Soli | ||
|
2026-12-31 in 803 days |
VIR | Trial | Phase 3 | — | $6B | Primary completion for Tobevibart trial (NCT06903338) in Viral Hepatitis | ||
|
2026-12-31 in 803 days |
IPSEY | Trial | Phase 3 | — | $300M | Primary completion for Odevixibat trial (NCT05035030) in Alagille Syndrome | ||
|
2026-12-31 in 803 days |
TGTX | Trial | Phase 3 | — | $9B | Primary completion for Ublituximab trial (NCT07211633) in Relapsing Multiple Sclerosis | ||
|
2026-12-31 in 803 days |
GALDY | Trial | Phase 3 | — | $3B | Primary completion for Trifarotene trial (NCT07186413) in Acne Vulgaris | ||
|
2026-12-31 in 803 days |
JNGHF | Trial | Phase 3 | — | $6B | Primary completion for Fuzuloparib , Abiraterone acetate and Prednisone trial (NCT04691804 | ||
|
2026-12-31 in 803 days |
NVO | PDUFA | — | — | — | For sickle cell disease. Novo Nordisk's etavopivat demonstrated significant efficacy in la | ||
|
2026-12-31 in 803 days |
IDYA | Trial | Phase 3 | — | $800M | Primary completion for IDE196 trial (NCT03947385) in Metastatic Uveal Melanoma | ||
|
2026-12-31 in 803 days |
HKPD | Trial | Phase 2 | — | $2B | Primary completion for EI-001 trial (NCT07223229) in Non-segmental Vitiligo | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Tocilizumab trial (NCT04524871) in Advanced Liver Cancers | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 2 | — | $5B | Primary completion for Atezolizumab trial (NCT05645692) in Urothelial Cancer | ||
|
2026-12-31 in 803 days |
GSK | Trial | Phase 2 | — | $2B | Primary completion for MMB trial (NCT03441113) in Neoplasms | ||
|
2026-12-31 in 803 days |
RHHBY | Trial | Phase 2 | — | $6B | Primary completion for Bevacizumab 15 mg/kg trial (NCT04524871) in Advanced Liver Cancers | ||
|
2026-12-31 in 803 days |
GOVX | Trial | Phase 2 | — | $15B | Primary completion for COVID-19 Vaccine trial (NCT04977024) in COVID-19 Infection | ||
|
2026-12-31 in 803 days |
SKBBY | Trial | Phase 2 | — | $3B | Primary completion for KL590586 Capsule trial (NCT05265091) in Advanced Solid Tumor | ||
|
2026-12-31 in 803 days |
MRK | Trial | Phase 2 | — | $15B | Primary completion for MK-1167 trial (NCT06721156) in Alzheimer Disease | ||
|
2026-12-31 in 803 days |
JAZZ | Trial | Phase 3 | — | $15B | Primary completion for Zanidatamab trial (NCT06695845) in Breast Cancer | ||
|
2026-12-31 in 803 days |
MRTX | Trial | Phase 3 | — | $5B | Primary completion for MRTX849 trial (NCT03785249) in Advanced Cancer | ||
|
2026-12-31 in 803 days |
PFE | Trial | Phase 3 | — | $18B | Primary completion for Palbociclib trial (NCT05226871) in Breast Cancer | ||
|
2026-12-31 in 803 days |
BIOE | Trial | Phase 2 | — | $5B | Primary completion for CD19-targeted chimeric antigen receptor T-cell trial (NCT05326243) | ||
|
2026-12-31 in 803 days |
MRTX | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT03785249) in Advanced Cancer | ||
|
2026-12-31 in 803 days |
CLCS | Trial | Phase 2 | — | $1B | Primary completion for Super DC Vaccine trial (NCT07146672) in Solid Tumor Cancer | ||
|
2026-12-31 in 803 days |
ANRO | Trial | Phase 2 | — | $6B | Primary completion for STI-6129 trial (NCT05565807) in Relapsed or Refractory Multiple Mye | ||
|
2026-12-31 in 803 days |
MNOV | Trial | Phase 2 | — | $8B | Primary completion for MN-001 trial (NCT05464784) in Diabetes Mellitus, Type 2 | ||
|
2026-12-31 in 803 days |
BPMC | Trial | Phase 2 | — | $800M | Primary completion for BLU-808 trial (NCT06931405) in Chronic Inducible Urticaria | ||
|
2026-12-31 in 803 days |
INCY | Trial | Phase 3 | — | $5B | Primary completion for tafasitamab trial (NCT04661007) in Non Hodgkins Lymphoma | ||
|
2026-12-31 in 803 days |
SBFM | Trial | Phase 2 | — | $5B | Primary completion for SSGJ-705 trial (NCT07022002) in Locally Advanced, Recurrent or Meta | ||
|
2026-12-31 in 803 days |
INCY | Trial | Phase 3 | — | $4B | Primary completion for lenalidomide trial (NCT04661007) in Non Hodgkins Lymphoma | ||
|
2026-12-31 in 803 days |
INO | Trial | Phase 2 | — | $2B | Primary completion for INO-5401 trial (NCT03491683) in Glioblastoma | ||
|
2026-12-31 in 803 days |
SUPN | Trial | Phase 2 | — | $15B | Primary completion for SPN-821 2400 mg trial (NCT07226661) in Major Depressive Disorder (M | ||
|
2026-12-31 in 803 days |
BMY | Trial | — | — | — | For Alzheimer's psychosis. Bristol Myers has extended the ADEPT-2 Phase 3 trial of Cobenfy | ||
|
2026-12-31 in 803 days |
POCI | Trial | Phase 2 | — | $4B | Primary completion for CD19 and CD22 targeted prime CAR-T cells trial (NCT04781634) in B-A | ||
|
2026-12-31 in 803 days |
MRTX | Trial | Phase 3 | — | $6B | Primary completion for Cetuximab trial (NCT03785249) in Advanced Cancer | ||
|
2026-12-31 in 803 days |
PFE | Trial | Phase 3 | — | $4B | Primary completion for Cetuximab trial (NCT05226871) in Breast Cancer | ||
|
2026-12-31 in 803 days |
POCI | Trial | Phase 2 | — | $15B | Primary completion for BCMA CAR-T cells trial (NCT04271644) in Multiple Myeloma | ||
|
2026-12-31 in 803 days |
INCY | Trial | Phase 2 | — | $9B | Primary completion for R-CHOP trial (NCT04661007) in Non Hodgkins Lymphoma | ||
|
2026-12-31 in 803 days |
POCI | Trial | Phase 2 | — | $15B | Primary completion for BCMA targeted prime CAR-T cells trial (NCT04776330) in Multiple Mye | ||
|
2026-12-31 in 803 days |
INCY | Trial | Phase 2 | — | $8B | Primary completion for parsaclisib trial (NCT04661007) in Non Hodgkins Lymphoma | ||
|
2026-12-31 in 803 days |
PFE | Trial | Phase 3 | — | $18B | Primary completion for Letrozole trial (NCT05226871) in Breast Cancer | ||
|
2026-12-31 in 803 days |
ESLA | Trial | Phase 2 | — | $6B | Primary completion for EB103 trial (NCT06343311) in B-Cell Non-Hodgkin's Lymphoma (NHL) | ||
|
2026-12-31 in 803 days |
PFE | Trial | Phase 3 | — | $4B | Primary completion for Fulvestrant trial (NCT05226871) in Breast Cancer | ||
|
2026-12-31 in 803 days |
RHHBY | PDUFA | — | — | — | Roche outlined its rejuvenation strategy for oncology and haematology, expecting to file u | ||
|
2026-12-31 in 803 days |
REGN | Trial | — | — | — | For PNH. Regeneron Pharmaceuticals outlined its C5 strategy with PNH data expected in Q4 2 | ||
|
2026-12-31 in 803 days |
WXI | Other | — | — | — | Thermo Fisher Scientific is closing its chemical analysis manufacturing facility in Frankl | ||
|
2027-01-01 in 9673 days |
EXEL | PDUFA | Phase 3 | — | $6B | For advanced hepatocellular carcinoma. sNDA filing. Extracted from SEC filing: 8-K | ||
|
2027-01-01 in 9673 days |
TAK | PDUFA | NDA | — | $2B | For Polycythemia Vera. NDA filing. AI-extracted from news: Takeda, Protagonist Say FDA Acc | ||
|
2027-01-01 in 9673 days |
REPL | Trial | Phase 2 | — | $3B | Primary completion for RP3 trial (NCT05733611) in Refractory Metastatic Colorectal Cancer | ||
|
2027-01-01 in 9673 days |
REPL | Trial | Phase 3 | — | $800M | Primary completion for RP2 trial (NCT05733611) in Refractory Metastatic Colorectal Cancer | ||
|
2027-01-01 in 9673 days |
GILD | Other | — | — | — | Galapagos and Gilead announced a partnership on Gamgertamig with Galapagos receiving $500M | ||
|
2027-01-01 in 9673 days |
PFE | Other | — | — | — | Pfizer plans to launch 15 new obesity studies next year, predominantly in Phase 3, as a st | ||
|
2027-01-01 in 9673 days |
NVO | Other | — | — | — | For weight management. Novo Nordisk announced significant reductions in US list prices for | ||
|
2027-01-01 in 9673 days |
NBP | Trial | — | — | — | For HER2-negative, first-line metastatic gastric cancer. NovaBridge Biosciences initiated | ||
|
2027-01-01 in 9673 days |
TLRY | Other | — | — | — | Tilray Brands and Carlsberg Group announced an exclusive multi-year U.S. brewing and comme | ||
|
2027-01-01 in 9673 days |
CNTA | Other | — | — | — | Centessa Pharmaceuticals announced a CEO transition with president Mario Alberto Accardi s | ||
|
2027-01-03 in 9675 days |
ARGX | PDUFA | Phase 3 | — | $500M | For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K | ||
|
2027-01-04 in 9676 days |
MRK | Trial | Phase 3 | — | $12B | Primary completion for Paclitaxel trial (NCT06356311) in Gastroesophageal Cancer | ||
|
2027-01-04 in 9676 days |
MRK | Trial | Phase 3 | — | $3B | Primary completion for Rescue medication trial (NCT06356311) in Gastroesophageal Cancer | ||
|
2027-01-04 in 9676 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Sacituzumab tirumotecan trial (NCT06356311) in Gastroesophageal Can | ||
|
2027-01-04 in 9676 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Supportive care measures trial (NCT06356311) in Gastroesophageal Ca | ||
|
2027-01-04 in 9676 days |
AZNCF | Trial | Phase 3 | — | $4B | Primary completion for AZD0780 trial (NCT07000136) in Heterozygous Familial Hypercholester | ||
|
2027-01-04 in 9676 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Trifluridine-Tipiracil trial (NCT06356311) in Gastroesophageal Canc | ||
|
2027-01-07 in 9679 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Ranibizumab trial (NCT04657289) in Neovascular Age-related Macular | ||
|
2027-01-07 in 9679 days |
SNYNF | Trial | Phase 3 | — | $4B | Primary completion for PCV21 trial (NCT07247188) in Sickle Cell Disease | ||
|
2027-01-07 in 9679 days |
NVSEF | Trial | Phase 2 | — | $1B | Primary completion for EYU688 trial (NCT06006559) in Dengue | ||
|
2027-01-07 in 9679 days |
AZN | Trial | Phase 2 | — | $12B | Primary completion for AZD9829 trial (NCT06179511) in Hematological Malignancies | ||
|
2027-01-08 in 9680 days |
SNY | Trial | Phase 3 | — | $15B | Primary completion for Itepekimab (SAR440340) trial (NCT06834347) in Chronic Rhinosinusiti | ||
|
2027-01-08 in 9680 days |
OCUL | Trial | Phase 3 | — | $8B | Primary completion for Aflibercept trial (NCT06495918) in Neovascular Age-related Macular | ||
|
2027-01-08 in 9680 days |
SNY | Trial | Phase 3 | — | $2B | Primary completion for Mometasone furoate nasal spray (MFNS) trial (NCT06834360) in Chroni | ||
|
2027-01-08 in 9680 days |
SNY | Trial | Phase 2 | — | $4B | Primary completion for Isatuximab SC-OBDS trial (NCT06356571) in Plasma Cell Myeloma Refra | ||
|
2027-01-11 in 9683 days |
AZNCF | Trial | Phase 3 | — | $900M | Primary completion for AZD0780 trial (NCT07000123) in Cardiovascular Disease | ||
|
2027-01-12 in 9684 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Sacituzumab Govitecan trial (NCT05609968) in Carcinoma, Non-Small-C | ||
|
2027-01-12 in 9684 days |
GSK | Trial | Phase 2 | — | $4B | Primary completion for Adjuvanted RSVPreF3 vaccine trial (NCT07092865) in Respiratory Sync | ||
|
2027-01-14 in 9686 days |
SBFM | Trial | Phase 3 | — | $12B | Primary completion for Placebo trial (NCT07261644) in Ankylosing Spondylitis | ||
|
2027-01-14 in 9686 days |
SBFM | Trial | Phase 3 | — | $3B | Primary completion for 608 dose trial (NCT07261644) in Ankylosing Spondylitis | ||
|
2027-01-14 in 9686 days |
NVO | Trial | Phase 2 | — | $15B | Primary completion for UBT251 trial (NCT07395687) in Overweight | ||
|
2027-01-14 in 9686 days |
REGN | Trial | Phase 3 | — | $15B | Primary completion for Sarilumab trial (NCT05125016) in Metastatic Castration-resistant Pr | ||
|
2027-01-14 in 9686 days |
REGN | Trial | Phase 3 | — | $1B | Primary completion for Cemiplimab trial (NCT05125016) in Metastatic Castration-resistant P | ||
|
2027-01-14 in 9686 days |
REGN | Trial | Phase 2 | — | $6B | Primary completion for REGN5678 trial (NCT05125016) in Metastatic Castration-resistant Pro | ||
|
2027-01-15 in 9687 days |
RARE | Trial | Phase 3 | — | $300M | Primary completion for setrusumab trial (NCT06636071) in Osteogenesis Imperfecta | ||
|
2027-01-15 in 9687 days |
GSK | Trial | Phase 3 | — | $20B | Primary completion for FF/UMEC/VI trial (NCT05757102) in Asthma | ||
|
2027-01-15 in 9687 days |
POCI | Trial | Phase 3 | — | $4B | Primary completion for 40 mg/day vormatrogine for 12 weeks trial (NCT07505004) in Focal Ep | ||
|
2027-01-15 in 9687 days |
PCVX | Trial | Phase 3 | — | $6B | Primary completion for 31 valent pneumococcal conjugate vaccine trial (NCT07284654) in Pne | ||
|
2027-01-15 in 9687 days |
SNY | Trial | Phase 3 | — | $5B | Primary completion for efanesoctocog alfa (BIVV001) trial (NCT04644575) in Hemophilia A | ||
|
2027-01-15 in 9687 days |
IDYA | Trial | Phase 3 | — | $800M | Primary completion for IDE196 trial (NCT05987332) in Metastatic Uveal Melanoma | ||
|
2027-01-15 in 9687 days |
PCVX | Trial | Phase 3 | — | $6B | Primary completion for PCV20 trial (NCT07284654) in Pneumococcal Vaccines | ||
|
2027-01-15 in 9687 days |
CRMD | Trial | Phase 3 | — | $800M | Primary completion for (taurolidine and heparin) catheter lock solution trial (NCT06822426 | ||
|
2027-01-15 in 9687 days |
IDYA | Trial | Phase 3 | — | $800M | Primary completion for Crizotinib trial (NCT05987332) in Metastatic Uveal Melanoma | ||
|
2027-01-15 in 9687 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Upadacitinib trial (NCT06701331) in Atopic Dermatitis | ||
|
2027-01-15 in 9687 days |
LLY | Trial | Phase 3 | — | $25B | Primary completion for Orforglipron trial (NCT06972472) in Obesity | ||
|
2027-01-15 in 9687 days |
MLTX | Trial | Phase 3 | — | $5B | Primary completion for Risankizumab trial (NCT06641089) in Arthritis, Psoriatic | ||
|
2027-01-15 in 9687 days |
AMGN | Trial | Phase 3 | — | $10B | Primary completion for Ocrelizumab (US) trial (NCT06700343) in Relapsing-remitting Multipl | ||
|
2027-01-15 in 9687 days |
AZTR | Trial | Phase 2 | — | $2B | Primary completion for ATR04-484 trial (NCT06830863) in EGFR Inhibitor-associated Rash | ||
|
2027-01-15 in 9687 days |
GILD | Trial | Phase 2 | — | $8B | Primary completion for Tilpisertib Fosmecarbil trial (NCT06029972) in Ulcerative Colitis | ||
|
2027-01-15 in 9687 days |
COYA | Trial | Phase 2 | — | $2B | Primary completion for COYA 302 trial (NCT07161999) in Amyotrophic Lateral Sclerosis (ALS) | ||
|
2027-01-15 in 9687 days |
LRMR | Trial | Phase 2 | — | $300M | Primary completion for CTI-1601 trial (NCT06447025) in Friedreich Ataxia | ||
|
2027-01-15 in 9687 days |
RXRX | Trial | Phase 2 | — | $200M | Primary completion for REC-4881 trial (NCT06005974) in AXIN1 Gene Mutation | ||
|
2027-01-15 in 9687 days |
RCUS | Trial | Phase 3 | — | $3B | Primary completion for Domvanalimab trial (NCT05329766) in Gastrointestinal Tract Malignan | ||
|
2027-01-15 in 9687 days |
BIOE | Trial | Phase 2 | — | $200M | Primary completion for Hemopfin+Green Light trial (NCT05171894) in Port-wine Birthmarks | ||
|
2027-01-15 in 9687 days |
RCUS | Trial | Phase 3 | — | $12B | Primary completion for Quemliclustat trial (NCT05329766) in Gastrointestinal Tract Maligna | ||
|
2027-01-15 in 9687 days |
MRNA | Trial | Phase 2 | — | $800M | Primary completion for mRNA-1647 trial (NCT05575492) in Cytomegalovirus | ||
|
2027-01-15 in 9687 days |
EWTX | Trial | Phase 2 | — | $1B | Primary completion for Sevasemten Dose 1 trial (NCT05540860) in Duchenne Muscular Dystroph | ||
|
2027-01-15 in 9687 days |
MPLT | Trial | Phase 2 | — | $12B | Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia | ||
|
2027-01-15 in 9687 days |
RCUS | Trial | Phase 3 | — | $15B | Primary completion for Zimberelimab trial (NCT05329766) in Gastrointestinal Tract Malignan | ||
|
2027-01-16 in 9688 days |
CRBP | Trial | Phase 2 | — | $2B | Primary completion for CRB-701 trial (NCT06265727) in Solid Tumor, Adult | ||
|
2027-01-17 in 9689 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for pembrolizumab trial (NCT03407144) in Hodgkin Lymphoma | ||
|
2027-01-17 in 9689 days |
MRK | Trial | Phase 2 | — | $6B | Primary completion for Sacituzumab Tirumotecan (sac-TMT) trial (NCT06469944) in Gastroesop | ||
|
2027-01-18 in 9690 days |
TKPHF | Trial | Phase 3 | — | $800M | Primary completion for Maribavir trial (NCT05319353) in Cytomegalovirus (CMV) | ||
|
2027-01-18 in 9690 days |
PFE | Trial | Phase 3 | — | $6B | Primary completion for RSVpreF trial (NCT05035212) in Lower Respiratory Tract Illness | ||
|
2027-01-18 in 9690 days |
SNY | Trial | Phase 2 | — | $3B | Primary completion for Investigational hMPV/RSV vaccine trial (NCT06686654) in Human Metap | ||
|
2027-01-18 in 9690 days |
AZNCF | Trial | Phase 3 | — | $4B | Primary completion for Durvalumab trial (NCT05374603) in Lung Cancer | ||
|
2027-01-18 in 9690 days |
AZN | Trial | Phase 3 | — | $4B | Primary completion for Savolitinib trial (NCT05374603) in Lung Cancer | ||
|
2027-01-19 in 9691 days |
SNY | Trial | Phase 2 | — | $3B | Primary completion for SAR445877 trial (NCT05584670) in Solid Tumor | ||
|
2027-01-20 in 9692 days |
GSK | Trial | Phase 2 | — | $3B | Primary completion for Bepirovirsen trial (NCT06497504) in Hepatitis B | ||
|
2027-01-21 in 9693 days |
AMGN | Trial | Phase 3 | — | $80B | Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mell | ||
|
2027-01-25 in 9697 days |
NVO | Trial | Phase 3 | — | $8B | Primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1 | ||
|
2027-01-25 in 9697 days |
VRTX | Trial | Phase 3 | — | $30B | Primary completion for Suzetrigine trial (NCT06696443) in Diabetic Peripheral Neuropathic | ||
|
2027-01-25 in 9697 days |
PFE | Trial | Phase 2 | — | $50B | Primary completion for MET233 and MET097 trial (NCT06924320) in Obesity and Obesity-relate | ||
|
2027-01-28 in 9700 days |
REGN | Trial | Phase 3 | — | $2B | Primary completion for Ravulizumab trial (NCT05133531) in Paroxysmal Nocturnal Hemoglobinu | ||
|
2027-01-28 in 9700 days |
REGN | Trial | Phase 3 | — | $2B | Primary completion for Cemdisiran trial (NCT05133531) in Paroxysmal Nocturnal Hemoglobinur | ||
|
2027-01-28 in 9700 days |
REGN | Trial | Phase 3 | — | $300M | Primary completion for Pozelimab trial (NCT05133531) in Paroxysmal Nocturnal Hemoglobinuri | ||
|
2027-01-28 in 9700 days |
VNDA | PDUFA | Phase 2 | — | $3B | For Rare Skin Disease. BLA filing. AI-extracted from news: Vanda Pharmaceuticals Says US F | ||
|
2027-01-28 in 9700 days |
AZN | Trial | Phase 3 | — | $4B | Primary completion for Rilvegostomig trial (NCT07069712) in Gastroesophageal Adenocarcinom | ||
|
2027-01-28 in 9700 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Capecitabine trial (NCT07069712) in Gastroesophageal Adenocarcinoma | ||
|
2027-01-28 in 9700 days |
AZN | Trial | Phase 2 | — | $6B | Primary completion for 5-Fluorouracil (5-FU) trial (NCT07069712) in Gastroesophageal Adeno | ||
|
2027-01-28 in 9700 days |
AZN | Trial | Phase 2 | — | $3B | Primary completion for AZD0901 trial (NCT07069712) in Gastroesophageal Adenocarcinoma | ||
|
2027-01-29 in 9701 days |
NVS | Trial | Phase 3 | — | $2B | Primary completion for iptacopan trial (NCT04817618) in C3G | ||
|
2027-01-29 in 9701 days |
IDYA | Trial | Phase 3 | — | $800M | Primary completion for Crizotinib trial (NCT03947385) in Metastatic Uveal Melanoma | ||
|
2027-01-30 in 9702 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Afimkibart trial (NCT06588855) in Moderately to Severely Active Ulc | ||
|
2027-01-31 in 9703 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Fluorouracil (5-FU) trial (NCT04241185) in Urinary Bladder Neoplasm | ||
|
2027-01-31 in 9703 days |
RHHBY | Trial | Phase 2 | — | $28B | Primary completion for Ocrelizumab Test Formulation trial (NCT07074886) in Multiple Sclero | ||
|
2027-01-31 in 9703 days |
DSKYF | Trial | Phase 2 | — | $1B | Primary completion for DS-5141b trial (NCT04433234) in Duchenne Muscular Dystrophy | ||
|
2027-01-31 in 9703 days |
CHHE | Trial | Phase 2 | — | $2B | Primary completion for MK-1045 trial (NCT05579132) in Acute Lymphoblastic Leukemia | ||
|
2027-01-31 in 9703 days |
CELZ | Trial | Phase 2 | — | $15B | Primary completion for CELZ-201 Administration trial (NCT05626712) in Type 1 Diabetes | ||
|
2027-01-31 in 9703 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Oxaliplatin trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma | ||
|
2027-01-31 in 9703 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Gemcitabine trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma | ||
|
2027-01-31 in 9703 days |
RHHBY | Trial | Phase 3 | — | $5B | Primary completion for Glofitamab trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma | ||
|
2027-01-31 in 9703 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Obinutuzumab trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma | ||
|
2027-02-01 in 9773 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Cisplatin trial (NCT04241185) in Urinary Bladder Neoplasms | ||
|
2027-02-01 in 9773 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04241185) in Urinary Bladder Neoplasms | ||
|
2027-02-01 in 9773 days |
MRK | Trial | Phase 3 | — | $2B | Primary completion for levoleucovorin trial (NCT04210115) in Esophageal Squamous Cell Carc | ||
|
2027-02-01 in 9773 days |
MRK | Trial | Phase 3 | — | $2B | Primary completion for 5-FU trial (NCT04210115) in Esophageal Squamous Cell Carcinoma (ESC | ||
|
2027-02-01 in 9773 days |
MRK | Trial | Phase 3 | — | $3B | Primary completion for leucovorin trial (NCT04210115) in Esophageal Squamous Cell Carcinom | ||
|
2027-02-01 in 9773 days |
NVS | Trial | Phase 2 | — | $500M | Primary completion for LEE011 trial (NCT01872260) in Breast Cancer | ||
|
2027-02-02 in 9774 days |
NVS | Trial | Phase 2 | — | $8B | Primary completion for LXH254 trial (NCT04417621) in Melanoma | ||
|
2027-02-03 in 9775 days |
BAYRY | Trial | Phase 3 | — | $4B | Primary completion for BAY2927088 trial (NCT06760819) in Advanced Solid Tumors | ||
|
2027-02-04 in 9776 days |
MLTX | Trial | Phase 3 | — | $1B | Primary completion for Sonelokimab trial (NCT06641076) in Arthritis, Psoriatic | ||
|
2027-02-05 in 9777 days |
BMY | Trial | Phase 3 | — | $15B | Primary completion for Carboplatin trial (NCT06946797) in Non-Small Cell Lung Cancer | ||
|
2027-02-05 in 9777 days |
BMY | Trial | Phase 3 | — | $8B | Primary completion for Ipilimumab trial (NCT06946797) in Non-Small Cell Lung Cancer | ||
|
2027-02-05 in 9777 days |
BMY | Trial | Phase 3 | — | $4B | Primary completion for Nivolumab trial (NCT06946797) in Non-Small Cell Lung Cancer | ||
|
2027-02-05 in 9777 days |
BMY | Trial | Phase 3 | — | $12B | Primary completion for Paclitaxel trial (NCT06946797) in Non-Small Cell Lung Cancer | ||
|
2027-02-05 in 9777 days |
BMY | Trial | Phase 2 | — | $15B | Primary completion for Pemetrexed trial (NCT06946797) in Non-Small Cell Lung Cancer | ||
|
2027-02-08 in 9780 days |
RHHBY | Trial | Phase 2 | — | $50B | Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus | ||
|
2027-02-08 in 9780 days |
RHHBY | Trial | Phase 2 | — | $55B | Primary completion for Semaglutide trial (NCT07112872) in Type 2 Diabetes Mellitus | ||
|
2027-02-09 in 9781 days |
REGN | Trial | Phase 2 | — | $8B | Primary completion for REGN9933 trial (NCT07175428) in Atrial Fibrillation (AF) | ||
|
2027-02-09 in 9781 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for REGN7508 trial (NCT07175428) in Atrial Fibrillation (AF) | ||
|
2027-02-09 in 9781 days |
REGN | Trial | Phase 2 | — | $12B | Primary completion for Apixaban trial (NCT07175428) in Atrial Fibrillation (AF) | ||
|
2027-02-10 in 9782 days |
TAK | Trial | Phase 3 | — | $800M | Primary completion for Teduglutide trial (NCT06973304) in Short Bowel Syndrome | ||
|
2027-02-11 in 9783 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Ranibizumab trial (NCT04567303) in Macular Degeneration | ||
|
2027-02-11 in 9783 days |
RHHBY | Trial | Phase 2 | — | $10B | Primary completion for Zifibancimig trial (NCT04567303) in Macular Degeneration | ||
|
2027-02-11 in 9783 days |
AZNCF | Trial | Phase 2 | — | $8B | Primary completion for AZD4144 trial (NCT07215702) in Sepsis | ||
|
2027-02-12 in 9784 days |
DCPH | PDUFA | NDA | — | $200M | For relapsed or refractory PCNSL. NDA accepted. AI-extracted from: Deciphera Pharmaceutica | ||
|
2027-02-12 in 9784 days |
OCUL | PDUFA | NDA | — | $12B | For wet-AMD. NDA submitted. AI-extracted from: Ocular: 'Buy' As AXPAXLI Program For Wet-AM | ||
|
2027-02-13 in 9785 days |
EPZM | Trial | Phase 3 | — | $8B | Primary completion for Tazemetostat trial (NCT04224493) in Relapsed/Refractory Follicular | ||
|
2027-02-13 in 9785 days |
MRK | Trial | Phase 2 | — | $7B | Primary completion for vinblastine trial (NCT03407144) in Hodgkin Lymphoma | ||
|
2027-02-13 in 9785 days |
PFE | Trial | Phase 2 | — | $3B | Primary completion for PF-07868489 trial (NCT06137742) in Pulmonary Arterial Hypertension | ||
|
2027-02-13 in 9785 days |
MRK | Trial | Phase 3 | — | $18B | Primary completion for doxorubicin trial (NCT03407144) in Hodgkin Lymphoma | ||
|
2027-02-13 in 9785 days |
MRK | Trial | Phase 2 | — | $4B | Primary completion for etoposide trial (NCT03407144) in Hodgkin Lymphoma | ||
|
2027-02-15 in 9787 days |
BIO | Trial | Phase 2 | — | $2B | Primary completion for NH002 (Perflutren Lipid Microspheres) Injectable Suspension trial ( | ||
|
2027-02-15 in 9787 days |
GMAB | Trial | Phase 3 | — | $4B | Primary completion for Paclitaxel trial (NCT06619236) in Platinum-resistant Ovarian Cancer | ||
|
2027-02-15 in 9787 days |
GILD | Trial | Phase 3 | — | $5B | Primary completion for Sacituzumab Govitecan-hziy trial (NCT05382286) in Triple Negative B | ||
|
2027-02-15 in 9787 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Atogepant trial (NCT06806293) in Menstrual Migraine (MM) | ||
|
2027-02-15 in 9787 days |
LLY | Trial | Phase 3 | — | $25B | Primary completion for Orforglipron trial (NCT06672549) in Obesity | ||
|
2027-02-15 in 9787 days |
SBFM | Trial | Phase 3 | — | $20B | Primary completion for 610 trial (NCT06680947) in Asthma | ||
|
2027-02-15 in 9787 days |
GMAB | Trial | Phase 3 | — | $4B | Primary completion for Rina-S trial (NCT06619236) in Platinum-resistant Ovarian Cancer | ||
|
2027-02-15 in 9787 days |
MRNA | Trial | Phase 3 | — | $2B | Primary completion for mRNA-1403 trial (NCT06592794) in Acute Gastroenteritis | ||
|
2027-02-15 in 9787 days |
GILD | Trial | Phase 3 | — | $2B | Primary completion for Paclitaxel trial (NCT05382286) in Triple Negative Breast Cancer | ||
|
2027-02-15 in 9787 days |
NVS | Trial | Phase 3 | — | $300M | Primary completion for Inclisiran trial (NCT07102628) in Acute Coronary Syndrome | ||
|
2027-02-15 in 9787 days |
XLO | Trial | Phase 2 | — | $4B | Primary completion for XTX301 trial (NCT05684965) in Advanced Solid Tumor | ||
|
2027-02-15 in 9787 days |
ABBV | Trial | Phase 3 | — | $8B | Primary completion for Venetoclax trial (NCT04086264) in Acute Myeloid Leukemia | ||
|
2027-02-15 in 9787 days |
IRON | Trial | Phase 2 | — | $2B | Primary completion for DISC-3405 trial (NCT06985147) in Polycythemia Vera (PV) | ||
|
2027-02-15 in 9787 days |
ABCL | Trial | Phase 2 | — | $2B | Primary completion for ABCL635 trial (NCT07118891) in Vasomotor Symptoms Associated With M | ||
|
2027-02-15 in 9787 days |
GNLX | Trial | Phase 2 | — | $10B | Primary completion for Platinum chemotherapy: carboplatin or cisplatin trial (NCT06463665) | ||
|
2027-02-15 in 9787 days |
KRYS | Trial | Phase 2 | — | $10B | Primary completion for KB707 trial (NCT06228326) in Lung Cancer, Non-small Cell | ||
|
2027-02-15 in 9787 days |
ABBV | Trial | Phase 2 | — | $25B | Primary completion for Ravagalimab trial (NCT06972446) in Rheumatoid Arthritis | ||
|
2027-02-15 in 9787 days |
MGNX | Trial | Phase 2 | — | $8B | Primary completion for Lorigerlimab trial (NCT06730347) in Platinum-resistant Ovarian Canc | ||
|
2027-02-15 in 9787 days |
SXTPW | Trial | Phase 2 | — | $200M | Primary completion for Tafenoquine 100mg trial (NCT06656351) in Chronic Babesiosis | ||
|
2027-02-15 in 9787 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for IMGN632 trial (NCT04086264) in Acute Myeloid Leukemia | ||
|
2027-02-15 in 9787 days |
ABBV | Trial | Phase 3 | — | $1B | Primary completion for Lutikizumab trial (NCT06524635) in Hidradenitis Suppurativa | ||
|
2027-02-15 in 9787 days |
LLY | Trial | Phase 2 | — | $20B | Primary completion for Brenipatide trial (NCT07223840) in Smoking | ||
|
2027-02-15 in 9787 days |
IPIX | Trial | Phase 2 | — | $4B | Primary completion for GI-108 trial (NCT07172802) in Advanced Solid Tumor | ||
|
2027-02-15 in 9787 days |
MPLT | Trial | Phase 2 | — | $2B | Primary completion for ML-007C-MA trial (NCT06887192) in Psychosis Associated With Alzheim | ||
|
2027-02-15 in 9787 days |
GNLX | Trial | Phase 3 | — | $4B | Primary completion for Olvimulogene nanivacirepvec trial (NCT06463665) in Advanced Non-squ | ||
|
2027-02-17 in 9789 days |
MLTX | PDUFA | NDA | — | $8B | For inflammatory arthritis. BLA submitted. AI-extracted from: MoonLake has 'confidence' ah | ||
|
2027-02-18 in 9790 days |
AZN | Trial | Phase 3 | — | $5B | Primary completion for Zibotentan/Dapagliflozin trial (NCT06087835) in Chronic Kidney Dise | ||
|
2027-02-19 in 9791 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Fulvestrant trial (NCT06065748) in Estrogen Receptor-Positive, HER2 | ||
|
2027-02-19 in 9791 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Giredestrant trial (NCT06065748) in Estrogen Receptor-Positive, HER | ||
|
2027-02-20 in 9792 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for REGN7508 trial (NCT07015905) in Venous Thromboembolism (VTE) | ||
|
2027-02-20 in 9792 days |
REGN | Trial | Phase 2 | — | $8B | Primary completion for Enoxaparin trial (NCT07015905) in Venous Thromboembolism (VTE) | ||
|
2027-02-20 in 9792 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Placebo trial (NCT07015905) in Venous Thromboembolism (VTE) | ||
|
2027-02-20 in 9792 days |
SKBBY | Trial | Phase 2 | — | $11B | Primary completion for SKB518 trial (NCT07019675) in Lung Carcinoma | ||
|
2027-02-22 in 9794 days |
AZNCF | Trial | Phase 3 | — | $15B | Primary completion for Osimertinib trial (NCT05629234) in Cancer | ||
|
2027-02-22 in 9794 days |
NVS | Trial | Phase 3 | — | $12B | Primary completion for Remibrutinib trial (NCT06868212) in Chronic Spontaneous Urticaria ( | ||
|
2027-02-22 in 9794 days |
NVS | Trial | Phase 3 | — | $3B | Primary completion for Dupilumab trial (NCT06868212) in Chronic Spontaneous Urticaria (CSU | ||
|
2027-02-22 in 9794 days |
AMGN | Trial | Phase 2 | — | $2B | Primary completion for AMG 732 trial (NCT06401044) in Thyroid Eye Disease | ||
|
2027-02-23 in 9795 days |
PFE | Trial | Phase 3 | — | $25B | Primary completion for tofacitinib trial (NCT04624230) in Ulcerative Colitis | ||
|
2027-02-25 in 9797 days |
UCBJY | Trial | Phase 3 | — | $15B | Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy | ||
|
2027-02-26 in 9798 days |
AZN | Trial | Phase 3 | — | $55B | Primary completion for Placebo trial (NCT05138133) in Lupus Nephritis | ||
|
2027-02-26 in 9798 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Obinutuzumab trial (NCT06084936) in Lymphoma | ||
|
2027-02-26 in 9798 days |
RHHBY | Trial | Phase 3 | — | $25B | Primary completion for Rituximab trial (NCT06084936) in Lymphoma | ||
|
2027-02-26 in 9798 days |
AZN | Trial | Phase 3 | — | $900M | Primary completion for Anifrolumab trial (NCT05138133) in Lupus Nephritis | ||
|
2027-02-26 in 9798 days |
RHHBY | Trial | Phase 3 | — | $5B | Primary completion for Glofitamab trial (NCT06084936) in Lymphoma | ||
|
2027-02-26 in 9798 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Bendamustine trial (NCT06084936) in Lymphoma | ||
|
2027-02-26 in 9798 days |
ARDX | Trial | Phase 3 | — | $2B | Primary completion for Tenapanor 5 mg BID trial (NCT07382167) in Chronic Idiopathic Consti | ||
|
2027-02-26 in 9798 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Tocilizumab trial (NCT05535244) in Multiple Myeloma | ||
|
2027-02-26 in 9798 days |
NVS | Trial | Phase 3 | — | $18B | Primary completion for Letrozole trial (NCT01872260) in Breast Cancer | ||
|
2027-02-26 in 9798 days |
NVS | Trial | Phase 2 | — | $18B | Primary completion for BYL719 trial (NCT01872260) in Breast Cancer | ||
|
2027-02-26 in 9798 days |
NVS | Trial | Phase 3 | — | $12B | Primary completion for Alpelisib trial (NCT04524000) in Advanced Breast Cancer | ||
|
2027-02-26 in 9798 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Cabozantinib trial (NCT03634540) in Renal Cell Carcinoma (RCC) | ||
|
2027-02-26 in 9798 days |
RHHBY | Trial | Phase 2 | — | $15B | Primary completion for Cevostamab trial (NCT05535244) in Multiple Myeloma | ||
|
2027-02-28 in 9800 days |
REGN | Trial | Phase 3 | — | $2B | Primary completion for REGN5715 trial (NCT07309432) in Allergic Conjunctivitis | ||
|
2027-02-28 in 9800 days |
REGN | Trial | Phase 3 | — | $5B | Primary completion for REGN5713 trial (NCT07309432) in Allergic Conjunctivitis | ||
|
2027-02-28 in 9800 days |
FBRX | Trial | Phase 2 | — | $2B | Primary completion for FB102 trial (NCT06982963) in Celiac Disease | ||
|
2027-02-28 in 9800 days |
NTHI | Trial | Phase 2 | — | $400M | Primary completion for NEO212 Oral Capsule trial (NCT06047379) in Diffuse Astrocytoma, IDH | ||
|
2027-03-01 in 9873 days |
GSK | PDUFA | Phase 2 | — | $15B | For multiple myeloma. BLA filing. Extracted from SEC filing: 6-K | ||
|
2027-03-01 in 9873 days |
NVO | Trial | Phase 3 | — | $25B | Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT07011667) in | ||
|
2027-03-01 in 9873 days |
SXTPW | Trial | Phase 2 | — | $150M | Primary completion for Tafenoquine trial (NCT06207370) in Babesiosis | ||
|
2027-03-01 in 9873 days |
GENK | Trial | Phase 2 | — | $12B | Primary completion for SUL-238 (1500 mg t.i.d.) film-coated tablets trial (NCT07322887) in | ||
|
2027-03-02 in 9874 days |
NVSEF | Trial | Phase 2 | — | $200M | Primary completion for Cryptosporidium parvum oocysts (ABO809) trial (NCT07249463) in Cryp | ||
|
2027-03-04 in 9876 days |
XENE | PDUFA | Phase 3 | — | $15B | For epilepsy. NDA submitted. AI-extracted from: Xenon gets Phase 3 win with epilepsy drug, | ||
|
2027-03-05 in 9877 days |
PFE | Trial | Phase 3 | — | $800M | Primary completion for Ritlecitinib trial (NCT07228390) in Hidradenitis Suppurativa | ||
|
2027-03-07 in 9879 days |
HNSPF | Trial | Phase 3 | — | $5B | Primary completion for HS-20089 trial (NCT06855069) in Ovarian Cancer | ||
|
2027-03-08 in 9880 days |
MRK | Trial | Phase 3 | — | $12B | Primary completion for Methotrexate trial (NCT07176390) in Arthritis, Rheumatoid | ||
|
2027-03-08 in 9880 days |
MRK | Trial | Phase 3 | — | $1B | Primary completion for Tulisokibart trial (NCT07176390) in Arthritis, Rheumatoid | ||
|
2027-03-09 in 9881 days |
PFE | Trial | Phase 3 | — | $3B | Primary completion for Ritlecitinib 50 mg trial (NCT06873945) in Alopecia Areata | ||
|
2027-03-09 in 9881 days |
UCBJY | Trial | Phase 3 | — | $8B | Primary completion for bimekizumab trial (NCT06506916) in Moderate to Severe Plaque Psoria | ||
|
2027-03-09 in 9881 days |
PFE | Trial | Phase 3 | — | $2B | Primary completion for Ritlecitinib 100 mg trial (NCT06873945) in Alopecia Areata | ||
|
2027-03-10 in 9882 days |
AZN | Trial | Phase 2 | — | $6B | Primary completion for Surovatamig trial (NCT06526793) in B-cell Non-Hodgkin Lymphoma | ||
|
2027-03-11 in 9883 days |
BMY | Trial | Phase 3 | — | $8B | Primary completion for Ipilimumab trial (NCT03873402) in Renal Cell Carcinoma | ||
|
2027-03-11 in 9883 days |
BMY | Trial | Phase 3 | — | $4B | Primary completion for Nivolumab trial (NCT03873402) in Renal Cell Carcinoma | ||
|
2027-03-11 in 9883 days |
REGN | Trial | Phase 2 | — | $8B | Primary completion for Fixed Dose Combination (FDC) cemiplimab+fianlimab trial (NCT0619095 | ||
|
2027-03-11 in 9883 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for Placebo trial (NCT06190951) in Melanoma | ||
|
2027-03-12 in 9884 days |
TVTX | Trial | Phase 3 | — | $2B | Primary completion for Sparsentan trial (NCT05003986) in Focal Segmental Glomerulosclerosi | ||
|
2027-03-13 in 9885 days |
RYTM | Trial | Phase 3 | — | $15B | Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity | ||
|
2027-03-13 in 9885 days |
OTSKF | Trial | Phase 2 | — | $2B | Primary completion for Sibeprenlimab trial (NCT06928142) in Sjogren Disease | ||
|
2027-03-14 in 9886 days |
ZLAB | Trial | Phase 3 | — | $2B | Primary completion for ZL-1109 (VRDN-003) trial (NCT07211776) in Thyroid Eye Disease (TED) | ||
|
2027-03-15 in 9887 days |
JNGHF | Trial | Phase 3 | — | $5B | Primary completion for Rezvilutamide Tablets trial (NCT07241416) in Metastatic Hormone-sen | ||
|
2027-03-15 in 9887 days |
AARD | Trial | Phase 3 | — | $800M | Primary completion for ARD-101 trial (NCT07197034) in Hyperphagia | ||
|
2027-03-15 in 9887 days |
PCVX | Trial | Phase 3 | — | $6B | Primary completion for PCV20 trial (NCT07425392) in Pneumococcal Vaccines | ||
|
2027-03-15 in 9887 days |
ARGX | Trial | Phase 3 | — | $1B | Primary completion for Efgartigimod IV trial (NCT04833894) in Generalized Myasthenia Gravi | ||
|
2027-03-15 in 9887 days |
ADVB | Trial | Phase 3 | — | $15B | Primary completion for [18F]PSMA-1007 trial (NCT06122584) in Prostate Cancer | ||
|
2027-03-15 in 9887 days |
ATXS | Trial | Phase 3 | — | $2B | Primary completion for navenibart trial (NCT06842823) in Hereditary Angioedema (HAE) | ||
|
2027-03-15 in 9887 days |
STOK | Trial | Phase 3 | — | $400M | Primary completion for zorevunersen trial (NCT06872125) in Dravet Syndrome | ||
|
2027-03-15 in 9887 days |
OCUL | Trial | Phase 3 | — | $2B | Primary completion for Single intravitreal injection of axitinib hydrogel implant followed | ||
|
2027-03-15 in 9887 days |
VTRS | Trial | Phase 3 | — | $15B | Primary completion for Transdermal system containing progestin trial (NCT06672016) in Fema | ||
|
2027-03-15 in 9887 days |
ITCI | Trial | Phase 3 | — | $900M | Primary completion for Lumateperone high dose trial (NCT06706674) in Irritability Associat | ||
|
2027-03-15 in 9887 days |
BGNE | Trial | Phase 3 | — | $4B | Primary completion for bendamustine trial (NCT04002297) in Mantle Cell Lymphoma; Non-Hodgk | ||
|
2027-03-15 in 9887 days |
IONS | Trial | Phase 3 | — | $200M | Primary completion for Olezarsen trial (NCT05681351) in Severe Hypertriglyceridemia | ||
|
2027-03-15 in 9887 days |
BGNE | Trial | Phase 3 | — | $1B | Primary completion for zanubrutinib trial (NCT04002297) in Mantle Cell Lymphoma; Non-Hodgk | ||
|
2027-03-15 in 9887 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Cariprazine trial (NCT04777357) in Depression | ||
|
2027-03-15 in 9887 days |
PCVX | Trial | Phase 3 | — | $6B | Primary completion for 31-valent pneumococcal conjugate vaccine trial (NCT07365826) in Pne | ||
|
2027-03-15 in 9887 days |
ITCI | Trial | Phase 3 | — | $900M | Primary completion for Lumateperone low dose trial (NCT06690398) in Irritability Associate | ||
|
2027-03-15 in 9887 days |
DCPH | Trial | Phase 2 | — | $15B | Primary completion for Inlexisertib trial (NCT05957367) in GIST | ||
|
2027-03-15 in 9887 days |
FDMT | Trial | Phase 2 | — | $8B | Primary completion for Aflibercept IVT trial (NCT05197270) in Neovascular (Wet) Age-Relate | ||
|
2027-03-15 in 9887 days |
JNGHF | Trial | Phase 2 | — | $2B | Primary completion for SHR0302 Tablets trial (NCT07251595) in Non-segmental Vitiligo | ||
|
2027-03-15 in 9887 days |
LLY | Trial | Phase 2 | — | $25B | Primary completion for Macupatide trial (NCT07215559) in Obesity | ||
|
2027-03-15 in 9887 days |
EWTX | Trial | Phase 2 | — | $1B | Primary completion for Sevasemten Dose 1 trial (NCT06100887) in Duchenne Muscular Dystroph | ||
|
2027-03-15 in 9887 days |
DCPH | Trial | Phase 3 | — | $2B | Primary completion for Ripretinib trial (NCT05957367) in GIST | ||
|
2027-03-15 in 9887 days |
LLY | Trial | Phase 2 | — | $3B | Primary completion for Solbinsiran trial (NCT07269210) in Severe Hypertriglyceridemia | ||
|
2027-03-15 in 9887 days |
GMAB | Trial | Phase 3 | — | $5B | Primary completion for Epcoritamab trial (NCT05451810) in Diffuse Large B-Cell Lymphoma | ||
|
2027-03-15 in 9887 days |
FDMT | Trial | Phase 2 | — | $4B | Primary completion for 4D-150 IVT trial (NCT05197270) in Neovascular (Wet) Age-Related Mac | ||
|
2027-03-15 in 9887 days |
ALLR | Trial | Phase 2 | — | $6B | Primary completion for 2X-121 trial (NCT03878849) in Advanced Ovarian Cancer | ||
|
2027-03-15 in 9887 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Paclitaxel trial (NCT06632951) in Urothelial Carcinoma | ||
|
2027-03-15 in 9887 days |
ABBV | Trial | Phase 2 | — | $5B | Primary completion for Gemcitabine trial (NCT06632951) in Urothelial Carcinoma | ||
|
2027-03-15 in 9887 days |
ABBV | Trial | Phase 3 | — | $15B | Primary completion for Docetaxel trial (NCT06632951) in Urothelial Carcinoma | ||
|
2027-03-15 in 9887 days |
ABBV | Trial | Phase 3 | — | $3B | Primary completion for Budigalimab trial (NCT06632951) in Urothelial Carcinoma | ||
|
2027-03-15 in 9887 days |
SPTX | Trial | Phase 2 | — | $15B | Primary completion for SPT-300 trial (NCT07065240) in Major Depressive Disorder (MDD) | ||
|
2027-03-15 in 9887 days |
MNKD | Trial | Phase 2 | — | $15B | Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu | ||
|
2027-03-15 in 9887 days |
ABBV | Trial | Phase 3 | — | $4B | Primary completion for Livmoniplimab trial (NCT06632951) in Urothelial Carcinoma | ||
|
2027-03-15 in 9887 days |
BMRN | Trial | Phase 2 | — | — | Primary completion for Vosoritide Injection trial (NCT06668805) in Short Stature Homeobox- | ||
|
2027-03-15 in 9887 days |
BIOE | Trial | Phase 2 | — | $3B | Primary completion for ROC-101 trial (NCT07175038) in Pulmonary Arterial Hypertension (PAH | ||
|
2027-03-15 in 9887 days |
CGEN | Trial | Phase 2 | — | $5B | Primary completion for COM701 trial (NCT06888921) in Ovarian Cancer | ||
|
2027-03-15 in 9887 days |
ALGS | Trial | Phase 2 | — | $8B | Primary completion for ALG-000184 trial (NCT06963710) in Chronic Hepatitis B Infection | ||
|
2027-03-15 in 9887 days |
OCGN | Trial | Phase 2 | — | $300M | Primary completion for OCU400 Low Dose trial (NCT05203939) in Retinitis Pigmentosa | ||
|
2027-03-15 in 9887 days |
JNGHF | Trial | Phase 2 | — | $4B | Primary completion for HRS-4642 trial (NCT06520488) in Advanced Solid Tumors | ||
|
2027-03-15 in 9887 days |
NUVB | Trial | Phase 2 | — | $4B | Primary completion for NUV-1511 trial (NCT06334432) in Advanced Solid Tumor | ||
|
2027-03-15 in 9887 days |
COGT | Trial | Phase 2 | — | $1B | Primary completion for CGT4859 trial (NCT06777316) in Intrahepatic Cholangiocarcinoma (Icc | ||
|
2027-03-15 in 9887 days |
BIO | Trial | Phase 2 | — | $2B | Primary completion for BG1805 trial (NCT06118788) in Leukemia, Myeloid, Acute | ||
|
2027-03-15 in 9887 days |
PCRX | Trial | Phase 2 | — | $12B | Primary completion for Enekinragene Inzadenovec (PCRX-201) trial (NCT06884865) in Osteoart | ||
|
2027-03-15 in 9887 days |
PCRX | Trial | Phase 3 | — | $2B | Primary completion for Placebo trial (NCT06884865) in Osteoarthritis (OA) of the Knee | ||
|
2027-03-15 in 9887 days |
EWTX | Trial | Phase 2 | — | $1B | Primary completion for Sevasemten Dose 2 trial (NCT06100887) in Duchenne Muscular Dystroph | ||
|
2027-03-16 in 9888 days |
TKPHF | Trial | Phase 3 | — | $2B | Primary completion for TAK-755 trial (NCT04683003) in Thrombotic Thrombocytopenic Purpura | ||
|
2027-03-17 in 9889 days |
AZN | Trial | Phase 2 | — | $25B | Primary completion for AZD9550 trial (NCT06151964) in Overweight and Obesity | ||
|
2027-03-18 in 9890 days |
HELP | Trial | Phase 3 | — | $15B | Primary completion for CYB003 trial (NCT06793397) in Major Depressive Disorder (MDD) | ||
|
2027-03-19 in 9891 days |
UCBJY | Trial | Phase 3 | — | $8B | Primary completion for bimekizumab trial (NCT06506916) in Moderate to Severe Plaque Psoria | ||
|
2027-03-21 in 9893 days |
AZN | Trial | Phase 2 | — | $15B | Primary completion for Ramucirumab trial (NCT07098338) in Non-Small Cell Lung Cancer | ||
|
2027-03-21 in 9893 days |
AZN | Trial | Phase 3 | — | $4B | Primary completion for Rilvegostomig trial (NCT07098338) in Non-Small Cell Lung Cancer | ||
|
2027-03-22 in 9894 days |
REGN | Trial | Phase 3 | — | $8B | Primary completion for fianlimab trial (NCT06246916) in Melanoma | ||
|
2027-03-22 in 9894 days |
REGN | Trial | Phase 3 | — | $1B | Primary completion for cemiplimab trial (NCT06246916) in Melanoma | ||
|
2027-03-22 in 9894 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Lenvatinib trial (NCT04976634) in Neoplasm Malignant | ||
|
2027-03-22 in 9894 days |
MRK | Trial | Phase 3 | — | $8B | Primary completion for Belzutifan trial (NCT03634540) in Renal Cell Carcinoma (RCC) | ||
|
2027-03-22 in 9894 days |
NVS | Trial | Phase 2 | — | $300M | Primary completion for LXE408 trial (NCT06632600) in Chagas Disease | ||
|
2027-03-22 in 9894 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04976634) in Neoplasm Malignant | ||
|
2027-03-24 in 9896 days |
NVS | Trial | Phase 3 | — | $1B | Primary completion for Ianalumab trial (NCT05639114) in Systemic Lupus Erythematosus | ||
|
2027-03-25 in 9897 days |
SNYNF | Trial | Phase 3 | — | $8B | Primary completion for Fitusiran trial (NCT05662319) in Hemophilia | ||
|
2027-03-25 in 9897 days |
REGN | Trial | Phase 3 | — | $15B | Primary completion for Sarilumab trial (NCT04590326) in Ovarian Cancer | ||
|
2027-03-25 in 9897 days |
REGN | Trial | Phase 2 | — | $5B | Primary completion for REGN5668 trial (NCT04590326) in Ovarian Cancer | ||
|
2027-03-25 in 9897 days |
REGN | Trial | Phase 3 | — | $1B | Primary completion for Cemiplimab trial (NCT04590326) in Ovarian Cancer | ||
|
2027-03-26 in 9898 days |
AZN | Trial | Phase 3 | — | $4B | Primary completion for AZD0780 trial (NCT07000136) in Heterozygous Familial Hypercholester | ||
|
2027-03-26 in 9898 days |
IPSEY | Trial | Phase 3 | — | $2B | Primary completion for IPN10200 trial (NCT06937931) in Cervical Dystonia | ||
|
2027-03-28 in 9900 days |
PFE | Trial | Phase 2 | — | $20B | Primary completion for PF-07275315 trial (NCT06977581) in Asthma | ||
|
2027-03-30 in 9902 days |
RHHBY | Trial | Phase 3 | — | $5B | Primary completion for Emicizumab trial (NCT06998524) in Von Willebrand Disease, Type 3 | ||
|
2027-03-30 in 9902 days |
RHHBY | Trial | Phase 3 | — | $400M | Primary completion for von Willebrand Factor (VWF) Concentrates trial (NCT06998524) in Von | ||
|
2027-03-31 in 9903 days |
AAPG | Trial | Phase 3 | — | $2B | Primary completion for Olverembatinib trial (NCT06640361) in GIST | ||
|
2027-03-31 in 9903 days |
RHHBY | Trial | Phase 3 | — | $6B | Primary completion for Atezolizumab trial (NCT04543617) in Esophageal Squamous Cell Carcin | ||
|
2027-03-31 in 9903 days |
RHHBY | Trial | Phase 3 | — | $500M | Primary completion for Satralizumab trial (NCT05199688) in Neuromyelitis Optica Spectrum D | ||
|
2027-03-31 in 9903 days |
RHHBY | Trial | Phase 3 | — | $4B | Primary completion for Tiragolumab trial (NCT04543617) in Esophageal Squamous Cell Carcino | ||
|
2027-03-31 in 9903 days |
NVSEF | Trial | Phase 3 | — | $2B | Primary completion for CTL019 trial (NCT04094311) in B-cell Acute Lymphoblastic Leukemia | ||
|
2027-03-31 in 9903 days |
ALT | Trial | Phase 2 | — | $8B | Primary completion for Pemvidutide trial (NCT07009860) in Alcohol Liver Disease | ||
|
2027-03-31 in 9903 days |
TNGX | Trial | Phase 2 | — | $15B | Primary completion for TNG456 trial (NCT06810544) in Non Small Cell Lung Cancer | ||
|
2027-03-31 in 9903 days |
ESALY | Trial | Phase 2 | — | $4B | Primary completion for E7386 trial (NCT04008797) in Endometrial Neoplasms | ||
|
2027-03-31 in 9903 days |
MSCLF | Trial | Phase 2 | — | $1B | Primary completion for SAT-3247 trial (NCT07287189) in Duchenne Muscular Dystrophy | ||
|
2027-03-31 in 9903 days |
ESALY | Trial | Phase 2 | — | $3B | Primary completion for E7389-LF trial (NCT04078295) in Solid Neoplasms | ||
|
2027-03-31 in 9903 days |
CGON | Trial | Phase 3 | — | $4B | Primary completion for Cretostimogene Grenadenorepvec trial (NCT06567743) in High-Risk Non | ||
|
2027-03-31 in 9903 days |
SWTX | Trial | Phase 3 | — | $300M | Primary completion for Nirogacestat oral tablet trial (NCT07170644) in Desmoid Tumor | ||
|
2027-03-31 in 9903 days |
RHHBY | Trial | Phase 3 | — | $9B | Primary completion for Tocilizumab trial (NCT04077723) in Lymphoma, Non-Hodgkin | ||
|
2027-03-31 in 9903 days |
INVA | Trial | Phase 2 | — | $15B | Primary completion for VI-0609 trial (NCT06915246) in Lymphoma | ||
|
2027-03-31 in 9903 days |
AZN | Trial | Phase 2 | — | $3B | Primary completion for AZD4360 trial (NCT06921928) in Gastric Cancer | ||
|
2027-03-31 in 9903 days |
RHHBY | Trial | Phase 2 | — | $12B | Primary completion for Englumafusp alfa trial (NCT04077723) in Lymphoma, Non-Hodgkin | ||
|
2027-03-31 in 9903 days |
ESALY | Trial | Phase 2 | — | $18B | Primary completion for BB-1701 trial (NCT06188559) in Breast Cancer | ||
|
2027-04-01 in 9973 days |
JNGHF | Trial | Phase 3 | — | $5B | Primary completion for XLJDOD compound granule trial (NCT05709249) in Colon Cancer | ||
|
2027-04-01 in 9973 days |
TLSA | Trial | Phase 2 | — | $200M | Primary completion for Foralumab Nasal trial (NCT06868628) in Multiple System Atrophy | ||
|
2027-04-04 in 9976 days |
CFOO | PDUFA | NDA | — | $12B | For Unresectable or Metastatic HER2-Positive Adult Breast Cancer. BLA accepted. AI-extract | ||
|
2027-04-06 in 9978 days |
AZN | Trial | Phase 3 | — | $12B | Primary completion for Olaparib trial (NCT04421963) in Ovarian Cancer | ||
|
2027-04-06 in 9978 days |
VRTX | Trial | Phase 3 | — | $30B | Primary completion for Suzetrigine trial (NCT07231419) in Diabetic Peripheral Neuropathic | ||
|
2027-04-06 in 9978 days |
VRTX | Trial | Phase 3 | — | $6B | Primary completion for IVA trial (NCT05331183) in Cystic Fibrosis | ||
|
2027-04-06 in 9978 days |
VRTX | Trial | Phase 3 | — | $6B | Primary completion for ELX/TEZ/IVA trial (NCT05331183) in Cystic Fibrosis | ||
|
2027-04-06 in 9978 days |
ESALY | Trial | Phase 2 | — | $1B | Primary completion for Perampanel Oral Suspension trial (NCT04015141) in Pediatric Epilept | ||
|
2027-04-08 in 9980 days |
SNY | Trial | Phase 2 | — | $500M | Primary completion for SAR444336 trial (NCT07156175) in Microscopic Colitis | ||
|
2027-04-10 in 9982 days |
NHPAP | PDUFA | NDA | — | $4B | sBLA accepted. AI-extracted from: Mabwell Announces Acceptance of Supplemental Biologics L | ||
|
2027-04-12 in 9984 days |
SNY | Trial | Phase 3 | — | $500M | Primary completion for Dupilumab trial (NCT06687980) in Lichen Simplex Chronicus | ||
|
2027-04-12 in 9984 days |
NVSEF | Trial | Phase 3 | — | $2B | Primary completion for ianalumab trial (NCT05624749) in Systemic Lupus Erythematosus | ||
|
2027-04-13 in 9985 days |
AMGN | Trial | Phase 3 | — | $400M | Primary completion for Inebilizumab trial (NCT05549258) in Neuromyelitis Optica Spectrum D | ||
|
2027-04-14 in 9986 days |
TKPHF | Trial | Phase 3 | — | — | Primary completion for TDV trial (NCT06579755) in Dengue Fever | ||
|
2027-04-15 in 9987 days |
MRK | Trial | Phase 2 | — | $2B | Primary completion for Placebo trial (NCT06489028) in Venous Leg Ulcer | ||
|
2027-04-15 in 9987 days |
FOLD | Trial | Phase 3 | — | $400M | Primary completion for Miglustat trial (NCT04808505) in Glycogen Storage Disease Type II I | ||
|
2027-04-15 in 9987 days |
ITCI | Trial | Phase 3 | — | $15B | Primary completion for Lumateperone trial (NCT06372964) in Bipolar Depression | ||
|
2027-04-15 in 9987 days |
MNOV | Trial | Phase 3 | — | $2B | Primary completion for MN-166 trial (NCT04057898) in Amyotrophic Lateral Sclerosis | ||
|
2027-04-15 in 9987 days |
XENE | Trial | Phase 3 | — | $4B | Primary completion for XEN1101 trial (NCT05667142) in Primary Generalized Tonic-Clonic Sei | ||
|
2027-04-15 in 9987 days |
FOLD | Trial | Phase 3 | — | $400M | Primary completion for Cipaglucosidase alfa trial (NCT04808505) in Glycogen Storage Diseas | ||
|
2027-04-15 in 9987 days |
CODX | Trial | Phase 3 | — | $1B | Primary completion for allo-APZ2-CVU trial (NCT06489028) in Venous Leg Ulcer | ||
|
2027-04-15 in 9987 days |
WXI | Trial | Phase 2 | — | $4B | Primary completion for D3S-001 trial (NCT05410145) in KRAS P.G12C | ||
|
2027-04-15 in 9987 days |
NKTX | Trial | Phase 2 | — | $1B | Primary completion for NKX019 trial (NCT06557265) in Lupus Nephritis | ||
|
2027-04-15 in 9987 days |
KYTX | Trial | Phase 3 | — | $1B | Primary completion for KYV-101 trial (NCT06384976) in Multiple Sclerosis, Primary Progress | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 3 | — | $8B | Primary completion for Cetuximab trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung | ||
|
2027-04-15 in 9987 days |
KYTX | Trial | Phase 2 | — | $5B | Primary completion for Anti-CD20 mAB trial (NCT06384976) in Multiple Sclerosis, Primary Pr | ||
|
2027-04-15 in 9987 days |
ABBV | Trial | Phase 2 | — | $8B | Primary completion for ABBV-932 trial (NCT07220460) in Bipolar I or II Disorder | ||
|
2027-04-15 in 9987 days |
NKTX | Trial | Phase 2 | — | $900M | Primary completion for Fludarabine, Cyclophosphamide trial (NCT06557265) in Lupus Nephriti | ||
|
2027-04-15 in 9987 days |
KPTI | Trial | Phase 3 | — | $8B | Primary completion for Selinexor trial (NCT02343042) in Multiple Myeloma | ||
|
2027-04-15 in 9987 days |
HR | Trial | Phase 3 | — | $2B | Primary completion for MBK-01 trial (NCT06687382) in Diverticulitis | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for LY3537982 trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung | ||
|
2027-04-15 in 9987 days |
CGTX | Trial | Phase 2 | — | $9B | Primary completion for CT1812 trial (NCT05531656) in Early Alzheimer's Disease | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Pemetrexed trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung | ||
|
2027-04-15 in 9987 days |
IPIX | Trial | Phase 2 | — | $15B | Primary completion for S095018 trial (NCT06162572) in Non-small Cell Lung Cancer (NSCLC) | ||
|
2027-04-15 in 9987 days |
MIRM | Trial | Phase 2 | — | $1B | Primary completion for Volixibat trial (NCT05050136) in Primary Biliary Cholangitis | ||
|
2027-04-15 in 9987 days |
KYTX | Trial | Phase 3 | — | $900M | Primary completion for Standard lymphodepletion regimen trial (NCT06384976) in Multiple Sc | ||
|
2027-04-15 in 9987 days |
RAPT | Trial | Phase 2 | — | $2B | Primary completion for RPT904 trial (NCT07220811) in Ig-E Mediated Food Allergy | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 3 | — | $15B | Primary completion for Cisplatin trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung | ||
|
2027-04-15 in 9987 days |
KPTI | Trial | Phase 3 | — | $15B | Primary completion for Bortezomib trial (NCT02343042) in Multiple Myeloma | ||
|
2027-04-15 in 9987 days |
KPTI | Trial | Phase 3 | — | $15B | Primary completion for Dexamethasone trial (NCT02343042) in Multiple Myeloma | ||
|
2027-04-15 in 9987 days |
KPTI | Trial | Phase 2 | — | $15B | Primary completion for Lenalidomide trial (NCT02343042) in Multiple Myeloma | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 2 | — | $12B | Primary completion for LY3016859 ISA trial (NCT05986292) in Osteoarthritis, Knee | ||
|
2027-04-15 in 9987 days |
LLY | Trial | Phase 3 | — | $18B | Primary completion for Carboplatin trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung | ||
|
2027-04-16 in 9988 days |
SGIOY | Trial | Phase 2 | — | $1B | Primary completion for S-531011 trial (NCT05101070) in Solid Tumors | ||
|
2027-04-17 in 9989 days |
RHHBY | Trial | Phase 3 | — | $8B | Primary completion for Afimkibart trial (NCT07137598) in Rheumatoid Arthritis | ||
|
2027-04-20 in 9992 days |
PFE | Trial | Phase 3 | — | $2B | Primary completion for Ritlecitinib higher dose trial (NCT07029711) in Severe Alopecia Are | ||
|
2027-04-20 in 9992 days |
AZNCF | Trial | Phase 3 | — | $8B | Primary completion for Camizestrant trial (NCT05774951) in Breast Cancer, Early Breast Can | ||
|
2027-04-20 in 9992 days |
AZNCF | Trial | Phase 2 | — | $2B | Primary completion for AZD5148 trial (NCT07285213) in Clostridioides Difficile Infection | ||
|
2027-04-21 in 9993 days |
SNY | Trial | Phase 2 | — | $1B | Primary completion for Rotavirus vaccine trial (NCT06647407) in Meningococcal Immunization | ||
|
2027-04-21 in 9993 days |
SNY | Trial | Phase 3 | — | $500M | Primary completion for MenACYW conjugate vaccine trial (NCT06647407) in Meningococcal Immu | ||
|
2027-04-23 in 9995 days |
PFE | Trial | Phase 3 | — | $2B | Primary completion for Ritlecitinib 100 mg trial (NCT06163326) in Vitiligo | ||
|
2027-04-23 in 9995 days |
PFE | Trial | Phase 3 | — | $800M | Primary completion for Ritlecitinib trial (NCT06163326) in Vitiligo | ||
|
2027-04-23 in 9995 days |
MRK | Trial | Phase 3 | — | $3B | Primary completion for Enfortumab Vedotin trial (NCT06305767) in Bladder Cancer | ||
|
2027-04-23 in 9995 days |
GSK | Trial | Phase 2 | — | $4B | Primary completion for RTS,S/AS01E vaccine trial (NCT07036159) in Malaria | ||
|
2027-04-23 in 9995 days |
MRK | Trial | Phase 3 | — | $15B | Primary completion for Pembrolizumab trial (NCT06305767) in Bladder Cancer | ||
|
2027-04-23 in 9995 days |
MRK | Trial | Phase 3 | — | $4B | Primary completion for Intismeran autogene trial (NCT06305767) in Bladder Cancer | ||
|
2027-04-27 in 9999 days |
AMGN | Trial | Phase 3 | — | $80B | Primary completion for Maridebart cafraglutide trial (NCT06987695) in Obesity Disease | ||
|
2027-04-27 in 9999 days |
INCY | Trial | Phase 3 | — | $5B | Primary completion for INCB123667 trial (NCT07023627) in Ovarian Cancer | ||
|
2027-04-27 in 9999 days |
NVS | Trial | Phase 2 | — | $12B | Primary completion for GXV813 trial (NCT07467993) in Schizophrenia | ||
|
2027-04-28 in 10000 days |
PFE | Trial | Phase 3 | — | $25B | Primary completion for tofacitinib trial (NCT04624230) in Ulcerative Colitis | ||
|
2027-04-28 in 10000 days |
SNY | Trial | Phase 3 | — | $15B | Primary completion for Frexalimab trial (NCT06111586) in Type 1 Diabetes Mellitus |